{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.14055"}, {"@name": "filename", "#text": "20303_Dissertacao%20-%20Bernardo%20Times%20de%20Carvalho.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "1 \n \n\nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE  \nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM CI\u00caNCIAS DA SA\u00daDE \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n\nUFPE \n \n \n \n \n\n \n\nCINTILOGRAFIA DE PERFUS\u00c3O NA AVALIA\u00c7\u00c3O DA \nHEMODIN\u00c2MICA HEP\u00c1TICA NA ESQUISTOSSOMOSE \n\nHEPATOESPL\u00caNICA \n\n \n \n \n \n \n \n \n \n \n \n\n \n\nBERNARDO TIMES DE CARVALHO \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nRecife, 2015\n\n \n\n\n\n2 \n \n\nBERNARDO TIMES DE CARVALHO \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n\nUFPE \n \n \n \n \n \n \n \n\n \nCINTILOGRAFIA DE PERFUS\u00c3O NA AVALIA\u00c7\u00c3O DA \n\nHEMODIN\u00c2MICA HEP\u00c1TICA NA ESQUISTOSSOMOSE \nHEPATOESPL\u00caNICA \n\n \n \n \n \n \n \n \n \n\n \n\nDisserta\u00e7\u00e3o apresentada ao Programa de P\u00f3s-\nGradua\u00e7\u00e3o em Ci\u00eancia da Sa\u00fade do Centro de \nCi\u00eancias da Sa\u00fade da Universidade Federal de \nPernambuco, como requisito parcial para \nobten\u00e7\u00e3o do grau de Mestre. \n\n \n \n \n \n\nOrientadora \n\nProf\u00aa Dra. Ana L\u00facia Coutinho Domingues  \nProf\u00aa Adjunta do Depto de Medicina Cl\u00ednica, CCS-  \n\n      UFPE \n \n \n \n \n\n  \n\nRecife, 2015 \n\n \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\nFicha catalogr\u00e1fica elaborada pela \n\nBibliotec\u00e1ria: M\u00f4nica Uch\u00f4a, CRB4-1010 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nC331c Carvalho, Bernardo Times de. \n\n      Cintilografia de perfus\u00e3o na avalia\u00e7\u00e3o da hemodin\u00e2mica hep\u00e1tica na \nesquistossomose hepatoespl\u00eanica / Bernardo Times de Carvalho. \u2013 2015. \n\n                        145 f.: il.; tab.; 30 cm. \n \nOrientadora: Ana L\u00facia Coutinho Domingues. \nDisserta\u00e7\u00e3o (mestrado) \u2013 universidade federal de pernambuco, ccs. \n\nPrograma de p\u00f3s-gradua\u00e7\u00e3o em ci\u00eancias da sa\u00fade. Recife, 2015. \nInclui refer\u00eancias, ap\u00eandices e anexos. \n \n1. Esquistossomose. 2. Cintilografia. 3. Hemodin\u00e2mica. 4. Perfus\u00e3o \n\nhep\u00e1tica. 5. Esquistossomose hepatoespl\u00eanica. I. Domingues, Ana L\u00facia \nCoutinho (orientadora). Ii. T\u00edtulo. \n \n \n 610 CDD (23.ed.)                UFPE (CCS2016-065) \n       \n\n\n\niv \n \n\nBERNARDO TIMES DE CARVALHO \n \n \n \n \n \n\nCINTILOGRAFIA DE PERFUS\u00c3O NA AVALIA\u00c7\u00c3O DA HEMODIN\u00c2MICA \nHEP\u00c1TICA NA ESQUISTOSSOMOSE HEPATOESPL\u00caNICA \n\n \n \n \n \n \n \n\nDisserta\u00e7\u00e3o ou Tese apresentada \nao Programa de P\u00f3s-Gradua\u00e7\u00e3o em \nCi\u00eancias da Sa\u00fade da Universidade \nFederal de Pernambuco, como \nrequisito parcial para a obten\u00e7\u00e3o do \nt\u00edtulo de MESTRE em CI\u00caNCIAS DA \nSA\u00daDE. \n\n \n \n \n \nAprovada em: 10/09/2015 \n \n \n \n \n \n\nBANCA EXAMINADORA \n \n\n________________________________________ \nProf\u00b0. Dr\u00b0. Edmundo Pessoa de Almeida Lopes (Presidente) \n\nUniversidade Federal de Pernambuco \n \n\n________________________________________ \nProf\u00b0. Dr\u00b0. Jos\u00e9 Eymard Moraes Medeiros Filho (Examinador Externo) \n\nUniversidade Federal da Para\u00edba \n \n\n_________________________________________ \nProf\u00b0. Dr\u00b0. Cl\u00e1udio Moura Lacerda (Examinador Externo) \n\nUniversidade Federal de Pernambuco \n \n\n \n\n\n\nv \n \n\n   UNIVERSIDADE FEDERAL DE PERNAMBUCO \n\n \n\n     \n  \n\n \n\n     \n             UFPE \n\n \nREITOR \n\nProf. An\u00edsio Brasileiro de Freitas Dourado \n\n \n\nVICE-REITOR \nProf. Silvio Romero de Barros Marques \n\n \n\nPR\u00d3-REITOR PARA ASSUNTOS DE PESQUISA \n\nE P\u00d3S-GRADUA\u00c7\u00c3O \n\nCENTRO DE CI\u00caNCIAS DA SA\u00daDE \n\nDIRETOR \nProf. Nicodemos Teles de Pontes Filho \n\n \n\nHOSPITAL DAS CL\u00cdNICAS \n\nDIRETOR SUPERINTENDENTE \nProf. Frederico Jorge Ribeiro \n\n \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM \n\nCI\u00caNCIAS DA SA\u00daDE \n\n \n\nCOORDENADOR \n\nProf. Emanuel S\u00e1vio Cavalcanti Sarinho \n\nVICE-COORDENADOR \n\nProf. Brivaldo Markamn Filho \n\nCORPO DOCENTE \n\n \n\nProf\u00aa. Ana L\u00facia Coutinho Domingues \n\nProf\u00aa. \u00c2ngela Luiza Pinto Duarte \n\nProf\u00ba. Ary Gomes Filho \n\nProf\u00ba Brivaldo Markman Filho \n\nProf\u00ba. Bruno Severo Gomes \n\nProf\u00aa. Cl\u00e1udia Diniz Lopes Neto \n\nProf\u00ba. D\u00e9cio Medeiros Peixoto \n\nProf\u00ba. Dinaldo Cavalcanti de Oliveira \n\nProf\u00ba Edgar Guimar\u00e3es Victor \n\nProf\u00ba Edmundo Pessoa de Almeida Lopes Neto \n\nProf\u00ba. Emanuel S\u00e1vio Cavalcanti Sarinho \n\nProf\u00aa. Em\u00edlia Chagas Costa \n\nProf\u00aa Helo\u00edsa Ramos Lacerda de Melo \n\nProf\u00ba. Jeymesson Raphael Cardoso Vieira \n\nProf\u00ba Jos\u00e9 \u00c2ngelo Rizzo \n\nProf\u00aa. Lucila Maria Valente \n\nProf\u00ba Lucio Villar Rabelo Filho \n\nProf\u00ba. Marcelo Renato Guerino \n\nProf\u00ba. Marcelo Tavares Viana \n\nProf\u00ba. Paulo S\u00e9rgio Ramos Ara\u00fajo \n\nProf\u00aa Patr\u00edcia \u00c9rika de Melo Marinho \n\nProf\u00aa. Romualda Castro do R\u00eago Barros \n\nProf\u00ba. Sandro Gon\u00e7alves de Lima \n\nProf\u00ba. Simone Cristina Soares Brand\u00e3o \n  \n\n\n\nvi \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n\u00c0 minha fam\u00edlia, Marcela, Bruno e Mabel \n\n e aos meus pais S\u00f3crates e Rejane \n\n \n\n  \n\n\n\nvi \n \n\nAGRADECIMENTOS \n\n \n\n\u00c0 minha orientadora Prof\u00aa Dra Ana L\u00facia Coutinho Domingues por sua paci\u00eancia e \n\nserenidade maternais; \n\n \n\n\u00c0 Prof\u00aa Dra Simone Cristina Soares Brand\u00e3o que desde o in\u00edcio acreditou mais em mim do \n\nque eu mesmo; \n\n \n\n\u00c0 minha m\u00e3e Rejane de Moraes Rego, pelo exemplo e carinho; \n\n \n\nAo meu pai S\u00f3crates Times de Carvalho Neto, pela sabedoria e presen\u00e7a indispens\u00e1vel no \n\nmomento crucial; \n\n \n\n\u00c0 minha esposa Marcela Amaral, por estar ao meu lado desde sempre; \n\n \n\nAo meu filho Bruno, pela alegria di\u00e1ria; \n\n \n\nAo amigo Taciano Rocha pela especial ajuda e incentivos constantes; \n\n \n\nEm especial aos PACIENTES que, sem os mesmos, o trabalho n\u00e3o seria concretizado; \n\n \n\nAos Amigos da turma 2013, pela ajuda m\u00fatua e companhia prazerosa nesta trajet\u00f3ria; \n\n \n\nAos meus Preceptores da Cl\u00ednica M\u00e9dica e Gastroenterologia do Hospital das Cl\u00ednicas \u2013 UFPE \n\npelos preciosos e eternos ensinamentos; \n\n \n\n\u00c0s indispens\u00e1veis amigas da secretaria Esmeralda e Cybelli, sempre empenhadas em nos \n\najudar; \n\n \n\nE a todos que contribu\u00edram de maneira importante para realiza\u00e7\u00e3o deste estudo \n\n \n\n\n\nix \n \n\nRESUMO \n\n \n\nA esquistossomose mansoni \u00e9 uma doen\u00e7a infecto-parasit\u00e1ria end\u00eamica em 78 pa\u00edses da \u00c1frica, \n\n\u00c1sia, Am\u00e9ricas Central e do Sul. A forma hepatoespl\u00eanica (EHE) constitui a fase evolutiva \n\nmais grave da doen\u00e7a, caracterizada pela hipertens\u00e3o portal. Nela observam-se les\u00f5es \n\nobstrutivas da veia porta associadas \u00e0 hipertrofia do territ\u00f3rio da art\u00e9ria hep\u00e1tica. A cintilografia \n\nde perfus\u00e3o hep\u00e1tica \u00e9 um m\u00e9todo radioisot\u00f3pico utilizado na investiga\u00e7\u00e3o da perfus\u00e3o do \n\nf\u00edgado nas doen\u00e7as hep\u00e1ticas. Uma vez que a esquistossomose cursa com altera\u00e7\u00f5es da \n\nfisiologia da perfus\u00e3o portal secund\u00e1rias \u00e0 redu\u00e7\u00e3o da vasculariza\u00e7\u00e3o portal intra-hep\u00e1tica, \n\npode-se sugerir que ocorram modifica\u00e7\u00f5es perfusionais semelhantes \u00e0 cirrose onde est\u00e1 \n\ndocumentado um aumento compensat\u00f3rio da perfus\u00e3o atrav\u00e9s da art\u00e9ria hep\u00e1tica. O presente \n\nobjetivou verificar altera\u00e7\u00f5es da hemodin\u00e2mica hep\u00e1tica em esquistossom\u00f3ticos com a forma \n\nhepatoespl\u00eanica atrav\u00e9s da cintilografia de perfus\u00e3o hep\u00e1tica. Buscou, tamb\u00e9m, relacionar estas \n\naltera\u00e7\u00f5es com vari\u00e1veis cl\u00ednico-laboratoriais (antecedente de hemorragias, presen\u00e7a de varizes \n\nesof\u00e1gicas e contagem plaquet\u00e1ria) e ultrassonogr\u00e1ficas (calibre da veia porta e espl\u00eanica, \n\ndi\u00e2metro longitudinal do ba\u00e7o e padr\u00e3o de fibrose hep\u00e1tica) encontradas na EHE, no intuito de \n\nampliar o conhecimento sobre esta enfermidade multifatorial e bastante heterog\u00eanea, podendo \n\nacrescentar novas perspectivas na condu\u00e7\u00e3o de pacientes com EHE. Dezenove pacientes \n\nesquistossom\u00f3ticos foram submetidos \u00e0 avalia\u00e7\u00e3o ultrassonogr\u00e1fica do grau de fibrose hep\u00e1tica, \n\nmedida do ba\u00e7o, veia porta e espl\u00eanica, endoscopia digestiva e quantifica\u00e7\u00e3o de plaquetas. \n\nPosteriormente foram submetidos \u00e0 angiocintilografia com medida do \u00edndice de perfus\u00e3o \n\nhep\u00e1tica (IPH). Foi observado que pacientes com esquistossomose hepatoespl\u00eanica apresentam \n\nsignificativo aumento do IPH comparado a indiv\u00edduos normais (p=0,0029) e que este aumento \n\nse correlaciona com o comprimento espl\u00eanico (p=0,038) e calibre das varizes esof\u00e1gicas \n\n(p=0,0060). Conclui-se que a angiocintilografia foi capaz demonstrar que pacientes com EHE \n\napresentavam aumento do IPH, caracterizando uma maior \u201carterializa\u00e7\u00e3o\u201d hep\u00e1tica, \u00e0 \n\nsemelhan\u00e7a do descrito previamente em cirr\u00f3ticos. Observou-se tamb\u00e9m correla\u00e7\u00e3o entre o IPH \n\ne o comprimento longitudinal do ba\u00e7o e com o calibre das varizes esof\u00e1gicas, bem como, com \n\no calibre da veia porta e com a contagem de plaquetas. No presente estudo, a medida do IPH \n\nn\u00e3o se correlacionou com o padr\u00e3o da fibrose hep\u00e1tica, nem com o calibre da veia espl\u00eanica ou \n\ncom o antecedente de hemorragia digestiva. A angiocintilografia representa um campo \n\npromissor na avalia\u00e7\u00e3o da esquistossomose hepatoespl\u00eanica. \n\nPalavras \u2013 Chave: \n\nEsquistossomose hepatoespl\u00eanica. cintilografia. perfus\u00e3o hep\u00e1tica. hemodin\u00e2mica  \n\n\n\nx \n \n\nABSTRACT \n\n \n\nSchistosomiasis is an infectious parasitic disease endemic in 78 countries of Africa, Asia, \n\nCentral and South America. In Brazil, it is estimated that 25 million people are at risk of \n\ninfection. The hepatosplenic form (HSS) is the most severe stage of the disease, characterized \n\nby portal hypertension. Portal vein obstructive lesions associated with hypertrophy of hepatic \n\nartery territory are observed. The liver perfusion scintigraphy is a radioisotope method used in \n\nthe evaluations of hepatic perfusion changes of liver diseases. Once schistosomiasis courses \n\nwith changes in the physiology of portal perfusion secondary to reduced intrahepatic portal \n\nvasculature, it may be suggested that likely in cirrhosis, where the compensatory increase in \n\nperfusion through the hepatic artery is documented, perfusion changes occur in hepatosplenic \n\nschistosomiasis. This study is aimed on determine changes in liver hemodynamics of \n\nhepatosplenic schistosomiasis through hepatic perfusion scintigraphy. It also tried to correlate \n\nthese changes with clinical and laboratory variables (history of bleeding, presence of \n\nesophageal varices and platelet count) and ultrasound findings (caliber of portal and splenic \n\nveins, the longitudinal splenic diameter and pattern of liver fibrosis) found in the EHE in order \n\nto increase knowledge of this very heterogeneous and multifactorial disease, and add new \n\nperspectives in the management of patients with EHE. Nineteen patients with schistosomiasis \n\nunderwent ultrasound evaluation of the degree of liver fibrosis, splenic length, splenic and \n\nportal vein diameters, digestive endoscopy and quantification of platelets. Subsequently \n\nunderwent perfusion scintigraphy with measurement of hepatic perfusion index (HPI). It was \n\nobserved that patients with hepatosplenic schistosomiasis had significantly increase the HPI \n\ncompared to normal individuals (p = 0.0029) and that this increase correlates with the splenic \n\nlength (p = 0.038) and the esophageal varices diameters (p = 0.0060). We concluded that \n\nangioscintigraphy was able to show that patients with HSS had increased HPI, featuring greater \n\nliver \"arterialization\", likely previously described in cirrhotic patients. It was also noted the \n\ncorrelation between the HPI and the longitudinal splenic length, with the caliber of esophageal \n\nvarices, with the caliber of the portal vein and with the blood platelet count. In this study, the \n\nmeasure of IPH was not correlated with the pattern of liver fibrosis or with the caliber of the \n\nsplenic vein or with a history of gastrointestinal bleeding. Angioscintigraphy is a promising \n\nfield in the evaluation of hepatosplenic schistosomiasis \n\nKey words: \n\nHepatosplenic schistosomiasis. scintigraphy. hepatic perfusion. hemodynamics  \n\n\n\nxi \n \n\nLISTA DE ABREVIATURAS \n\n \n\n? CAAE \u2013 Certificado de Apresenta\u00e7\u00e3o para Aprecia\u00e7\u00e3o \u00c9tica \n\n? DALY \u2013 Disability Adjusted Life Years \n\n? EHE \u2013 Esquistossomose Hepatoespl\u00eanica \n\n? HDA \u2013 Hemorragia Digestiva Alta \n\n? HABR \u2013 Hepatic Arterial Buffer Response \n\n? HC-UFPE \u2013 Hospital das Cl\u00ednicas Universidade Federal de Pernambuco \n\n? IPH \u2013 \u00cdndice de Perfus\u00e3o Hep\u00e1tica \n\n? PECE \u2013 Programa Especial de Controle da Esquistossomose \n\n? ROI \u2013 Region of Interest \n\n? USG \u2013 Ultrassonografia  \n\n? WHO \u2013 World Health Organization \n\n\n\nxiv \n \n\nLISTA DE FIGURAS \n\nFigura 1 \u2013 Tend\u00eancia da taxa de mortalidade ajustada para a idade \n\nrelacionada \u00e0 esquistossomose (por 100.000 habitantes) separada \n\npor regi\u00e3o do Brasil de 2000 a 2011. \n\nFigura 2 \u2013 Aspecto do f\u00edgado esquistossom\u00f3tico na forma hepatoespl\u00eanica \n\ncom intensa fibrose in vivo. \n\nFigura 3 \u2013 Aspecto de corte do f\u00edgado esquistossom\u00f3tico na forma \n\nhepatoespl\u00eanica evidenciando a fibrose periportal de Symmers. \n\nFigura 4 \u2013 Aspecto microsc\u00f3pico de f\u00edgado esquistossom\u00f3tico mostrando a \n\npreserva\u00e7\u00e3o do par\u00eanquima hep\u00e1tico a despeito da intensa fibrose \n\nem torno dos ramos portais intra-hep\u00e1ticos. \n\nFigura 5 \u2013 Classifica\u00e7\u00e3o ultrassonogr\u00e1fica de Niamey para as altera\u00e7\u00f5es \n\nhep\u00e1ticas da esquistossomose. (A) Padr\u00e3o A \u2013 F\u00edgado Normal. \n\n(B) Padr\u00e3o B \u2013 Pronunciada ecogenicidade dos ramos portais \n\nperif\u00e9ricos \u2013 \u201cpadr\u00e3o de c\u00e9u estrelado\u201d. (C) Padr\u00e3o C \u2013 \n\nEspessamento periportal perif\u00e9rico. (D) Padr\u00e3o D \u2013 \n\nEspessamento periportal central. (E) Padr\u00e3o E \u2013 Espessamento \n\nperiportal central com bandas ecog\u00eanicas expandindo pelo \n\npar\u00eanquima. (F) Padr\u00e3o F \u2013 Espessamento periportal central e \n\nperif\u00e9rico avan\u00e7ado. \n\nFigura 6 \u2013 Corte histol\u00f3gico de f\u00edgado evidenciando granuloma periovular \n\nna regi\u00e3o periportal, com a forma\u00e7\u00e3o de rea\u00e7\u00e3o inflamat\u00f3ria e \n\nfibrose periportais em torno do granuloma, com par\u00eanquima \n\nhep\u00e1tico adjacente preservado. No destaque, observam-se outros \n\novos impactados em vaso portal pr\u00f3ximos ao granuloma. \n\nFigura 7 \u2013 Corte histol\u00f3gico de f\u00edgado evidenciando in\u00fameros parasitas \n\nadultos do Schistosoma mansoni, impactados em ramos do leito \n\nvenoso portal intra-hep\u00e1tico. \n\nFigura 8 \u2013 Aspecto macrosc\u00f3pico de molde pl\u00e1stico da rede venosa portal de \n\nroedor saud\u00e1vel (A) e roedor com esquistossomose \n\nhepatoespl\u00eanica (B), mostrando uma redu\u00e7\u00e3o global na densidade \n\ndos vasos portais e \u201camputa\u00e7\u00e3o\u201d dos vasos especialmente na \n\nperiferia, diminui\u00e7\u00e3o abrupta do calibre dos vasos de m\u00e9dio e \n\ngrande calibre e pequenas ramifica\u00e7\u00f5es surgindo de vasos de \n\ngrande calibre. \n\n \n\n22 \n\n \n\n \n\n \n25 \n\n \n\n \n25 \n\n \n \n\n26 \n\n \n\n \n29 \n\n \n\n \n\n \n\n \n\n \n \n\n \n\n \n\n \n32 \n\n \n\n \n\n \n\n \n\n \n33 \n\n \n\n \n\n \n35 \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\nxv \n \n\nFigura 9 \u2013 Aspecto macrosc\u00f3pico de molde pl\u00e1stico de f\u00edgado de roedor com \n\nesquistossomose hepatoespl\u00eanica avan\u00e7ada evidenciando redu\u00e7\u00e3o \n\nimportante da densidade da rede venosa portal (branco), veias \n\nhep\u00e1ticas preservadas (azul) e aumento da densidade de vasos do \n\nsistema arterial (lil\u00e1s). \n\nFigura 10 \u2013 Representa\u00e7\u00e3o esquem\u00e1tica do mecanismo de hepatic arterial \n\nbuffer response (HABR). Segmento de l\u00f3bulo hep\u00e1tico em \n\ncondi\u00e7\u00f5es normais, demonstrando o fluxo sinusoidal \n\npreferencialmente pela veia porta (A). Condi\u00e7\u00f5es que levam \u00e0 \n\nredu\u00e7\u00e3o do fluxo portal, ocasionando, essencialmente ac\u00famulo de \n\nadenosina no espa\u00e7o de Mall, representada pela estrelas vermelhas \n\n(B). Aumento compensat\u00f3rio do fluxo pela art\u00e9ria hep\u00e1tica com \n\nwashout da adenosina (C).  \n\nFigura 11 \u2013 Representa\u00e7\u00e3o esquem\u00e1tica do suprimento sangu\u00edneo da art\u00e9ria \n\nhep\u00e1tica e da veia porta aos sinus\u00f3ides, com indica\u00e7\u00e3o do shunt \n\narteriolo-portal intra-hep\u00e1tico sob condi\u00e7\u00f5es normais (A) e sob \n\ncondi\u00e7\u00f5es de redu\u00e7\u00e3o do fluxo venoso portal com indu\u00e7\u00e3o da \n\nHABR (B) \n\nFigura 12 \u2013 Angiocintilografia hep\u00e1tica ilustrando as curvas tempo\u2013\n\natividade do f\u00edgado e do rim (esta \u00faltima utilizada para determinar \n\ntemporalmente os fluxos da art\u00e9ria hep\u00e1tica \u2013 G1 e veia porta \u2013 \n\nG2). As imagens demosntram uma cintilografia normal, com IPH \n\nem torno de 30% (A), um paciente cirr\u00f3tico com IPH pr\u00f3ximo de \n\n60% e um paciente cirr\u00f3tico com fluxo portal reverso e IPH \n\npr\u00f3ximo de 130% (C). \n\nFigura 13 \u2013 Fluxograma das etapas da Pesquisa. \n\nFigura 14 \u2013 Passo a passo da angiocintilografia hep\u00e1tica. (A) Demarca\u00e7\u00e3o do \n\nROI sobre o rim na imagem cintilogr\u00e1fica din\u00e2mica. (B) \n\nObten\u00e7\u00e3o da curva de tempo\u2013atividade renal com a defini\u00e7\u00e3o do \n\npico de capta\u00e7\u00e3o renal em 21 segundos. (C) Demarca\u00e7\u00e3o de ROIs \n\nsobre o f\u00edgado e ba\u00e7o, inicialmente em imagem cintilogr\u00e1fica \n\nest\u00e1tica e posteriormente (D) em imagem din\u00e2mica. (E) Obten\u00e7\u00e3o \n\nda curva de tempo\u2013atividade hep\u00e1tica com defini\u00e7\u00e3o do ponto \n\ncoincidente com o pico de capta\u00e7\u00e3o renal. (F) Obten\u00e7\u00e3o das \n\n\u201c\u00e1reas sobre a curva\u201d 10 segundos antes \u2013 G1 \u2013 e 10 segundos \n\nap\u00f3s \u2013 G2 \u2013 o pico de capta\u00e7\u00e3o renal para o c\u00e1lculo do \u00cdndice de \n\nPerfus\u00e3o Hep\u00e1tico. \n\n35 \n\n \n\n \n\n \n\n \n \n\n42 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\n43 \n \n\n \n\n \n\n \n\n \n\n \n46 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\n52 \n \n\n57 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\nxvi \n \n\nFigura 15. \u2013 Comparison of three time-activity curves. (A) control patient \n\nwith a HPI of 35% (B and C) patients with HSS with a HPI of \n\n47% and 48%, respectively. The dashed line indicates the \n\nmoment of the renal artery capture peak, used to delimit the \n\nhepatic artery and portal phases of liver perfusion. It is observed \n\na greater total liver uptake and a more pronounced arterial inflow.  \n\n \n\nFigura 16. \u2013 Scatterplot graphic for correlation of variables. Positive \n\ncorrelations through their respective trend lines and Pearson's \n\ncorrelation coefficient (?) between increased HPI and increased \n\nlongitudinal spleen length (A) and diameter of the portal vein (B) \n\nand a negative correlation between the increase in HPI and the \n\ntotal platelet count (C). \n\n \n\nFigura 17. \u2013 ROC curves. (A) Spleen ROC curve showing the best splenic \n\nlongitudinal length to predict an increased HPI at the cutoff point \n\n(?), corresponding to 14,4cm with a sensibility of 0,78 and \n\nspecificity of 0,90 and an AUC of 0,90 (B) HPI  ROC curve \n\nshowing the good accuracy of the HPI in predicting occurrence \n\nof large esophageal varices. Using the cutoff point (?), \n\ncorresponding to a HPI of 45%, it is possible to predict the \n\npresence of large varices with a sensibility of 1,0 and a specificity \n\nof 0,92, with an AUC of 0,96. \n\n85 \n\n \n\n \n\n \n\n \n\n \n\n \n\n87 \n\n \n\n \n\n \n\n \n\n \n\n \n\n88 \n\n \n\n\n\nxvii \n \n\nLISTA DE TABELAS \n\n \n\nTabela 1. \u2013 Sonographic findings \n\n \n\n \n\nTabela 2. \u2013 Results of Hepatic Perfusion Index (HPI) obtained by \n\nangioscintigraphy in patients with hepatosplenic schistosomiasis. \n\nThese patients were divided into two groups with respectively \n\nnormal and increased HPI. Differences between variables were \n\nanalyzed, with statistical significance of the HPI compared with \n\nnormal individuals, the presence of large varices (F3) and the \n\nlength of the spleen.\n\n \n\n \n\n84 \n\n \n\n86 \n\n \n\n\n\n0 \n \n\nSUM\u00c1RIO \n\n1. APRESENTA\u00c7\u00c3O .................................................................................................. 17 \n\n2. REFERENCIAL TE\u00d3RICO ....................................................................................... 20 \n\n2.1. Esquistossomose Mansoni ....................................................................................... 21 \n\n2.1.1. Aspectos Gerais e Epidemiol\u00f3gicos  .............................................................. 21 \n\n2.1.2. Esquistossomose Mansoni Forma Hepatoespl\u00eanica ....................................... 23 \n\n2.1.3. Ultrassonografia na Esquistossomose Hepatoespl\u00eanica.................................. 28 \n\n2.1.4. Altera\u00e7\u00f5es Hemodin\u00e2micas da Esquistossomose Hepatoespl\u00eanica................. 31 \n\n2.1.5. Hepatic Arterial Buffer Response ............................................................... 40 \n\n2.1.6. Cintilografia de Perfus\u00e3o Hep\u00e1tica ............................................................... 44 \n\n2.2. Justificativa .............................................................................................................. 48 \n\n2.3. Objetivos .............................................................................................................. 49 \n\n2.3.1. Objetivo Geral ....................................................................................... 49 \n\n2.3.2. Objetivos Espec\u00edficos ....................................................................................... 49 \n\n2.4. Hip\u00f3teses .............................................................................................................. 50 \n\n3. M\u00c9TODO .............................................................................................................. 51 \n\n3.1. Delineamento do Estudo ............................................................................................ 52 \n\n3.2. Local e Popula\u00e7\u00e3o do Estudo ..................................................................................... 53 \n\n3.2.1. Crit\u00e9rios de Inclus\u00e3o ........................................................................................ 53 \n\n3.2.2. Crit\u00e9rios de Exclus\u00e3o ....................................................................................... 53 \n\n3.3. Defini\u00e7\u00e3o e Categoriza\u00e7\u00e3o das Vari\u00e1veis .................................................................. 54 \n\n3.4. An\u00e1lise estat\u00edstica ...................................................................................................... 55 \n\n3.5. Aspectos \u00c9ticos ..........................................................................................................56 \n\n4. INCREASED HEPATIC ARTERIAL BLOOD FLOW MEASURED BY HEPATIC \n\nPERFUSION INDEX IN HEPATOSPLENIC SCHISTOSOMIASIS: NEW \n\nCONCEPTS OF AN OLD DISEASE ........................................................................... 58 \n\n\n\n1 \n \n\n5. HEMODYNAMIC CHANGES IN THE INTRA-HEPATIC CIRCULATION OF \n\nHEPATOSPLENIC SCHISTOSOMIASIS: THE ROLE OF HEPATIC ARTERY \n\n.............................................................................................................................................87 \n\n6. CONCLUS\u00d5ES E CONSIDERA\u00c7\u00d5ES FINAIS ................................................. 107 \n\n \n\nREFER\u00caNCIAS .................................................................................................................. 109 \n\n \n\nAP\u00caNDICES ........................................................................................................................ 119 \n\nAp\u00eandice A. \u2013 Protocolo de cintilografia de perfus\u00e3o de f\u00edgado e ba\u00e7o com enxofre \n\ncoloidal ..................................................................................................................... 120 \n\nAp\u00eandice B. \u2013 Termo de Consentimento Livre e Esclarecido ................................. 121 \n\nAp\u00eandice C. \u2013 Cover Letter e comprovante de submiss\u00e3o ao Digestive Disease and Sciences \n\ndo artigo de revis\u00e3o .................................................................................................... 123 \n\nAp\u00eandice D. \u2013 Cover Letter e Artigo publicado na Digestive Disease and Sciences \n\n.................................................................................................................................. 125 \n\n \n\nANEXOS .............................................................................................................................. 138 \n\nAnexo 1. \u2013 Parecer do Comit\u00ea de \u00c9tica e Pesquisa ................................................. 139 \n\nAnexo 2. \u2013 Instru\u00e7\u00f5es para publica\u00e7\u00e3o do Digestive Disease and Sciences \n\n.................................................................................................................................. 140 \n\n \n\n\n\n17 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAPRESENTA\u00c7\u00c3O \n\n \n\n\n\n18 \n \n\n1. APRESENTA\u00c7\u00c3O \n\n \n\nA esquistossomose mansoni \u00e9 uma doen\u00e7a infecto-parasit\u00e1ria causada por vermes do g\u00eanero \n\nSchistosoma e esp\u00e9cie Schistosoma mansoni \u2013 \u00fanica esp\u00e9cie descrita no Brasil (PEREIRA; \n\nTORRES, 1994). \u00c9 considerada end\u00eamica em 78 pa\u00edses da \u00c1frica, \u00c1sia, Am\u00e9ricas Central e do \n\nSul, ocorre nas localidades sem saneamento ou com saneamento b\u00e1sico inadequado (WHO, \n\n2013). Apesar de n\u00e3o haver um inqu\u00e9rito mundial espec\u00edfico para a esquistossomose \n\nmans\u00f4nica, estima-se que cerca de 200 milh\u00f5es de pessoas estejam infectadas pelo Schistosoma \n\nna \u00c1frica, \u00c1sia e Am\u00e9rica do Sul, 20 milh\u00f5es apresentando doen\u00e7a grave e outras 600 milh\u00f5es \n\nde pessoas estejam sob risco de contra\u00ed-la (ROSS et al., 2002; STEINMANN et al., 2006).  \n\n \n\nO nordeste brasileiro concentra 64,6% das mortes relacionadas \u00e0 esquistossomose, com taxas \n\nde mortalidade muito acima da m\u00e9dia nacional (MINIST\u00c9RIO DA SA\u00daDE, 2013). O Estado \n\nde Pernambuco apresenta alta endemicidade com 93 munic\u00edpios, 43 dos quais localizados na \n\nZona da Mata, end\u00eamicos para a doen\u00e7a (SILVA; DOMINGUES, 2011). A preval\u00eancia m\u00e9dia \n\nda doen\u00e7a no estado \u00e9 de 15,2%, por\u00e9m algumas localidades atingem a alarmante m\u00e9dia acima \n\nde 80%, como o munic\u00edpio de S\u00e3o Louren\u00e7o da Mata (BARBOSA; DA SILVA; BARBOSA, \n\n1996). Nos \u00faltimos anos a doen\u00e7a vem se expandindo para periferia das grandes cidades e para \n\ntoda Zona Litoral do Estado (GON\u00c7ALVES et al., 1991; BARBOSA et al., 2014). \n\n \n\nQuase todos os indiv\u00edduos infectados pelo S. mansoni t\u00eam algum grau de envolvimento \n\nhep\u00e1tico. A forma hepatoespl\u00eanica (EHE) constitui a fase evolutiva mais grave, por\u00e9m mais \n\nt\u00edpica da doen\u00e7a esquistossom\u00f3tica (DOMINGUES; DOMINGUES, 1994). Observam-se como \n\naltera\u00e7\u00f5es dominantes les\u00f5es obstrutivas da veia porta associadas \u00e0 hipertrofia do territ\u00f3rio da \n\nart\u00e9ria hep\u00e1tica. Em estudos de modelos pl\u00e1sticos da vasculariza\u00e7\u00e3o intra-hep\u00e1tica a veia porta \n\nmostra-se reduzida e a menos proeminente dos tr\u00eas setores vasculares (ANDRADE, 2004, \n\n2009). As altera\u00e7\u00f5es no leito vascular da art\u00e9ria hep\u00e1tica descritas como uma intensa rede \n\narterial podem ser consideradas compensat\u00f3rias \u00e0 diminui\u00e7\u00e3o da perfus\u00e3o venosa portal \n\n(MAGALH\u00c3ES-FILHO; MENEZES; COELHO, 1960; HIDAYAT; WAHID, 1971) .  \n\n \n\nA cintilografia de perfus\u00e3o hep\u00e1tica ou angiocintilografia \u00e9 um m\u00e9todo radioisot\u00f3pico utilizado \n\nna investiga\u00e7\u00e3o da perfus\u00e3o do f\u00edgado e suas altera\u00e7\u00f5es nas diferentes doen\u00e7as hep\u00e1ticas, \n\nespecialmente a cirrose e met\u00e1stases colorretais intra-hep\u00e1ticas (KORANDA et al., 1999; \n\n\n\n19 \n \n\nWARREN et al., 1998). Ela mede as fra\u00e7\u00f5es dos fluxos arterial e venoso portal do total de fluxo \n\nsangu\u00edneo hep\u00e1tico. A avalia\u00e7\u00e3o angiocintilogr\u00e1fica do fluxo arterial hep\u00e1tico em cirr\u00f3ticos \u00e9 \n\nfeita atrav\u00e9s do c\u00e1lculo do \u00edndice de perfus\u00e3o hep\u00e1tico (IPH). Ele consiste da raz\u00e3o entre o fluxo \n\npela art\u00e9ria hep\u00e1tica e o fluxo hep\u00e1tico total (O\u2019CONNOR et al., 1992; PANDHARIPANDE et \n\nal., 2005). Assim, quando h\u00e1 um aumento da perfus\u00e3o pela art\u00e9ria hep\u00e1tica, observa-se aumento \n\ndo IPH. Nas doen\u00e7as hep\u00e1ticas cr\u00f4nicas, um IPH superior a 50% sugere uma arterializa\u00e7\u00e3o da \n\nperfus\u00e3o hep\u00e1tica guiando o diagn\u00f3stico de hipoperfus\u00e3o portal (DRAGOTEANU et al., 2008).  \n\n \n\nAt\u00e9 o momento, os estudos que utilizaram a cintilografia hep\u00e1tica na esquistossomose foram \n\nlimitados ao aspecto morfol\u00f3gico, n\u00e3o havendo avalia\u00e7\u00e3o das caracter\u00edsticas perfusionais \n\n(RAZZAK, 1964; MUSTAFA et al., 1966; IIO et al., 1971). N\u00e3o h\u00e1, portanto, como na cirrose, \n\navalia\u00e7\u00f5es in vivo das repercuss\u00f5es na hemodin\u00e2mica hep\u00e1tica decorrentes das oclus\u00f5es dos \n\nramos portais e da hipertrofia do setor arterial intra-hep\u00e1ticos na EHE. Uma vez que a \n\nesquistossomose cursa com altera\u00e7\u00f5es da fisiologia da perfus\u00e3o portal secund\u00e1rias \u00e0 redu\u00e7\u00e3o da \n\nvasculariza\u00e7\u00e3o portal intra-hep\u00e1tica, pode-se sugerir que ocorram modifica\u00e7\u00f5es perfusionais \n\nsemelhantes \u00e0 cirrose que podem ser detectadas pela angiocintilografia. \n\nO presente objetiva, por conseguinte, preencher esta lacuna ao verificar altera\u00e7\u00f5es da \n\nhemodin\u00e2mica hep\u00e1tica em esquistossom\u00f3ticos com a forma hepatoespl\u00eanica atrav\u00e9s da \n\ncintilografia de perfus\u00e3o hep\u00e1tica. Busca, tamb\u00e9m, relacionar estas altera\u00e7\u00f5es com vari\u00e1veis \n\ncl\u00ednicas e ultrassonogr\u00e1ficas encontradas na EHE. Portanto, haver\u00e1 mais elementos capazes de \n\nampliar o conhecimento sobre esta enfermidade multifatorial e bastante heterog\u00eanea, podendo \n\nacrescentar novas perspectivas na condu\u00e7\u00e3o de pacientes com EHE \n\n \n\nComo resultado da pesquisa foram produzidos dois artigos. Um artigo de revis\u00e3o sobre as \n\nmodifica\u00e7\u00f5es da hemodin\u00e2mica intra-hep\u00e1tica na esquistossomose hepatoespl\u00eanica e o papel da \n\nart\u00e9ria hep\u00e1tica, intitulado \u201cHemodynamic changes in the intra-hepatic circulation of \n\nhepatosplenic schistosomiasis: the role of hepatic artery\u201d, submetido ao peri\u00f3dico Digestive \n\nDisease and Sciences. O segundo artigo consiste de um artigo original intitulado \u201cHepatic \n\nperfusion index in hepatosplenic schistosomiasis: new concepts of an old disease\u201d no qual se \n\ndemonstra as altera\u00e7\u00f5es da perfus\u00e3o hep\u00e1tica atrav\u00e9s do estudo cintilogr\u00e1fico e se relaciona com \n\nas vari\u00e1veis cl\u00ednicas e ultrassonogr\u00e1ficas conhecidas. Este \u00faltimo artigo foi submetido ao \n\nperi\u00f3dico Journal of Hepatology.  \n\n\n\n20 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nREFERENCIAL TE\u00d3RICO \n\n  \n\n\n\n21 \n \n\n2. REFERENCIAL TE\u00d3RICO \n\n \n\n2.1. Esquistossomose Mansoni \n\n2.1.1. Aspectos Gerais e Epidemiol\u00f3gicos \n\n \n\nA esquistossomose mansoni \u00e9 uma doen\u00e7a infecto-parasit\u00e1ria causada por vermes do g\u00eanero \n\nSchistosoma e esp\u00e9cie Schistosoma mansoni \u2013 \u00fanica esp\u00e9cie descrita no Brasil \u2013, tremat\u00f3deos \n\nde ciclo de vida duplo, cujo hospedeiro definitivo \u00e9 o ser humano (PEREIRA; TORRES, 1994). \n\nApesar de n\u00e3o haver um inqu\u00e9rito mundial espec\u00edfico para a esquistossomose mans\u00f4nica, \n\nestima-se que cerca de 200 milh\u00f5es de pessoas estejam infectadas por parasitas do g\u00eanero \n\nSchistosoma na \u00c1frica, \u00c1sia e Am\u00e9rica do Sul, 20 milh\u00f5es apresentem doen\u00e7a grave (ROSS et \n\nal., 2002) e outras 600 milh\u00f5es de pessoas estejam sob risco de contrair a doen\u00e7a \n\n(STEINMANN et al., 2006). Quase todos os indiv\u00edduos infectados pelo S. mansoni t\u00eam algum \n\ngrau de envolvimento hep\u00e1tico e, dependendo da intensidade da infec\u00e7\u00e3o \u2013 carga parasit\u00e1ria \u2013\n\ncerca de 30% da popula\u00e7\u00e3o infectada apresenta hepatomegalia (WARREN, 1978).  \n\n \n\nDe acordo com estimativas pr\u00e9vias, a infec\u00e7\u00e3o pelo Schistosoma causa uma perda de 1,7 a 4,5 \n\nmilh\u00f5es de anos ajustados de vida incapazes (disability adjusted life years \u2013 DALY), \n\nconsiderado um baixo peso de incapacidade atribu\u00eddo \u00e0 doen\u00e7a. Esse indicador mede a \n\nmorbimortalidade levando em conta os anos de vida perdidos ajustados pela incapacidade ou \n\nos anos de vida potencialmente perdidos por morte prematura devido \u00e0 doen\u00e7a (WHO, 2002). \n\nPor\u00e9m, metan\u00e1lises mais recentes sugerem que este impacto pode ser muito maior quando \n\ntamb\u00e9m demonstram uma significativa associa\u00e7\u00e3o entre a infec\u00e7\u00e3o por Schistosoma e sintomas \n\ncomo diarreia, dor abdominal e fadiga, bem como dados objetivos de anemia, desnutri\u00e7\u00e3o e \n\nredu\u00e7\u00e3o da toler\u00e2ncia ao exerc\u00edcio (KING; DANGERFIELD-CHA, 2008). Nelas, os autores \n\nrelacionam um impacto negativo na qualidade de vida dos indiv\u00edduos infectados com rela\u00e7\u00e3o \u00e0 \n\nredu\u00e7\u00e3o da capacidade laborativa e decl\u00ednio intelectual. Evidenciam uma redu\u00e7\u00e3o m\u00e9dia na \n\nhemoglobina de 4g/dL na presen\u00e7a de infec\u00e7\u00e3o detectada, e que este n\u00edvel de anemia est\u00e1 \n\nassociado \u00e0 redu\u00e7\u00e3o da capacidade ao exerc\u00edcio e da produtividade. Estes trabalhos alertam que, \n\nembora a esquistossomose infrequentemente seja letal, por ser uma infec\u00e7\u00e3o cr\u00f4nica, recorrente \n\ne end\u00eamica em muitas \u00e1reas ao interferir negativamente na condi\u00e7\u00e3o de sa\u00fade da pessoa \n\ninfectada deve ser levada em considera\u00e7\u00e3o independentemente da forma cl\u00ednica ou intensidade \n\nda infec\u00e7\u00e3o, contrariando an\u00e1lises anteriores que davam aten\u00e7\u00e3o apenas aos casos mais graves \n\n(GRYSEELS, 1989). \n\n\n\n22 \n \n\n \n\nNo Brasil, a esquistossomose mans\u00f4nica est\u00e1 presente em 19 das 27 unidades federadas de \n\nforma end\u00eamica ou focal. Entre os anos de 2000 e 2011, das 12.491.280 mortes registradas no \n\nBrasil, a esquistossomose foi mencionada em 8.756 delas. O n\u00famero m\u00e9dio de mortes \n\nrelacionadas \u00e0 esquistossomose foi de 729,7 por ano, com uma m\u00e9dia anual de taxa bruta de \n\nmortalidade de 0,39 por 100.000 habitantes durante esses 12 anos. A taxa ajustada para a idade \n\nfoi de 0,49 mortes por 100.000 habitantes, quando considerada a esquistossomose como causa \n\nsubjacente, havendo um aumento relativo de 40% na m\u00e9dia anual de mortalidade ajustada para \n\na idade ap\u00f3s a inclus\u00e3o da esquistossomose como causa associada (MARTINS-MELO et al., \n\n2014). O nordeste brasileiro concentra 64,6% das mortes relacionadas \u00e0 esquistossomose, com \n\ntaxas de mortalidade muito acima da m\u00e9dia nacional (1,19 mortes por 100.000 habitantes), com \n\nos estados de Alagoas, Pernambuco e Sergipe concentrando a maior preval\u00eancia e \n\npredomin\u00e2ncia de \u00f3bitos do Brasil. A Figura 1 ilustra o perfil geogr\u00e1fico da mortalidade por \n\nesquistossomose mans\u00f4nica no Brasil. \n\n \n\n \n\n \n\nFigura 1 \u2013 Tend\u00eancia da taxa de mortalidade ajustada para a idade relacionada \u00e0 \n\nesquistossomose (por 100.000 habitantes) separada por regi\u00e3o do Brasil de 2000 a 2011. \n\n(Martins-Melo 2014) \n\n \n\n\n\n23 \n \n\nO Estado de Pernambuco apresenta alta endemicidade com 93 munic\u00edpios, 43 dos quais \n\nlocalizados na Zona da Mata, end\u00eamicos para a doen\u00e7a (SILVA; DOMINGUES, 2011). A \n\npreval\u00eancia m\u00e9dia da doen\u00e7a no estado \u00e9 de 15,2% (BARBOSA; DA SILVA; BARBOSA, \n\n1996), por\u00e9m algumas localidades atingem a alarmante m\u00e9dia acima de 80%, como o munic\u00edpio \n\nde S\u00e3o Louren\u00e7o da Mata, onde foi registrada uma preval\u00eancia de 92% no engenho Bela Rosa \n\n(BARBOSA; SILVA, 1992). A expans\u00e3o da esquistossomose para o litoral do Estado vem \n\nsendo registrada desde 1992 com a detec\u00e7\u00e3o de casos agudos da doen\u00e7a em indiv\u00edduos de classe \n\nm\u00e9dia/alta e focos de moluscos vetores da esp\u00e9cie Biomphalaria glabrata (GON\u00c7ALVES et \n\nal., 1991). Estudo de Constan\u00e7a S Barbosa e colaboradores em 2014, por exemplo, ao avaliar a \n\npopula\u00e7\u00e3o de moluscos vetores nos munic\u00edpios litor\u00e2neos de Pernambuco, demonstrou elevada \n\nabund\u00e2ncia de caramujos da esp\u00e9cie B glabrata no balne\u00e1rio de Porto de Galinhas, munic\u00edpio \n\nde Ipojuca. Diferente das demais localidades, somente os caramujos de Porto de Galinhas \n\neliminavam cercarias com uma surpreendente taxa de infec\u00e7\u00e3o de 81,4% (BARBOSA et al., \n\n2014). \n\n \n\n2.1.2. Esquistossomose Mansoni Forma Hepatoespl\u00eanica \n\n \n\nA forma hepatoespl\u00eanica constitui a fase evolutiva mais grave, por\u00e9m mais t\u00edpica da doen\u00e7a \n\nesquistossom\u00f3tica (DOMINGUES; DOMINGUES, 1994). Nela observam-se altera\u00e7\u00f5es \n\nanat\u00f4micas e cl\u00ednicas resultantes de les\u00f5es teciduais hep\u00e1ticas, provocadas por est\u00edmulos \n\nimunocelulares relacionados \u00e0 presen\u00e7a do ovo do verme no f\u00edgado. A maior parte da rea\u00e7\u00e3o \n\ngranulomatosa provocada pelos ant\u00edgenos parasit\u00e1rios ocorre nos s\u00edtios de maior ac\u00famulo de \n\novos (ROSS et al., 2002). O marco anatomopatol\u00f3gico desta fase \u00e9 representado pela deposi\u00e7\u00e3o \n\nintensa e difusa de col\u00e1geno nos espa\u00e7os periportais com o surgimento de fibrose em torno dos \n\nramos intra-hep\u00e1ticos da veia porta, denominada fibrose periportal ou fibrose de Symmers. Esta \n\nfibrose leva, por sua vez, a progressiva semi-oclus\u00e3o e oclus\u00e3o dos ramos venosos portais, \n\nculminando na s\u00edndrome de hipertens\u00e3o portal. S\u00e3o necess\u00e1rios 10 \u2013 15 anos a partir da infec\u00e7\u00e3o \n\npara que esta forma se manifeste (DOMINGUES; DOMINGUES, 1994; GRYSEELS et al., \n\n2006; DOMINGUES, 2010;).  \n\n \n\nNas \u00e1reas end\u00eamicas, a forma hepatoespl\u00eanica \u00e9 encontrada em 4 \u2013 7% dos indiv\u00edduos \n\ninfectados (ROSS et al., 2002; DOMINGUES, 2010; FI\u00daZA, MATEUS PONTES, VILAS-\n\nBOAS, LIVIA, LYRA, 2011). Ocorre em indiv\u00edduos com alta carga parasit\u00e1ria, com m\u00faltiplas \n\ne sucessivas infec\u00e7\u00f5es e com uma resposta imunol\u00f3gica exacerbada quer do tipo celular Th1, \n\n\n\n24 \n \n\nsem que haja a imunomodula\u00e7\u00e3o, resultando na forma\u00e7\u00e3o de granulomas periovulares \n\nhiper\u00e9rgicos e maior est\u00edmulo para o desenvolvimento de fibrose, ou uma exacerba\u00e7\u00e3o da \n\nresposta Th2 com aumento de produ\u00e7\u00e3o de IL4 e IL13, citocinas fibrog\u00eanicas. Um mediador \n\nfibrog\u00eanico produzido por linf\u00f3citos CD4 e por fibroblastos ativados mostraram ser um grande \n\nest\u00edmulo para a prolifera\u00e7\u00e3o fibrobl\u00e1stica e aumento na bioss\u00edntese do col\u00e1geno. Deve haver \n\num balan\u00e7o entre as respostas Th1 e Th2, pois uma resposta imune exacerbada para qualquer \n\nlado \u00e9 patol\u00f3gica. (WARREN, 1975; MAGALH\u00c3ES-FILHO; SILVA, 1994; WILSON et al., \n\n2007; CHAWLA; DHIMAN, 2008; DOMINGUES, 2010; SOUZA et al., 2011).  \n\n \n\nAntes das campanhas de busca ativa e tratamento em massa elaboradas pelo governo federal \n\n(PECE \u2013 Programa Especial de Controle da Esquistossomose; PCE \u2013 Programa de Controle da \n\nEsquistossomose), e do surgimento do oxaminiquine e do praziquantel, drogas extremamente \n\neficazes e de posologia de tomada \u00fanica, a faixa et\u00e1ria dos indiv\u00edduos com a forma \n\nhepatoespl\u00eanica da esquistossomose girava em torno de 15 \u2013 30 anos (DOMINGUES, 2010). \n\nAtualmente, ap\u00f3s estes eventos, no Nordeste, especialmente em Pernambuco, houve uma \n\nredu\u00e7\u00e3o na preval\u00eancia das formas hepatoespl\u00eanica, melhora no quadro cl\u00ednico e aumento da \n\nfaixa et\u00e1ria acometida, passando a ocorrer entre 30 \u2013 50 anos (ANDRADE; BINA, 1985; \n\nDOMINGUES; DOMINGUES, 1994; DOMINGUES, 2010).  \n\n \n\nA EHE caracteriza-se pela hepatoesplenomegalia. O f\u00edgado pode estar aumentado de volume, \n\nno in\u00edcio de forma homog\u00eanea e reflete a presen\u00e7a da inflama\u00e7\u00e3o granulomatosa que ocorre \n\nprecocemente na evolu\u00e7\u00e3o da doen\u00e7a cr\u00f4nica (ROSS et al., 2002). Com a progress\u00e3o da fibrose \n\nperiportal e o surgimento da hipertens\u00e3o portal, este aumento se d\u00e1 especialmente \u00e0 custa do \n\nlobo esquerdo, devido ao fluxo venoso espl\u00eanico que tende a dirigir-se preferencialmente ao \n\nlobo esquerdo, com consequente diminui\u00e7\u00e3o do fluxo sangu\u00edneo ao lobo direito, levando a sua \n\natrofia (DOMINGUES, 2010). A superf\u00edcie hep\u00e1tica exibe um aspecto grosseiro, com \n\nondula\u00e7\u00f5es ligeiramente profundas, com a c\u00e1psula irregularmente espessada, podendo assumir \n\naspecto nodular (MAGALH\u00c3ES-FILHO; SILVA, 1994; ANDRADE, 2004), como mostra a \n\nFigura 2. Macroscopicamente, na superf\u00edcie de corte, a fibrose de Symmers apresenta-se como \n\nfaixas ou eixos fibrosos que se irradiam do hilo ao longo dos espa\u00e7os portais. A Figura 3 ilustra \n\neste aspecto macrosc\u00f3pico. A arquitetura lobular, no entanto, est\u00e1 preservada sem a forma\u00e7\u00e3o \n\ndos n\u00f3dulos de regenera\u00e7\u00e3o na cirrose, como ilustra a Figura 4 (DE COCK, 1986; ROSS et al., \n\n2002; ANDRADE, 2004).  \n\n \n\n\n\n25 \n \n\n \n\n \n\n \n\nFigura 2 \u2013 Aspecto do f\u00edgado esquistossom\u00f3tico na forma hepatoespl\u00eanica com intensa \n\nfibrose in vivo. (Lambertucci,  J. R. 2009) \n\n \n\n \n\nFigura 3 \u2013 Aspecto de corte do f\u00edgado esquistossom\u00f3tico na forma hepatoespl\u00eanica \n\nevidenciando a fibrose periportal de Symmers. (http://anatpat.unicamp.br/pecasfig8.html) \n\n \n\nhttp://anatpat.unicamp.br/pecasfig8.html\n\n\n26 \n \n\n \n\nFigura 4 \u2013 Aspecto microsc\u00f3pico de f\u00edgado esquistossom\u00f3tico mostrando a preserva\u00e7\u00e3o do \n\npar\u00eanquima hep\u00e1tico a despeito da intensa fibrose em torno dos ramos portais intra-\n\nhep\u00e1ticos. (Filho, HSL \u2013 www.medimagemsp.com.br) \n\n \n\nO ba\u00e7o cresce inicialmente devido \u00e0 prolifera\u00e7\u00e3o das c\u00e9lulas do sistema reticuloendotelial \n\nespl\u00eanico provocada pelo est\u00edmulo antig\u00eanico dos produtos do ovo e do pr\u00f3prio verme. Com o \n\nsurgimento da hipertens\u00e3o portal, altera\u00e7\u00f5es congestivas se somam aos fen\u00f4menos \n\nhiperpl\u00e1sicos, havendo congest\u00e3o e dilata\u00e7\u00e3o intra-espl\u00eanicas e fibrose dos cord\u00f5es espl\u00eanicos \n\n(MAGALH\u00c3ES-FILHO; SILVA, 1994; DOMINGUES, 2010). A esquistossomose \u00e9 uma das \n\ndoen\u00e7as que cursam com as maiores esplenomegalias, podendo o ba\u00e7o ultrapassar 1 kg, \n\ngeralmente relacionada \u00e0 intensidade da infec\u00e7\u00e3o (DE COCK, 1986). \n\n \n\nClinicamente, na fase compensada da esquistossomose hepatoespl\u00eanica, os pacientes \n\ngeralmente s\u00e3o jovens e se apresentam em bom estado geral com pouca sintomatologia e sem \n\nsinais de doen\u00e7a hep\u00e1tica cr\u00f4nica. Os sintomas mais frequentes, quando presentes, s\u00e3o de \n\nfraqueza, falta de apetite, plenitude p\u00f3s-prandial, dores abdominais, sensa\u00e7\u00e3o de peso em \n\nhipoc\u00f4ndrio esquerdo e epis\u00f3dios de diarreia espor\u00e1dicos, alternados com evacua\u00e7\u00e3o normal ou \n\nper\u00edodos de constipa\u00e7\u00e3o (DOMINGUES; DOMINGUES, 1994; DOMINGUES, 2010). A \n\nfibrose periportal leva a uma obstru\u00e7\u00e3o ao fluxo portal vindo do sistema esplenomesent\u00e9rico \n\nque, associado ao hiperfluxo portal secund\u00e1rio \u00e0 esplenomegalia geram a s\u00edndrome de \n\nhipertens\u00e3o portal, traduzida clinicamente pela forma\u00e7\u00e3o de varizes esof\u00e1gicas e epis\u00f3dios de \n\n\n\n27 \n \n\nhemorragia digestiva alta. Na forma hepatoespl\u00eanica, as varizes esof\u00e1gicas t\u00eam sido \n\ndemonstradas em at\u00e9 80% dos pacientes (DOMINGUES; DOMINGUES, 1994).  \n\n \n\nA fun\u00e7\u00e3o de s\u00edntese hep\u00e1tica mostra-se conservada, evidenciando-se albumina, bilirrubinas e \n\ntempo de protrombina normais. As aminotransferases est\u00e3o normais ou ligeiramente elevadas. \n\nA eleva\u00e7\u00e3o das enzimas canaliculares, fosfatase alcalina e gama-glutamil-transferase ocorrem \n\ndevido \u00e0 les\u00e3o ductular provocada pela resposta inflamat\u00f3ria consequente \u00e0 presen\u00e7a dos \n\ngranulomas no espa\u00e7o porta, e pela distor\u00e7\u00e3o da arquitetura decorrente da fibrose periportal, \n\ncom altera\u00e7\u00f5es ductop\u00eanicas (DOMINGUES; DOMINGUES, 1994; OLIVEIRA; ANDRADE, \n\n2005; BRANT et al., 2008; DOMINGUES, 2010; FI\u00daZA, MATEUS PONTES, VILAS-\n\nBOAS, LIVIA, LYRA, 2011). As altera\u00e7\u00f5es relacionadas \u00e0 esplenomegalia s\u00e3o as citopenias \n\n(anemia, leucopenia e plaquetopenia) devido ao sequestro espl\u00eanico \u2013 hiperesplenismo \u2013, \n\ngeralmente sem repercuss\u00e3o cl\u00ednica e discreta eleva\u00e7\u00e3o de bilirrubina indireta por hem\u00f3lise \n\nintra-espl\u00eanicas (DE COCK, 1986).  \n\n \n\nA esplenomegalia possui uma rela\u00e7\u00e3o direta com a gravidade da doen\u00e7a hep\u00e1tica, com maiores \n\ndi\u00e2metros longitudinais sendo encontrados nas fibroses mais avan\u00e7adas, ao passo que a \n\nplaquetopenia apresenta rela\u00e7\u00e3o inversa. (LEITE et al., 2013; MEDEIROS et al., 2014). A \n\neosinofilia geralmente tem rela\u00e7\u00e3o com a atividade da doen\u00e7a, com pacientes excretando mais \n\novos nas fezes (DOMINGUES; DOMINGUES, 1994; DOMINGUES, 2010; FI\u00daZA, \n\nMATEUS PONTES, VILAS-BOAS, LIVIA, LYRA, 2011).  \n\n \n\nA fase descompensada da doen\u00e7a apresenta-se do ponto de vista cl\u00ednico e laboratorial \n\nindistingu\u00edvel da cirrose propriamente dita. Esta fase geralmente surge ap\u00f3s alguma \n\ncomplica\u00e7\u00e3o da esquistossomose, caracteristicamente eventos repetidos de hemorragia \n\ndigestiva que levam a uma perda proteica e a epis\u00f3dios de sofrimento hep\u00e1tico, ou a associa\u00e7\u00e3o \n\ncom outra doen\u00e7a hep\u00e1tica cr\u00f4nica, particularmente as hepatites virais e a doen\u00e7a hep\u00e1tica \n\nalco\u00f3lica (DOMINGUES; DOMINGUES, 1994; DOMINGUES, 2010; SOUZA et al., 2011).  \n\n \n\n \n\n \n\n \n\n\n\n28 \n \n\n2.1.3. Ultrassonografia na Esquistossomose Hepatoespl\u00eanica \n\n \n\nA ultrassonografia tem sido usada como uma fidedigna e reprodut\u00edvel t\u00e9cnica, sendo, \n\natualmente, exame de escolha para o diagn\u00f3stico das altera\u00e7\u00f5es hep\u00e1ticas, espl\u00eanicas e da \n\ncircula\u00e7\u00e3o hepato-portal provocadas pela esquistossomose. N\u00e3o apenas sua sensibilidade e \n\nespecificidade j\u00e1 foram comprovadas em diversas regi\u00f5es end\u00eamicas, mas trata-se de exame \n\nn\u00e3o-invasivo, in\u00f3cuo, econ\u00f4mico e podendo ser repetido periodicamente (PINTO-SILVA et al., \n\n2010; SEBASTIANES et al., 2010). Nas fases iniciais da fibrose periportal, a ultrassonografia \n\n\u00e9 pouco sens\u00edvel e muito dependente da experi\u00eancia do examinador. No entanto, pode tornar-\n\nse at\u00e9 mais sens\u00edvel que a bi\u00f3psia hep\u00e1tica no diagn\u00f3stico da fibrose de Symmers nas fases mais \n\navan\u00e7adas (ABDEL-WAHAB et al., 1992).  \n\n \n\nExistem diferentes classifica\u00e7\u00f5es ecogr\u00e1ficas propostas para a avalia\u00e7\u00e3o das altera\u00e7\u00f5es da \n\nesquistossomose. As mais utilizadas s\u00e3o a do Cairo e a de Niamey. A classifica\u00e7\u00e3o quantitativa \n\ndo Cairo de 1992 classifica a fibrose periportal em tr\u00eas graus, dependendo da espessura dos \n\nramos portais ap\u00f3s a terceira bifurca\u00e7\u00e3o: grau I de 3-5 mm, grau II de 5-7 mm e grau III acima \n\nde 7 mm. A classifica\u00e7\u00e3o de Niamey, entretanto, \u00e9 do tipo qualitativa e baseia-se em padr\u00f5es \n\nde imagem preestabelecidos, como mostra a Figura 5 (ABDEL-WAHAB et al., 1992; \n\nRICHTER et al., 2000). M\u00e9todos descritivos mostraram-se mais satisfat\u00f3rios em rela\u00e7\u00e3o aos \n\nquantitativos, que devem ser interpretados com cautela. A especificidade da classifica\u00e7\u00e3o do \n\nCairo para doen\u00e7a precoce tem sido questionada, com relatos de superestima\u00e7\u00e3o das altera\u00e7\u00f5es \n\nperiportais. Em outras situa\u00e7\u00f5es a classifica\u00e7\u00e3o do Cairo leva \u00e0 subestima\u00e7\u00e3o da fibrose nos \n\ncasos j\u00e1 complicados com hemorragia digestiva varicosa. Por outro lado, gradua\u00e7\u00f5es por \n\nm\u00e9todos qualitativos t\u00eam boa correla\u00e7\u00e3o com os achados cl\u00ednicos e parasitol\u00f3gicos, permitindo \n\nprever complica\u00e7\u00f5es. Uma grande vantagem da avalia\u00e7\u00e3o ultrassonogr\u00e1fica qualitativa \u00e9 \n\napresentar menor variabilidade inter e intra-observador (RICHTER, 2000).  \n\n \n\n\n\n29 \n \n\n \n\nFigura 5 \u2013 Classifica\u00e7\u00e3o ultrassonogr\u00e1fica de Niamey para as altera\u00e7\u00f5es hep\u00e1ticas da \n\nesquistossomose. (A) Padr\u00e3o A \u2013 F\u00edgado Normal. (B) Padr\u00e3o B \u2013 Pronunciada \n\necogenicidade dos ramos portais perif\u00e9ricos \u2013 \u201cpadr\u00e3o de c\u00e9u estrelado\u201d. (C) Padr\u00e3o C \u2013 \n\nEspessamento periportal perif\u00e9rico. (D) Padr\u00e3o D \u2013 Espessamento periportal central. (E) \n\nPadr\u00e3o E \u2013 Espessamento periportal central com bandas ecog\u00eanicas expandindo pelo \n\npar\u00eanquima. (F) Padr\u00e3o F \u2013 Espessamento periportal central e perif\u00e9rico avan\u00e7ado. \n(WHO, 2000) \n\n \n\nAs principais altera\u00e7\u00f5es \u00e0 ultrassonografia na esquistossomose hepatoespl\u00eanica s\u00e3o o aumento \n\nvolum\u00e9trico do lobo esquerdo do f\u00edgado, com atrofia relativa do lobo direito, aumento da \n\necogenicidade ao redor dos vasos portais do hilo \u00e0 periferia do f\u00edgado. Em casos mais avan\u00e7ados \n\na superf\u00edcie hep\u00e1tica pode apresentar pseudon\u00f3dulos como resultado da fibrose e retra\u00e7\u00e3o da \n\nc\u00e1psula. A parede da ves\u00edcula biliar tamb\u00e9m pode se apresentar espessada e hiperecog\u00eanica. O \n\nba\u00e7o frequentemente encontra-se aumentado de volume. Anormalidades relacionadas \u00e0 \n\nhipertens\u00e3o portal s\u00e3o demonstradas pelo aumento do calibre das veias porta e espl\u00eanica e \n\npresen\u00e7a de circula\u00e7\u00e3o colateral portossist\u00eamica com fluxo hepatofugal. As colaterais mais \n\nfrequentes s\u00e3o a veia g\u00e1strica esquerda, g\u00e1stricas curtas, espleno-renal, retroperitoneal e \n\nparaumbilical. Trombose da veia porta, tamb\u00e9m foi um achado descrito na esquistossomose \n\nhepatoespl\u00eanica (ABDEL-WAHAB et al., 1989; VEZOZZO et al., 2006; AZEREDO et al., \n\n2010; PINTO-SILVA et al., 2010; SKELLY, 2013). As veias hep\u00e1ticas mant\u00eam-se patentes \n\n\n\n30 \n \n\ncom fluxo f\u00e1sico normal. Ferreira et al, em avalia\u00e7\u00e3o da hemodin\u00e2mica portal com \n\nultrassonografia Doppler, ap\u00f3s a cirurgia de desvasculariza\u00e7\u00e3o esofagog\u00e1strica e \n\nesplenectomia, observou que antes da cirurgia havia uma resist\u00eancia intra-hep\u00e1tica aumentada \n\ncom redu\u00e7\u00e3o da propor\u00e7\u00e3o da veia porta no fluxo hep\u00e1tico total. Ap\u00f3s a cirurgia detectou \n\nredu\u00e7\u00e3o do calibre da veia porta, bem como na velocidade de fluxo (FERREIRA et al., 2009). \n\nN\u00e3o h\u00e1 consenso quanto \u00e0s altera\u00e7\u00f5es do fluxo da art\u00e9ria hep\u00e1tica ao ultrassom (PINTO-SILVA \n\net al., 2010).  \n\n \n\nAzeredo em tese de doutorado avaliou diversos aspectos ultrassonogr\u00e1ficos e \n\ndopplervelocim\u00e9tricos da esquistossomose. Entre os achados hemodin\u00e2micos, foi observado \n\nque havia maior dificuldade em identificar a art\u00e9ria hep\u00e1tica nos doentes de zona end\u00eamica com \n\nfibrose hep\u00e1tica avan\u00e7ada e maiores espessamentos da veia porta, n\u00e3o identificando a art\u00e9ria \n\nem 13,2% dos 554 doentes estudados. Nos demais foi observado que a art\u00e9ria hep\u00e1tica \n\napresentava-se com calibre normal em quase todos os pacientes, estando apenas 1% (5 \n\npacientes) com aumento da art\u00e9ria. O \u00edndice de resistividade tamb\u00e9m apresentava-se dentro dos \n\nlimites da normalidade \u2013 com m\u00e9dia de 0,7. Foi observada uma correla\u00e7\u00e3o direta entre o calibre \n\nda veia porta e da art\u00e9ria hep\u00e1tica, demonstrando que os di\u00e2metros dos dois vasos aumentavam \n\nou diminu\u00edam paralelamente. Viu-se, tamb\u00e9m, uma correla\u00e7\u00e3o entre a velocidade m\u00e1xima de \n\nfluxo na veia porta e a velocidade de pico sist\u00f3lico da art\u00e9ria hep\u00e1tica, revelando que na \n\nesquistossomose n\u00e3o h\u00e1, como na cirrose, uma rela\u00e7\u00e3o inversa entre os fluxos arterial e portal, \n\nou seja, quando o fluxo portal aumenta, o fluxo arterial diminui e vice-versa (AZEREDO, 2009) \n\n \n\nAlguns achados ultrassonogr\u00e1ficos apresentaram correla\u00e7\u00e3o com a gravidade da doen\u00e7a \n\nesquistossom\u00f3tica, bem como risco de complica\u00e7\u00f5es. O grau de fibrose hep\u00e1tica estimada pela \n\nultrassonografia, seja por avalia\u00e7\u00f5es quantitativas ou qualitativas, correlacionou-se \n\npositivamente com a gravidade cl\u00ednica da doen\u00e7a e com o risco de hemorragia digestiva \n\nvaricosa (ABDEL-WAHAB et al., 1993; DOMINGUES et al., 1993; KING et al., 2003). Outras \n\naltera\u00e7\u00f5es, isoladamente ou em conjunto, tamb\u00e9m tiveram o poder de estimar gravidade e risco \n\nde complica\u00e7\u00f5es hemorr\u00e1gicas, como o aumento do calibre das veias porta e espl\u00eanica, di\u00e2metro \n\nlongitudinal espl\u00eanico, presen\u00e7a e calibre de colaterais portossist\u00eamicos, aumento da \n\nvelocidade de fluxo nas veias porta e espl\u00eanica e redu\u00e7\u00e3o do \u00edndice de congest\u00e3o da veia porta \n\n\u2013 calculado pelo quociente da \u00e1rea transversal da veia porta em cm2 pela velocidade do fluxo \n\nsangu\u00edneo em cm/sec (ABDEL-WAHAB; ESMAT, 1992; ABDEL-WAHAB et al., 1993; \n\nMARTINS et al., 2000; DE ARRUDA; BARRETO; DO AMARAL, 2008).  \n\n\n\n31 \n \n\n2.1.4. Altera\u00e7\u00f5es Hemodin\u00e2micas da Esquistossomose Hepatoespl\u00eanica \n\n \n\nA hepatopatia esquistossom\u00f3tica representa um tipo especial de doen\u00e7a hep\u00e1tica cr\u00f4nica, a qual \n\napresenta caracter\u00edsticas peculiares que a diferenciam das encontradas na cirrose especialmente \n\nno que concernem as altera\u00e7\u00f5es vasculares (ANDRADE, 2004). A esquistossomose avan\u00e7ada \n\nproduz uma das mais caracter\u00edsticas apresenta\u00e7\u00f5es da patologia hep\u00e1tica, a fibrose de Symmers. \n\nNa superf\u00edcie de corte, observam-se placas fibr\u00f3ticas esbranqui\u00e7adas ocupando espa\u00e7os portais \n\nsobre um par\u00eanquima hep\u00e1tico de aspecto normal, sem a forma\u00e7\u00e3o de septos fibrosos e n\u00f3dulos \n\nregenerativos t\u00edpicos da cirrose (STRAUSS, 2002).  \n\n \n\nA fibrose hep\u00e1tica provavelmente n\u00e3o \u00e9 importante por si s\u00f3. O espa\u00e7o ocupado pela fibrose \n\nnas doen\u00e7as cr\u00f4nicas do f\u00edgado n\u00e3o \u00e9 suficiente para ter impacto na fisiologia de um \u00f3rg\u00e3o com \n\ntamanha reserva funcional. O significado da fibrose hep\u00e1tica est\u00e1 relacionado ao fato dessa \n\naltera\u00e7\u00e3o servir como um tecido de suporte para uma vasculariza\u00e7\u00e3o anormal. As modifica\u00e7\u00f5es \n\nvasculares intra-hep\u00e1ticas, venosa ou arterial, provocadas por insultos hep\u00e1ticos cr\u00f4nicos s\u00e3o a \n\ncausa das altera\u00e7\u00f5es fisiol\u00f3gicas (ANDRADE; BAPTISTA; SANTANA, 2006). Na \n\nesquistossomose, as les\u00f5es obstrutivas da veia porta s\u00e3o as altera\u00e7\u00f5es dominantes, ao passo que, \n\nna cirrose predominam shunts porto-hep\u00e1ticos, hipertrofia da art\u00e9ria hep\u00e1tica e capilariza\u00e7\u00e3o \n\nsinusoidal (ANDRADE, 2004). As altera\u00e7\u00f5es do territ\u00f3rio vascular da art\u00e9ria hep\u00e1tica ainda \n\ns\u00e3o motivos de grande controv\u00e9rsia na literatura, com alguns autores, defendendo n\u00e3o haver \n\nmodifica\u00e7\u00f5es, enquanto outros relatam haver hipertrofia desse setor ( JORGE; CARVALHAL, \n\n1967; WIDMAN et al., 1973; ALVES et al., 1977; MIES et al., 1980, 1997; SARIN et al., 1991; \n\nCLEVA et al., 1999; ANDRADE, 2004) \n\n \n\nNa infec\u00e7\u00e3o pelo S. mansoni, a f\u00eamea do parasita produz uma enorme quantidade de ovos \n\ndiariamente que s\u00e3o depositados nos ramos das v\u00eanulas mesent\u00e9ricas, principalmente da \n\ninferior, para serem excretados nas fezes do hospedeiro. A maioria dos ovos fica retida na \n\nparede intestinal ou \u00e9 excretado nas fezes, mas um ter\u00e7o cai de volta na circula\u00e7\u00e3o em dire\u00e7\u00e3o \n\nao f\u00edgado e impactam nos pequenos ramos portais, causando obstru\u00e7\u00e3o parcial ao fluxo \n\nsangu\u00edneo portal. Ant\u00edgenos sol\u00faveis produzidos pela larva no interior dos ovos impactados e \n\nexcretados pela sua superf\u00edcie estimulam uma cascata de rea\u00e7\u00f5es imunol\u00f3gicas que culminam \n\nna forma\u00e7\u00e3o de um granuloma periovular, como mostra a Figura 6. Este \u00faltimo determina \n\nextenso dano ao sistema vascular hepatoportal. Dessa forma, as rea\u00e7\u00f5es inflamat\u00f3rias e \n\n\n\n32 \n \n\nfibrovasculares no hospedeiro s\u00e3o o principal fator respons\u00e1vel pela obstru\u00e7\u00e3o ao fluxo venoso \n\nportal (WARREN, 1975; ANDRADE, 2009). \n\n \n\nO pr\u00f3prio verme, por outro lado, participa das altera\u00e7\u00f5es oclusivas portais intra-hep\u00e1ticas. Ap\u00f3s \n\nsua morte, ele pode funcionar como micro\u00eambolos ocluindo ramos do leito venoso portal \n\n(WARREN, 1975) como ilustra a Figura 7. Estas les\u00f5es provocadas pelos vermes mortos, \n\nembora maiores em extens\u00e3o, causam menos impacto, por serem em menor n\u00famero, e, portanto, \n\nlocalizadas. Outro mecanismo envolvido refere-se aos ant\u00edgenos sol\u00faveis secretados pelo \n\nverme. Estes promovem altera\u00e7\u00f5es na fisiologia da vasculatura portal intra-hep\u00e1tica, \n\ncaracterizada por um aumento da sensibilidade dos ramos portais a agentes vasoconstrictores \n\nend\u00f3genos como serotonina e acetilcolina (SILVA et al., 2003; ARAUJO et al., 2007). Aliada \n\nao aumento da matriz extracelular, a contra\u00e7\u00e3o vascular contribuiria por aumentar a resist\u00eancia \n\nportal (SILVA et al., 2003). \n\n \n\n \n\n \n\nFigura 6 \u2013 Corte histol\u00f3gico de f\u00edgado evidenciando granuloma periovular na regi\u00e3o \n\nperiportal, com a forma\u00e7\u00e3o de rea\u00e7\u00e3o inflamat\u00f3ria e fibrose periportais em torno do \n\ngranuloma, com par\u00eanquima hep\u00e1tico adjacente preservado. No destaque, observam-se \n\noutros ovos impactados em vaso portal pr\u00f3ximo ao granuloma. \n\n(http://pathology.class.kmu.edu.tw/ch05/Slide48.htm) \n\nhttp://pathology.class.kmu.edu.tw/ch05/Slide48.htm\n\n\n33 \n \n\n \n\nFigura 7 \u2013 Corte histol\u00f3gico de f\u00edgado evidenciando in\u00fameros parasitas adultos do \n\nSchistosoma mansoni, impactados em ramos do leito venoso portal intra-hep\u00e1tico. \n\n(http://www.askjpc.org/wsco/wsc_showcase2.php?id=26) \n\n \n\nA extensa fibrose hep\u00e1tica vista na esquistossomose avan\u00e7ada est\u00e1 na depend\u00eancia de uma \n\nelevada carga parasit\u00e1ria, devido a uma maci\u00e7a emboliza\u00e7\u00e3o de ovos ao sistema portal causando \n\na oblitera\u00e7\u00e3o de vasos portais de pequeno calibre da periferia do sistema porta e da resposta \n\nimune desenvolvida pelo hospedeiro. Na forma\u00e7\u00e3o do granuloma periovular, h\u00e1 prolifera\u00e7\u00e3o \n\nvascular que vai progressivamente tomando a periferia do granuloma \u00e0 medida que este vai \n\ncrescendo pela forma\u00e7\u00e3o de fibrose. Quando h\u00e1 a fus\u00e3o de granulomas, como ocorre na fibrose \n\nperiportal da doen\u00e7a avan\u00e7ada, os pequenos vasos sangu\u00edneos proliferados exibem-se \n\nproeminentes no tecido inter-granuloma, assumindo um aspecto angiomat\u00f3ide. Apesar dessa \n\nprolifera\u00e7\u00e3o vascular, muitos vasos portais, de fato, encontram-se distorcidos, com \n\nespessamento da camada muscular, e oclu\u00eddos (MAGALH\u00c3ES-FILHO; SILVA, 1994; \n\nSTRAUSS, 2002; ANDRADE, 2004, 2009; ANDRADE; SANTANA, 2010).  \n\n \n\nA emboliza\u00e7\u00e3o de ovos e oclus\u00e3o de ramos portais distais provoca aumento na press\u00e3o venosa \n\nportal intra-hep\u00e1tica, que induz a forma\u00e7\u00e3o de colaterais periportais em ramos mais calibrosos, \n\npermitindo o desvio do fluxo sangu\u00edneo. Com a cont\u00ednua chegada de ovos ocorrer\u00e1, ent\u00e3o, \n\ndanos \u00e0s veias de calibres maiores, com forma\u00e7\u00e3o de inflama\u00e7\u00e3o periportal granulomatosa, \n\nfibrose inter-granuloma e oclus\u00e3o vascular, o que, consequentemente, promove a hipertens\u00e3o \n\nportal, aumentando a esplenomegalia e colaterais portossist\u00eamicos (ANDRADE, 2004, 2009; \n\nANDRADE; SANTANA, 2010).  \n\n \n\n\n\n34 \n \n\nFisiologicamente, o suprimento sangu\u00edneo hep\u00e1tico se faz de maneira dupla, com \n\naproximadamente 70-80% do aporte feito atrav\u00e9s da veia porta e os 20-30% restantes pela \n\nart\u00e9ria hep\u00e1tica (MCCUSKEY, 2012). Na esquistossomose hepatoespl\u00eanica avan\u00e7ada, apesar \n\ndas altera\u00e7\u00f5es obliterativas do sistema venoso portal, o fluxo sangu\u00edneo hep\u00e1tico total mant\u00e9m-\n\nse nos limites da normalidade (STRAUSS, 2002). Este fen\u00f4meno se deve a uma \n\nhipertrofia/hiperplasia do sistema arterial hep\u00e1tico (WARREN, 1975; DE COCK, 1986; \n\nANDRADE, 1987). Estudos da vasculariza\u00e7\u00e3o hep\u00e1tica, em modelos pl\u00e1sticos, obtidos atrav\u00e9s \n\nda inje\u00e7\u00e3o nos diferentes sistemas vasculares \u2013 veia porta, veias hep\u00e1ticas e art\u00e9ria hep\u00e1tica \u2013 \n\nde subst\u00e2ncia pl\u00e1stica com colora\u00e7\u00e3o diferente puderam documentar as altera\u00e7\u00f5es vasculares \n\nintra-hep\u00e1ticas da esquistossomose hepatoespl\u00eanica ( JORGE; CARVALHAL, 1967; \n\nANDRADE, 2009).  \n\n \n\nOs ramos portais intra-hep\u00e1ticos mostram-se reduzidos e os menos proeminentes dos tr\u00eas \n\nsetores vasculares. Diferentemente da cirrose, as altera\u00e7\u00f5es vasculares da esquistossomose \n\natingem ramos portais mais calibrosos, com consider\u00e1vel distor\u00e7\u00e3o e redu\u00e7\u00e3o dos pequenos \n\nramos perif\u00e9ricos (MAGALH\u00c3ES-FILHO; MENEZES; COELHO, 1960). Ramos portais de \n\nm\u00e9dio e grande calibre frequentemente apresentam dilata\u00e7\u00e3o, tortuosidade e redu\u00e7\u00e3o s\u00fabita do \n\nseu di\u00e2metro sem emitir os ram\u00fasculos terminais, com uma rede de finos vasos neoformados \n\nsurgindo dos ramos principais e anastomosando-se entre si (MAGALH\u00c3ES-FILHO; \n\nMENEZES; COELHO, 1960; JORGE; CARVALHAL, 1967; HIDAYAT; WAHID, 1971; \n\nANDRADE, 2004, 2009). O setor das veias hep\u00e1ticas n\u00e3o mostra, por sua vez, altera\u00e7\u00f5es em \n\nrela\u00e7\u00e3o aos modelos normais. J\u00e1 o setor da art\u00e9ria hep\u00e1tica mostra consider\u00e1vel hiperplasia e \n\nhipertrofia com uma rede vascular muito mais densa e tortuosa, especialmente no plexo \n\nperibiliar (ANDRADE, 2004, 2009, 2013). As Figuras 8 e 9 ilustram os achados descritos. \n\n \n\n \n\n\n\n35 \n \n\n \n\n \n\nFigura 8 \u2013 Aspecto macrosc\u00f3pico de molde pl\u00e1stico da rede venosa portal de roedor \n\nsaud\u00e1vel (A) e roedor com esquistossomose hepatoespl\u00eanica (B), mostrando uma redu\u00e7\u00e3o \n\nglobal na densidade dos vasos portais e \u201camputa\u00e7\u00e3o\u201d dos vasos especialmente na periferia, \n\ndiminui\u00e7\u00e3o abrupta do calibre dos vasos de m\u00e9dio e grande calibre e pequenas \n\nramifica\u00e7\u00f5es surgindo de vasos de grande calibre. (Andrade, ZA 2006) \n\n \n\n \n\nFigura 9 \u2013 Aspecto macrosc\u00f3pico de molde pl\u00e1stico de f\u00edgado de roedor com \n\nesquistossomose hepatoespl\u00eanica avan\u00e7ada evidenciando redu\u00e7\u00e3o importante da \n\nA \n\nB \n\n\n\n36 \n \n\ndensidade da rede venosa portal (branco), veias hep\u00e1ticas preservadas (azul) e aumento \n\nda densidade de vasos do sistema arterial (vermelho). (Andrade, ZA 2009) \n\n \n\nEstas altera\u00e7\u00f5es no leito vascular da art\u00e9ria hep\u00e1tica podem ser consideradas compensat\u00f3rias \u00e0 \n\ndiminui\u00e7\u00e3o da perfus\u00e3o venosa portal (HIDAYAT; WAHID, 1971) consequente ao desarranjo \n\ndo sistema venoso porta pelas oclus\u00f5es ou amputa\u00e7\u00f5es de seus ramos. Forma-se uma intensa \n\nrede arterial que se insinua por entre os ramos venosos anastom\u00f3ticos e distorcidos em torno \n\ndos grossos troncos da veia porta, al\u00e9m de preencher os espa\u00e7os onde faltam os ramos portais \n\n(MAGALH\u00c3ES-FILHO; MENEZES; COELHO, 1960). Desta forma, mant\u00e9m-se o fluxo \n\nsangu\u00edneo hep\u00e1tico total inalterado. Entretanto, este aumento do fluxo arterial intra-hep\u00e1tico \u00e9 \n\nrespons\u00e1vel por uma eleva\u00e7\u00e3o na press\u00e3o sinusoidal causando um maior ac\u00famulo de fibras \n\ncol\u00e1genas no espa\u00e7o de Disse. Estas altera\u00e7\u00f5es determinam a capilariza\u00e7\u00e3o dos sinus\u00f3ides \n\nhep\u00e1ticos e prejudica a superf\u00edcie de troca entre os sinus\u00f3ides e os hepat\u00f3citos, contribuindo, \n\nem epis\u00f3dios de hemorragias, para a descompensa\u00e7\u00e3o da esquistossomose hepatoespl\u00eanica \n\n(ANDRADE, 1987, 2004, 2009; DOMINGUES; DOMINGUES, 1994).   \n\n \n\nA principal desvantagem da hipertrofia da art\u00e9ria hep\u00e1tica \u00e9 a depend\u00eancia do par\u00eanquima \n\nhep\u00e1tico ao fluxo arterial. Quando ocorrem epis\u00f3dios de hemorragia digestiva volumosa \u2013 \n\ncomplica\u00e7\u00e3o comum da esquistossomose hepatoespl\u00eanica \u2013 h\u00e1 hipoperfus\u00e3o hep\u00e1tica, em \n\nvirtude do fluxo arterial ser mais dependente da press\u00e3o arterial m\u00e9dia. Como consequ\u00eancia \n\ndestes insultos isqu\u00eamicos surgem \u00e1reas de necrose que se transformam em cicatrizes p\u00f3s-\n\nnecr\u00f3ticas focais e perif\u00e9ricas com a forma\u00e7\u00e3o de septos fibrosos isolando n\u00f3dulos, num aspecto \n\nindistingu\u00edvel da cirrose, nestas \u00e1reas, uma das causas de progress\u00e3o para o est\u00e1gio \n\ndescompensado da doen\u00e7a (ANDRADE, 1987, 2004, 2009).  \n\n \n\nApesar destes aspectos anatomopatol\u00f3gicos descritos acima, alguns estudos angiogr\u00e1ficos do \n\nsistema vascular hep\u00e1tico na esquistossomose hepatoespl\u00eanica revelaram resultados \n\ndiscordantes. Speranzini em 1971, utilizando estudos arteriogr\u00e1ficos para avalia\u00e7\u00e3o de f\u00edgados \n\nesquistossom\u00f3ticos, demonstrou pouca participa\u00e7\u00e3o do sistema arterial nos doentes n\u00e3o \n\noperados, relatando que a art\u00e9ria hep\u00e1tica apresentava-se de calibre normal, um pouco menor \n\nque a art\u00e9ria espl\u00eanica, com ramifica\u00e7\u00f5es intra-hep\u00e1ticas finas, retil\u00edneas, alongadas e de \n\ndistribui\u00e7\u00e3o normal (SPERANZINI, 1971, apud CERRI, 1984).  \n\n \n\n\n\n37 \n \n\nOutros estudos angiogr\u00e1ficos mantiveram a teoria da pouca participa\u00e7\u00e3o arterial nas altera\u00e7\u00f5es \n\nda hemodin\u00e2mica hep\u00e1tica da EHE, onde foi observada redu\u00e7\u00e3o do calibre da art\u00e9ria hep\u00e1tica, \n\ncom diminui\u00e7\u00e3o da vasculariza\u00e7\u00e3o arterial intra-hep\u00e1tica (MIES et al., 1980; DA SILVA, 1992; \n\nDA SILVA; CHIEFFI; CARRILHO, 2005). Os autores sugeriam que, em decorr\u00eancia da \n\nesplenomegalia volumosa, haveria uma hipertrofia da art\u00e9ria espl\u00eanica com consequente desvio \n\ndo fluxo da art\u00e9ria hep\u00e1tica, num mecanismo semelhante \u00e0 s\u00edndrome do roubo da art\u00e9ria \n\nespl\u00eanica (Splenic Artery Steal Syndrome), descrita em casos de complica\u00e7\u00e3o vascular do \n\ntransplante hep\u00e1tico (N\u00dcSSLER et al., 2003; AKAMATSU et al., 2014). No entanto, o \n\nmecanismo de \u201csif\u00e3o\u201d descrito para explicar este roubo de fluxo foi questionado, sendo \n\natribu\u00eddo o hipofluxo da art\u00e9ria hep\u00e1tica ao mecanismo regulat\u00f3rio intra-hep\u00e1tico conhecido \n\ncomo hepatic arterial buffer response (LAUTT, 1985). Neste, o hiperfluxo portal causado pelo \n\naumento do fluxo espl\u00eanico vindo da art\u00e9ria espl\u00eanica, compensatoriamente reduziria o fluxo \n\nda art\u00e9ria hep\u00e1tica (QUINTINI et al., 2008).  \n\n \n\nCleva et al, em avalia\u00e7\u00e3o angiogr\u00e1fica da hemodin\u00e2mica sist\u00eamica em pacientes \n\nesquistossom\u00f3ticos antes a ap\u00f3s esplenectomia com ligadura da veia g\u00e1strica esquerda, \n\nobservaram pobre vasculariza\u00e7\u00e3o arterial intra-hep\u00e1tica. Documentaram exuberante \n\nvasculariza\u00e7\u00e3o tanto arterial, quanto venosa espl\u00eanica, com medidas hemodin\u00e2micas sugerindo \n\nestado de circula\u00e7\u00e3o sist\u00eamica hiperdin\u00e2mica \u00e0 semelhan\u00e7a da cirrose, com aumento do \u00edndice \n\ne trabalho card\u00edaco e redu\u00e7\u00e3o da resist\u00eancia vascular perif\u00e9rica. Sugeriram que os grandes \n\nmantenedores do estado hiperdin\u00e2mico sist\u00eamico eram a esplenomegalia. juntamente com a \n\ncircula\u00e7\u00e3o colateral portossist\u00eamica que funcionavam como f\u00edstulas arterio-venosas, desviando \n\no fluxo portal hipertenso (CLEVA et al., 1999, 2007). Outro estudo, do mesmo autor, utilizando \n\nt\u00e9cnicas de termodilui\u00e7\u00e3o demonstrou que 56% dos 16 pacientes esquistossom\u00f3ticos \n\napresentavam fluxo portal acima do considerado normal para um fluxo hep\u00e1tico total (maior \n\nque 1500ml/min) contrariando a ideia de um fluxo hep\u00e1tico total normal nesses doentes \n\n(CLEVA et al., 2004). \n\n \n\nMies et al tamb\u00e9m estudaram a hemodin\u00e2mica sist\u00eamica em doentes com EHE, desta vez \n\navaliando os efeitos do tratamento com propranolol. Observaram os mesmos achados de Cleva \n\net al em rela\u00e7\u00e3o ao aumento do \u00edndice card\u00edaco, redu\u00e7\u00e3o da resist\u00eancia vascular perif\u00e9rica \n\npreserva\u00e7\u00e3o do fluxo hep\u00e1tico total. Relataram, tamb\u00e9m, aumento do fluxo atrav\u00e9s da veia \n\n\u00e1zigo, indicando uma maior drenagem sangu\u00ednea pela circula\u00e7\u00e3o colateral portossist\u00eamica, com \n\nredu\u00e7\u00e3o significativa ap\u00f3s o tratamento com propranolol. Neste estudo demonstraram um fluxo \n\n\n\n38 \n \n\nreduzido pela art\u00e9ria hep\u00e1tica que aumentava ap\u00f3s o uso do propranolol, acompanhado de \n\nredu\u00e7\u00e3o no fluxo pela veia porta, veia espl\u00eanica e veia mesent\u00e9rica superior (MIES et al., 1997). \n\n \n\nLacerda e Pereira ao avaliarem os efeitos hemodin\u00e2micos da esplenectomia associada \u00e0 \n\ndesvasculariza\u00e7\u00e3o esofagog\u00e1strica e ligadura da veia g\u00e1strica esquerda, respectivamente, \n\nevidenciaram haver aumento no calibre e fluxo da art\u00e9ria hep\u00e1tica, apenas ap\u00f3s a cirurgia, \n\nassociado \u00e0 redu\u00e7\u00e3o do calibre e fluxo na veia porta acompanhada de a um leve aumento na \n\npress\u00e3o sinusoidal (LACERDA et al., 1993; PEREIRA et al., 2013). Lacerda sugere que, nos \n\npacientes com EHE com grandes shunts, a aus\u00eancia de aumento do setor arterial se justificaria \n\npelo hiperfluxo portal, que manteria a perfus\u00e3o hep\u00e1tica normal, desviando apenas o sangue \n\n\u201cexcedente\u201d dispens\u00e1vel pela circula\u00e7\u00e3o colateral. Com a cirurgia o mecanismo de hiperfluxo \n\ncessaria, diminuindo a perfus\u00e3o portal, havendo, ent\u00e3o, aumento compensat\u00f3rio da circula\u00e7\u00e3o \n\narterial (LACERDA et al., 1993).  \n\n \n\nEsta discord\u00e2ncia poderia ser explicada pelo car\u00e1ter evolutivo da doen\u00e7a esquistossom\u00f3tica, \n\natribuindo os achados dos estudos angiogr\u00e1ficos a uma fase mais compensada da doen\u00e7a, na \n\nqual a importante esplenomegalia causaria esse desvio funcional do fluxo arterial, ao passo que \n\nos estudos anatomopatol\u00f3gicos representavam doentes com formas mais avan\u00e7adas da mol\u00e9stia \n\nou esplenectomizados (DOMINGUES; DOMINGUES, 1994).  \n\n \n\nOutros estudos din\u00e2micos in vivo, no entanto, documentaram resultados opostos. Coutinho em \n\n1968 atrav\u00e9s de estudo hemodin\u00e2mico, realizando avalia\u00e7\u00f5es press\u00f3ricas intra-espl\u00eanica, intra-\n\nhep\u00e1tica, direta da veia porta e da veia hep\u00e1tica livre e oclu\u00edda, al\u00e9m de estudo angiogr\u00e1fico \n\ncom esplenoportografia, observou eleva\u00e7\u00e3o das press\u00f5es intra-espl\u00eanica e portal, press\u00e3o \n\nsinusoidal normal ou levemente aumentada e fluxo hep\u00e1tico total mantido. No estudo \n\nangiogr\u00e1fico, documentou dilata\u00e7\u00e3o dos ramos direito e esquerdo da veia porta com arboriza\u00e7\u00e3o \n\nvenosa reduzida, a semelhan\u00e7a do descrito como sinal de Bogliolo, e preserva\u00e7\u00e3o do sistema \n\narterial. Assim, este autor levanta, entre as possibilidades para a manuten\u00e7\u00e3o do fluxo hep\u00e1tico \n\ntotal, a conserva\u00e7\u00e3o do sistema arterial que poderia permitir um aumento compensat\u00f3rio no \n\nfluxo ao f\u00edgado (COUTINHO, 1968) \n\n \n\nEm outro estudo angiogr\u00e1fico, Ramos et al documentaram um bloqueio intra-hep\u00e1tico pr\u00e9-\n\nsinusoidal ao fluxo portal, com manuten\u00e7\u00e3o do fluxo hep\u00e1tico total, indicando um aumento \n\ncompensat\u00f3rio no fluxo arterial (RAMOS; SAAD; LESER, 1964; apud WARREN, 1968). \n\n\n\n39 \n \n\nAlves et al, em 5 pacientes esquistossom\u00f3ticos, durante a cirurgia de esplenectomia, \n\nposicionaram um cateter na veia hep\u00e1tica para aferir as press\u00f5es intra-hep\u00e1ticas. O passo \n\nseguinte foi o clampeamento da art\u00e9ria hep\u00e1tica, no seu tronco principal, percebendo uma queda \n\nna press\u00e3o sinusoidal de mais de 15mmHg. Em seguida no indiv\u00edduo controle com \n\nesplenomegalia secund\u00e1ria a um hemangioma cavernoso, foram medidas as mesmas press\u00f5es \n\ndurante a esplenectomia, com achado de press\u00f5es sinusoidais normais e sem altera\u00e7\u00f5es ap\u00f3s o \n\nclampeamento da art\u00e9ria hep\u00e1tica. Com esses achados os autores destacam a import\u00e2ncia do \n\nsetor arterial na EHE (ALVES et al., 1977) \n\n \n\nEstudos din\u00e2micos em modelos animais tamb\u00e9m descrevem altera\u00e7\u00f5es na circula\u00e7\u00e3o arterial do \n\nf\u00edgado das cobaias. Morgan et al estudando um modelo de EHE em hamsters demonstrou que \n\ncom a progress\u00e3o da doen\u00e7a hep\u00e1tica havia um decl\u00ednio significativo no fluxo sangu\u00edneo portal \n\ncompensado parcialmente por um incremento no fluxo arterial (MORGAN et al., 1990). Sarin \n\net al, em modelo murino de EHE, utilizando t\u00e9cnica de microesferas radioativas, demonstrou \n\nque a queda no fluxo portal dos animais infectados era 61% maior que nos saud\u00e1veis, sendo \n\nobservado tamb\u00e9m um aumento de duas vezes no fluxo arterial dos animais doentes, \n\ncomparados com os controles. Al\u00e9m dessas observa\u00e7\u00f5es, evidenciou medidas compat\u00edveis com \n\nestado de circula\u00e7\u00e3o hiperdin\u00e2mica \u00e0 semelhan\u00e7a de Cleva et al, com aumento do \u00edndice \n\ncard\u00edaco, redu\u00e7\u00e3o da resist\u00eancia vascular perif\u00e9rica e espl\u00e2ncnica (SARIN et al., 1991) \n\n \n\nNo sistema venoso extra-hep\u00e1tico, dilata\u00e7\u00e3o das veias porta e espl\u00eanica est\u00e3o geralmente \n\npresentes. Observam-se eleva\u00e7\u00e3o das press\u00f5es espl\u00eanica e portal direta, por\u00e9m com gradiente \n\nde press\u00e3o venosa hep\u00e1tica \u2013 obtido por cateteriza\u00e7\u00e3o da veia supra-hep\u00e1tica \u2013 normal ou \n\nligeiramente elevado, caracterizando o tipo pr\u00e9-sinusoidal da hipertens\u00e3o portal (COUTINHO, \n\n1968; DA SILVA; CHIEFFI; CARRILHO, 2005). Podem ser observadas tamb\u00e9m revers\u00e3o do \n\nfluxo portal e forma\u00e7\u00e3o de circula\u00e7\u00e3o colateral, especialmente ao n\u00edvel da veia g\u00e1strica esquerda \n\ne hilo espl\u00eanico (STRAUSS, 2002).  \n\n \n\nEstes aspectos relacionados \u00e0 fibrose hep\u00e1tica e \u00e0s altera\u00e7\u00f5es vasculares, no entanto, \n\ndemonstraram-se revers\u00edveis em estudos experimentais ap\u00f3s a terapia medicamentosa \n\nespec\u00edfica. Nestes experimentos, al\u00e9m da redu\u00e7\u00e3o do tecido conectivo periportal e intravascular \n\ncom reparo vascular e desobstru\u00e7\u00e3o, foram observados, intensa angiog\u00eanese e remodelamento \n\nvascular, com ramifica\u00e7\u00e3o de in\u00fameros novos vasos a partir das veias de maior di\u00e2metro. As \n\nirregularidades vasculares descritas anteriormente foram revertidas, bem como os sinais de \n\n\n\n40 \n \n\nhipertens\u00e3o portal, com redu\u00e7\u00e3o do ba\u00e7o e desaparecimento das varizes esof\u00e1gicas, mostrando \n\na caracter\u00edstica din\u00e2mica da doen\u00e7a (ANDRADE, 2005, 2013).  \n\n \n\n2.1.5. Hepatic Arterial Buffer Response \n\n \n\nO f\u00edgado constitui o maior \u00f3rg\u00e3o s\u00f3lido do corpo, representando 2,5% do peso corporal. Ele \n\nrecebe 25% do d\u00e9bito card\u00edaco atrav\u00e9s de uma peculiaridade anat\u00f4mica de duplo suprimento \n\nvascular pela veia porta e art\u00e9ria hep\u00e1tica. O fluxo hep\u00e1tico total varia entre 800 e 1200 ml/min. \n\nA veia porta \u00e9 um vaso avalvular aferente que drena sangue dos intestinos, ba\u00e7o, omento, \n\nestomago, p\u00e2ncreas e ves\u00edcula biliar, e contribui por 75-80% do fluxo hep\u00e1tico total. Os 20-\n\n25% restantes s\u00e3o supridos pela art\u00e9ria hep\u00e1tica. O consumo de oxig\u00eanio pelo f\u00edgado representa \n\n20% do consumo corporal total. Acompanhando o fluxo arterial bem oxigenado, a veia porta \n\ncarrega sangue parcialmente oxigenado, por\u00e9m rico em nutrientes e fatores tr\u00f3ficos. Entretanto, \n\nmesmo suprindo um sangue desoxigenado, uma m\u00e9dia de 50% das necessidades de oxig\u00eanio \n\ndo f\u00edgado \u00e9 provida pelo fluxo venoso portal, em consequ\u00eancia de sua alta taxa de fluxo. Assim, \n\na oxigena\u00e7\u00e3o hep\u00e1tica depende igualmente dos dois grandes vasos aferentes (VOLLMAR; \n\nMENGER, 2009; EIPEL; ABSHAGEN; VOLLMAR, 2010) \n\n \n\nO duplo suprimento sangu\u00edneo hep\u00e1tico \u00e9 um mecanismo \u00fanico e distinto que permite uma \n\n\u00edntima rela\u00e7\u00e3o entre os dois sistemas vasculares, determinando uma regula\u00e7\u00e3o intr\u00ednseca do \n\nfluxo sangu\u00edneo. Esta inter-rela\u00e7\u00e3o representa a chamada hepatic arterial buffer response \n\n(HABR), descrita inicialmente por Lautt (LAUTT, 1980), na qual a art\u00e9ria hep\u00e1tica \u00e9 capaz de \n\nproduzir altera\u00e7\u00f5es compensat\u00f3rias em seu fluxo, em resposta \u00e0s mudan\u00e7as do fluxo portal, \n\npara garantir um fluxo hep\u00e1tico total constante (LAUTT, 1985). Em associa\u00e7\u00e3o ao mecanismo \n\ncl\u00e1ssico de autorregula\u00e7\u00e3o arterial, no qual h\u00e1 uma resposta miog\u00eanica de contra\u00e7\u00e3o vascular \n\nem resposta aos aumentos da press\u00e3o arterial, e que, no caso da art\u00e9ria hep\u00e1tica, \u00e9 considerado \n\npequeno, existe um segundo mecanismo onde a art\u00e9ria hep\u00e1tica dilata quando o fluxo portal \n\ndiminui e contrai quando o fluxo portal aumenta (LAUTT, 1985, 2009; VOLLMAR; \n\nMENGER, 2009; EIPEL; ABSHAGEN; VOLLMAR, 2010). Este mecanismo de HABR tem \n\nsido demonstrado n\u00e3o s\u00f3 em condi\u00e7\u00f5es fisiol\u00f3gicas, mas tamb\u00e9m em fetos, f\u00edgados cirr\u00f3ticos e \n\nno transplante hep\u00e1tico (RICHTER et al., 2000; G\u00dcLBERG et al., 2002; ZIPPRICH et al., \n\n2003; AOKI et al., 2005; KELLY et al., 2009; VOLLMAR; MENGER, 2009; SAAD, 2012; \n\nMOELLER et al., 2015). O aumento do fluxo arterial \u00e9 capaz de compensar 25 a 60% de queda \n\n\n\n41 \n \n\nno fluxo portal. Kollmar et al demonstrou que ap\u00f3s 14 dias da ligadura do ramo esquerdo da \n\nveia porta de ratos houve um aumento do fluxo da art\u00e9ria hep\u00e1tica t\u00e3o significativo que atingia \n\nn\u00edveis pr\u00f3ximos aos dos fluxos arterial e portal iniciais (KOLLMAR et al., 2007). Uma vez que, \n\na veia porta \u00e9 incapaz de controlar seu fluxo, o qual \u00e9 a simples soma dos efluxos dos \u00f3rg\u00e3os \n\nespl\u00e2ncnicos, n\u00e3o existe reciprocidade da HABR, ou seja, altera\u00e7\u00f5es na perfus\u00e3o da art\u00e9ria \n\nhep\u00e1tica n\u00e3o induzem mudan\u00e7as compensat\u00f3rias no territ\u00f3rio da veia porta (VOLLMAR; \n\nMENGER, 2009; EIPEL; ABSHAGEN; VOLLMAR, 2010).  \n\n \n\nDiversos mecanismos t\u00eam sido propostos para esta resposta arterial compensat\u00f3ria. Na cirrose, \n\na redu\u00e7\u00e3o do fluxo venoso portal, o desenvolvimento de shunts intra-hep\u00e1ticos e a capilariza\u00e7\u00e3o \n\nsinusoidal, contribuiriam para a redu\u00e7\u00e3o do suprimento de oxig\u00eanio aos hepat\u00f3citos \u2013 teoria da \n\nlimita\u00e7\u00e3o de oxig\u00eanio (ZIPPRICH et al., 2003; KOLLMAR et al., 2007; MOELLER et al., \n\n2015). De fato, estudos experimentais sugerem melhora na fun\u00e7\u00e3o hepatocit\u00e1ria ap\u00f3s \n\nsuplementa\u00e7\u00e3o de oxig\u00eanio (HARVEY et al., 2000). Dessa forma, o aumento do fluxo arterial \n\nhep\u00e1tico compensaria uma oxigena\u00e7\u00e3o deficiente causada pela redu\u00e7\u00e3o da perfus\u00e3o portal, com \n\nmelhora da fun\u00e7\u00e3o hepatocit\u00e1ria, por vezes mensurada pela depura\u00e7\u00e3o de certas subst\u00e2ncias \n\ncomo o acetaminofen e a teofilina (FROOMES et al., 1999; ZIPPRICH et al., 2003). Entretanto, \n\nalguns autores relatam que, diante de um aumento da demanda de oxig\u00eanio do f\u00edgado, este \n\nsimplesmente aumenta sua taxa de extra\u00e7\u00e3o, mantendo o calibre da art\u00e9ria hep\u00e1tica inalterado \n\n(EIPEL; ABSHAGEN; VOLLMAR, 2010) Outro mecanismo seria o do \u201cdesrecrutamento\u201d que \n\nenvolve um fator press\u00f3rico. A redu\u00e7\u00e3o da perfus\u00e3o venosa portal sinusoidal acarreta uma \n\nqueda na press\u00e3o de perfus\u00e3o abaixo do necess\u00e1rio para manter os sinus\u00f3ides abertos. O \n\n\u201cdesrecrutamento\u201d sinusoidal agiria como est\u00edmulo para o aumento do fluxo arterial hep\u00e1tico \n\nnecess\u00e1rio para reabrir os sinus\u00f3ides colabados (ZIPPRICH et al., 2003).  \n\n \n\nA teoria mais aceita, no entanto, envolve a depura\u00e7\u00e3o de adenosina intra-hep\u00e1tica (LAUTT, \n\n1980, 1985, 2009; EZZAT; LAUTT, 1987; KLEBER et al., 1999). Esta hip\u00f3tese descreve que \n\na adenosina, um potente vasodilatador arterial, \u00e9 liberada numa taxa constante no fluido do \n\nespa\u00e7o de Mall que circunda os vasos portais. Este espa\u00e7o \u00e9 delimitado pela placa limitante que \n\no separa dos outros compartimentos. A concentra\u00e7\u00e3o de adenosina \u00e9 regulada pela depura\u00e7\u00e3o \u2013 \n\nwashout \u2013 atrav\u00e9s da veia porta e da art\u00e9ria hep\u00e1tica. Nos casos onde h\u00e1 redu\u00e7\u00e3o do fluxo portal, \n\nmenos adenosina \u00e9 depurada do espa\u00e7o de Mall e, o ac\u00famulo de adenosina leva \u00e0 dilata\u00e7\u00e3o da \n\nart\u00e9ria hep\u00e1tica e aumento do fluxo arterial. Da mesma forma, quando o fluxo portal aumenta, \n\nmaior quantidade de adenosina \u00e9 depurada contraindo a art\u00e9ria hep\u00e1tica e diminuindo seu fluxo, \n\n\n\n42 \n \n\ndemonstrando a rela\u00e7\u00e3o inversa dos fluxos portal e arterial (AOKI et al., 2005; KELLY et al., \n\n2009; VOLLMAR; MENGER, 2009; EIPEL; ABSHAGEN; VOLLMAR, 2010; SAAD, \n\n2012).Em associa\u00e7\u00e3o \u00e0 adenosina, outros mediadores vasoativos foram descritos na \n\nparticipa\u00e7\u00e3o da HABR, como o \u00f3xido n\u00edtrico, o mon\u00f3xido de carbono, a adenosina trifosfato \n\n(ATP) e sulfeto de hidrog\u00eanio (VOLLMAR; MENGER, 2009; EIPEL; ABSHAGEN; \n\nVOLLMAR, 2010). A Figura 10 ilustra uma representa\u00e7\u00e3o esquem\u00e1tica do mecanismo de \n\nHABR.  \n\n \n\n \n\nFigura 10 \u2013 Representa\u00e7\u00e3o esquem\u00e1tica do mecanismo de hepatic arterial buffer response \n\n(HABR). Segmento de l\u00f3bulo hep\u00e1tico em condi\u00e7\u00f5es normais, demonstrando o fluxo \n\nsinusoidal preferencialmente pela veia porta (A). Condi\u00e7\u00f5es que levam \u00e0 redu\u00e7\u00e3o do fluxo \n\nportal, ocasionando, essencialmente ac\u00famulo de adenosina no espa\u00e7o de Mall, \n\nrepresentada pela estrelas vermelhas (B). Aumento compensat\u00f3rio do fluxo pela art\u00e9ria \n\nhep\u00e1tica com washout  da adenosina (C).  \n\n \n\n\n\n43 \n \n\nAs arter\u00edolas hep\u00e1ticas se ramificam envolta das v\u00eanulas portais, emitindo pequenos ramos para \n\nas v\u00eanulas que formar\u00e3o anastomoses \u2013 shunts \u2013 arteriolo-portais, para os capilares do plexo \n\nperibiliar e, em seus ramos mais delgados as arter\u00edolas suprir\u00e3o as paredes venulares portais \n\ncomo um vasa-vasorum (VOLLMAR; MENGER, 2009). Em condi\u00e7\u00f5es normais, cerca de 30% \n\ndo fluxo pela art\u00e9ria hep\u00e1tica \u00e9 desviado pelos shunts \u00e0 circula\u00e7\u00e3o portal (SAAD, 2012). Esse \n\ndesvio foi demonstrado garantir o suprimento nutricional e a oferta de oxig\u00eanio na HABR em \n\nratos, com seus autores sugerindo n\u00e3o haver altera\u00e7\u00e3o dos di\u00e2metros vasculares, mas sim a \n\npropor\u00e7\u00e3o de fluxo atrav\u00e9s dos shunts (RICHTER et al., 2001). Em condi\u00e7\u00f5es normais, a grande \n\nmaioria dos sinus\u00f3ides s\u00e3o perfundidos por sangue portal, com pequena parcela adicionalmente \n\nsuprida diretamente pelas arter\u00edolas hep\u00e1ticas terminais. Sob condi\u00e7\u00f5es de fluxo portal reduzido \n\ncom indu\u00e7\u00e3o da HABR, a perfus\u00e3o preferencial atrav\u00e9s dos shunts leva a um desproporcional \n\nincremento na contribui\u00e7\u00e3o da art\u00e9ria hep\u00e1tica \u00e0 perfus\u00e3o sinusoidal (RICHTER et al., 2001; \n\nVOLLMAR; MENGER, 2009). A Figura 11 ilustra esse mecanismo. \n\n \n\n \n\n \n\nFigura 11 \u2013 Representa\u00e7\u00e3o esquem\u00e1tica do suprimento sangu\u00edneo da art\u00e9ria hep\u00e1tica e \n\nda veia porta aos sinus\u00f3ides, com indica\u00e7\u00e3o do shunt arteriolo-portal intra-hep\u00e1tico sob \n\ncondi\u00e7\u00f5es normais (A) e sob condi\u00e7\u00f5es de redu\u00e7\u00e3o do fluxo venoso portal com indu\u00e7\u00e3o da \n\nHABR (B). (Richter et al 2001) \n\n \n\nDiversos estudos t\u00eam demonstrado a manuten\u00e7\u00e3o da HABR em f\u00edgados cirr\u00f3ticos. Moeller et \n\nal em modelo animal de cirrose demonstrou haver redu\u00e7\u00e3o da resist\u00eancia e aumento do fluxo \n\nna art\u00e9ria hep\u00e1tica de ratos cirr\u00f3ticos mesmo sem hipertens\u00e3o portal, ou seja, com resist\u00eancia \n\nda veia porta normal (MOELLER et al., 2015). Richter et al, tamb\u00e9m em modelo roedor de \n\n\n\n44 \n \n\ncirrose, evidenciou diminui\u00e7\u00e3o do fluxo hep\u00e1tico total, com marcada redu\u00e7\u00e3o do fluxo portal e \n\naumento compensat\u00f3rio do fluxo atrav\u00e9s da art\u00e9ria hep\u00e1tica. Demonstrou que a raz\u00e3o do fluxo \n\nhep\u00e1tico total passava de 79,8% via veia porta e 20,2% via art\u00e9ria hep\u00e1tica, antes da indu\u00e7\u00e3o \n\nqu\u00edmica da cirrose, para 59,2% via veia porta e 40,8% via art\u00e9ria hep\u00e1tica nos animais \n\ncirr\u00f3ticos. O autor relata, tamb\u00e9m que, apesar do valor absoluto do fluxo arterial ser semelhante \n\naos animais controles, o aumento proporcional foi muito maior (RICHTER et al., 2000). Aoki \n\net al, por sua vez, em estudo humano utilizando o clampeamento da veia porta em cirr\u00f3ticos \n\ndurante a cirurgia de transplante hep\u00e1tico, demonstrou que o fluxo da veia porta encontrava-se \n\nreduzido ao passo que o fluxo da art\u00e9ria hep\u00e1tica mostrava-se aumentado e que o clampeamento \n\nda veia porta induzia um incremento adicional ao fluxo arterial (AOKI et al., 2005). G\u00fclberg et \n\nal, avaliando a HABR em cirr\u00f3ticos submetidos \u00e0 coloca\u00e7\u00e3o de TIPS (Transjugular \n\nintrahepatic portal shunt), evidenciou que o \u00edndice de resist\u00eancia da art\u00e9ria hep\u00e1tica \n\nencontrava-se diminu\u00eddo em cirr\u00f3ticos, reduzindo ainda mais ap\u00f3s a queda da perfus\u00e3o portal \n\ninduzida pela coloca\u00e7\u00e3o do TIPS (G\u00dcLBERG et al., 2002). \n\n \n\nA HABR encontra-se preservada tamb\u00e9m nas hepatectomias e no transplante hep\u00e1tico. Como \n\no aumento do fluxo hep\u00e1tico no f\u00edgado remanescente ap\u00f3s hepatectomia ou no f\u00edgado \n\ntransplantado, seja ele um enxerto completo ou parcial (nos casos de transplante intervivos ou \n\nsplit-liver), se faz essencialmente pela veia porta, a manuten\u00e7\u00e3o da HABR causa redu\u00e7\u00e3o no \n\nfluxo arterial, que pode ser potencialmente prejudicial \u00e0 fun\u00e7\u00e3o do \u00f3rg\u00e3o (VOLLMAR; \n\nMENGER, 2009; EIPEL; ABSHAGEN; VOLLMAR, 2010). A s\u00edndrome do small-for-size \n\nvista no transplante split-liver e no intervivos est\u00e1 associada a um hiperfluxo e hipertens\u00e3o \n\nportal exagerada para o tamanho do enxerto hep\u00e1tico, tendo como consequ\u00eancia, uma marcante \n\nredu\u00e7\u00e3o do fluxo arterial e vasoespamo arterial, induzindo em casos graves uma \n\n\u201cdesarterializa\u00e7\u00e3o\u201d funcional secund\u00e1ria a uma resposta preservada da HABR (KELLY et al., \n\n2009).  \n\n \n\n2.1.6. Cintilografia de Perfus\u00e3o Hep\u00e1tica  \n\n \n\nA cintilografia de perfus\u00e3o hep\u00e1tica ou angiocintilografia \u00e9 um m\u00e9todo radioisot\u00f3pico utilizado \n\nna investiga\u00e7\u00e3o da perfus\u00e3o do f\u00edgado nas doen\u00e7as hep\u00e1ticas. Foi bem estudado na cirrose e na \n\npresen\u00e7a de met\u00e1stases malignas intra-hep\u00e1ticas (LEEN et al., 1993; WARREN et al., 1998; \n\nDRAGOTEANU et al., 2004a). Ela mede as fra\u00e7\u00f5es entre os fluxos arterial e venoso portal do \n\ntotal de fluxo sangu\u00edneo hep\u00e1tico. A porcentagem de fluxo sangu\u00edneo hep\u00e1tico suprido pela \n\n\n\n45 \n \n\nart\u00e9ria hep\u00e1tica \u00e9 estimada matematicamente pelo \u00edndice de perfus\u00e3o hep\u00e1tica (IPH), \n\nnormalmente situado entre 25 \u2013 40%. As altera\u00e7\u00f5es na din\u00e2mica da circula\u00e7\u00e3o hep\u00e1tica na \n\ncirrose e consequentemente dos achados cintilogr\u00e1ficos s\u00e3o determinadas pelo mecanismo \n\nvascular de hepatic arterial buffer response (HABR) (DRAGOTEANU et al., 2004a; LAUTT, \n\n2009).  \n\n \n\nA avalia\u00e7\u00e3o angiocintilogr\u00e1fica do fluxo arterial hep\u00e1tico em cirr\u00f3ticos \u00e9 feita atrav\u00e9s do c\u00e1lculo \n\ndo \u00edndice de perfus\u00e3o hep\u00e1tico (IPH), tendo como base fisiol\u00f3gica o HABR. Ele consiste do \n\nquociente entre o fluxo pela art\u00e9ria hep\u00e1tica e o fluxo hep\u00e1tico total (art\u00e9ria hep\u00e1tica + veia \n\nporta) (O\u2019CONNOR; MACMATHUNA; KEELING, 1988; O\u2019CONNOR et al., 1992; \n\nWARREN et al., 1998; PANDHARIPANDE et al., 2005). Um \u00edndice normal, como dito \n\nanteriormente, situa-se entre 25-40%. Assim, quando h\u00e1 um aumento da perfus\u00e3o pela art\u00e9ria \n\nhep\u00e1tica, observa-se aumento do IPH. Nas doen\u00e7as hep\u00e1ticas cr\u00f4nicas, um IPH superior a 50% \n\nsugere uma arterializa\u00e7\u00e3o da perfus\u00e3o hep\u00e1tica guiando o diagn\u00f3stico de cirrose e hipertens\u00e3o \n\nportal. Na cirrose, por sua vez, um IPH maior que 100% ressalta a revers\u00e3o do fluxo portal. \n\nEntretanto, como descrito anteriormente, esse quociente, aparentemente \u201csuprafisiol\u00f3gico\u201d \n\npode estar relacionado aos shunts arterioportais intra-hep\u00e1ticos, contribuindo por esse \n\nincremento no componente arterial (AOKI et al., 2005). A Figura 12 ilustra a representa\u00e7\u00e3o \n\ngr\u00e1fica das curvas de tempo \u2013 atividade da angiocintilografia em diferentes situa\u00e7\u00f5es refletindo \n\nnas modifica\u00e7\u00f5es do IPH.  \n\n \n\nEstas altera\u00e7\u00f5es perfusionais detectadas pelos estudos de perfus\u00e3o, principalmente a \n\nangiocintilografia, revestem-se de import\u00e2ncia cl\u00ednica em virtude de sua precocidade, podendo \n\nser encontradas antes de altera\u00e7\u00f5es morfol\u00f3gicas da circula\u00e7\u00e3o porto-hep\u00e1tica vistas em exames \n\nde imagem convencionais (DRAGOTEANU et al., 2004b, 2008). O aumento do IPH pode ser \n\ndetectado inclusive nos casos de hipertens\u00e3o portal n\u00e3o cirr\u00f3ticas e obstru\u00e7\u00e3o portal extra-\n\nhep\u00e1tica, como observado por Shikare e cols (SHIKARE et al., 1996).  \n\n \n\n\n\n46 \n \n\n \n\nFigura 12 \u2013 Angiocintilografia hep\u00e1tica ilustrando as curvas tempo x atividade do f\u00edgado \n\ne do rim (esta \u00faltima utilizada para determinar temporalmente os fluxos da art\u00e9ria \n\nhep\u00e1tica \u2013 G1 e veia porta \u2013 G2). As imagens demosntram uma cintilografia normal, com \n\nIPH em torno de 30% (A), um paciente cirr\u00f3tico com IPH pr\u00f3ximo de 60% (B) e um \n\npaciente cirr\u00f3tico com fluxo portal reverso e IPH pr\u00f3ximo de 130% (C). (Dragoteanu, M \n\n2008) \n\n \n\nAs modifica\u00e7\u00f5es da perfus\u00e3o hep\u00e1tica, com aumento do fluxo arterial sobre o portal podem ser \n\ndetectadas n\u00e3o s\u00f3 na cirrose como tamb\u00e9m nas met\u00e1stases hep\u00e1ticas de tumores malignos \n\ncolorretais. (LEEN et al., 1991, 1993, 1996; HAYANO, 2014;) Estes tumores hipervasculares \n\npromovem angiog\u00eanese e neovasculariza\u00e7\u00e3o arterial, culminando em aumento da perfus\u00e3o \n\narterial e diminui\u00e7\u00e3o do fluxo portal ao f\u00edgado, com aumento do IPH \u00e0 semelhan\u00e7a da cirrose. \n\n(LEEN et al., 1993) Tumores benignos n\u00e3o alteram a rela\u00e7\u00e3o portal/arterial da perfus\u00e3o \n\nhep\u00e1tica. Fato relevante \u00e9 que as met\u00e1stases aumentam o fluxo arterial, e consequentemente o \n\nIPH, de forma muito r\u00e1pida, antes mesmo que possam ser observadas em exames de imagem \n\nconvencionais (LEVESON et al., 1983; DRAGOTEANU et al., 2004b).  \n\n \n\nEstudos utilizando cintilografia hep\u00e1tica em esquistossom\u00f3ticos s\u00e3o limitados ao aspecto \n\nmorfol\u00f3gico, n\u00e3o havendo avalia\u00e7\u00e3o das caracter\u00edsticas perfusionais. Razzak e cols. na d\u00e9cada \n\nde 1960 no Egito realizaram cintilografia hep\u00e1tica com ouro coloidal (Au198) em 60 \n\n\n\n47 \n \n\nesquistossom\u00f3ticos previamente categorizados em quatro grupos de acordo com a gravidade da \n\ndoen\u00e7a (Grau I \u2013 assintom\u00e1ticos; Grau II \u2013 presen\u00e7a de hepatoesplenomegalia; Grau III \u2013 \n\npresen\u00e7a de varizes esof\u00e1gicas; Grau IV \u2013 presen\u00e7a de ascite). Este autor estimou o fluxo \n\nsangu\u00edneo hep\u00e1tico atrav\u00e9s do tempo de meia vida de desaparecimento do radiois\u00f3topo do \n\npar\u00eanquima hep\u00e1tico. Entre os achados, foi evidenciado que pacientes classificados como Grau \n\nI apresentavam fluxo sangu\u00edneo hep\u00e1tico normal, enquanto pacientes classificados como Graus \n\nII, III e IV apresentavam redu\u00e7\u00e3o do fluxo sangu\u00edneo hep\u00e1tico, sendo esta redu\u00e7\u00e3o proporcional \n\n\u00e0 gravidade da doen\u00e7a hep\u00e1tica (RAZZAK, 1964).  \n\n \n\nIio e cols. estudando 466 pacientes japoneses com teste cut\u00e2neo positivo para Schistosoma \n\njaponica atrav\u00e9s da cintilografia hep\u00e1tica com ouro coloidal, encontraram como caracter\u00edstica \n\nda doen\u00e7a a atrofia do lobo hep\u00e1tico direito, altera\u00e7\u00e3o esta, relacionada com a gravidade do \n\nacometimento hep\u00e1tico (IIO et al., 1971).  Mustafa e cols, por sua vez, no Egito, onde a \n\nesquistossomose tamb\u00e9m \u00e9 end\u00eamica, correlacionaram a gravidade da doen\u00e7a \n\nesquistossom\u00f3tica com as altera\u00e7\u00f5es do aspecto hep\u00e1tico \u00e0 cintilografia, tamb\u00e9m com ouro \n\ncoloidal (MUSTAFA et al., 1966).  \n\n \n\nPercebe-se, ent\u00e3o, que na avalia\u00e7\u00e3o cintilogr\u00e1fica da esquistossomose, n\u00e3o h\u00e1 estudos com o \n\nobjetivo de estimar a perfus\u00e3o hep\u00e1tica ou observar poss\u00edveis altera\u00e7\u00f5es no fluxo sangu\u00edneo do \n\nf\u00edgado desta que \u00e9 uma das principais causas de doen\u00e7a hep\u00e1tica cr\u00f4nica do mundo, com um \n\nmecanismo fisiopatol\u00f3gico caracter\u00edstico bem documentado. \n\n \n\n \n\n \n\n  \n\n\n\n48 \n \n\n2.2.JUSTIFICATIVA \n\n \n\nUma vez que a esquistossomose cursa com altera\u00e7\u00f5es da fisiologia da perfus\u00e3o portal \n\nsecund\u00e1rias \u00e0 redu\u00e7\u00e3o da vasculariza\u00e7\u00e3o portal intra-hep\u00e1tica, pode-se sugerir que ocorram \n\nmodifica\u00e7\u00f5es perfusionais semelhantes \u00e0 cirrose onde est\u00e1 documentado um aumento \n\ncompensat\u00f3rio da perfus\u00e3o atrav\u00e9s da art\u00e9ria hep\u00e1tica. Estas altera\u00e7\u00f5es podem ser detectadas \n\npela angiocintilografia e relacionadas a vari\u00e1veis cl\u00ednicas e crit\u00e9rios de gravidade. \n\n \n\nAt\u00e9 o momento, os estudos que utilizaram a cintilografia hep\u00e1tica na esquistossomose foram \n\nlimitados ao aspecto morfol\u00f3gico, n\u00e3o havendo avalia\u00e7\u00e3o das caracter\u00edsticas perfusionais. N\u00e3o \n\nh\u00e1, portanto, como na cirrose, avalia\u00e7\u00f5es in vivo das repercuss\u00f5es na hemodin\u00e2mica hep\u00e1tica \n\ndecorrentes das oclus\u00f5es dos ramos portais e da hipertrofia do setor arterial intra-hep\u00e1ticos na \n\nEHE. O presente, ao tentar, preencher esta lacuna e relacionar as altera\u00e7\u00f5es da \n\nangiocintilografia com vari\u00e1veis cl\u00ednicas e ultrassonogr\u00e1ficas conhecidas ser\u00e1 capaz de ampliar \n\no conhecimento sobre esta enfermidade multifatorial e bastante heterog\u00eanea, podendo \n\nacrescentar novas perspectivas na condu\u00e7\u00e3o de pacientes com EHE. \n\n \n\n  \n\n\n\n49 \n \n\n2.3.OBJETIVOS \n\n \n\n2.3.1. Objetivo Geral \n\n \n\nVerificar altera\u00e7\u00f5es da hemodin\u00e2mica hep\u00e1tica em esquistossom\u00f3ticos com a forma \n\nhepatoespl\u00eanica atrav\u00e9s da cintilografia de perfus\u00e3o hep\u00e1tica, e correlacion\u00e1-las com vari\u00e1veis \n\ncl\u00ednicas e ultrassonogr\u00e1ficas de hipertens\u00e3o portal. \n\n \n\n2.3.2. Objetivos espec\u00edficos  \n\n \n\n? Comparar o IPH em esquistossom\u00f3ticos com forma HE com indiv\u00edduos sem doen\u00e7a \n\nhep\u00e1tica; \n\n? Relacionar o IPH com os calibres das veias porta e espl\u00eanica e di\u00e2metro longitudinal do \n\nba\u00e7o, avaliados pela USG do abdome e com a quantifica\u00e7\u00e3o de plaquetas; \n\n? Relacionar o IPH com o padr\u00e3o de fibrose periportal avaliado pela USG, empregando o \n\nescore de Niamey (ABDEL-WAHAB et al., 1992); \n\n? Relacionar o IPH com achados endosc\u00f3picos de varizes esof\u00e1gicas e seu calibre, \n\nempregando a classifica\u00e7\u00e3o de Palmer e Brick (PALMER; BRICK, 1956); \n\n? Relacionar o IPH com a hist\u00f3ria de epis\u00f3dios de hemorragia digestiva. \n\n \n\n \n\n  \n\n\n\n50 \n \n\n2.4.HIP\u00d3TESES \n\n \n\n? Na forma hepatoespl\u00eanica da esquistossomose mans\u00f4nica, a angiocintilografia \n\napresenta-se alterada com aumento do IPH; \n\n? Quanto maior o IPH medido pela angiocintilografia, maior o calibre das veias porta e \n\nespl\u00eanica, maior o di\u00e2metro longitudinal espl\u00eanico e menor a concentra\u00e7\u00e3o de plaquetas; \n\n? Pacientes com padr\u00f5es mais avan\u00e7ados de fibrose hep\u00e1tica apresentam maiores IPH; \n\n? Pacientes com maiores IPH exibem varizes esof\u00e1gicas mais calibrosas \u00e0 endoscopia \n\ndigestiva; \n\n? Esquistossom\u00f3ticos com passado de hemorragia digestiva apresentam maiores IPH. \n\n  \n\n\n\n51 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nM\u00c9TODOS \n\n  \n\n\n\n52 \n \n\n3. M\u00c9TODOS \n\n \n\n3.1.Delineamento do Estudo \n\nConstituiu de um estudo de natureza transversal e anal\u00edtica, por meio do qual foram avaliadas \n\naltera\u00e7\u00f5es da hemodin\u00e2mica hep\u00e1tica, atrav\u00e9s da cintilografia de perfus\u00e3o hep\u00e1tica. Foram \n\nfeitas as aferi\u00e7\u00f5es dos \u00edndices de perfus\u00e3o hep\u00e1tica, capta\u00e7\u00e3o de radiois\u00f3topo pelo f\u00edgado e pelo \n\nba\u00e7o em esquistossom\u00f3ticos com a forma hepatoespl\u00eanica da doen\u00e7a, em compara\u00e7\u00e3o com \n\nindiv\u00edduos sem doen\u00e7a hep\u00e1tica. A Figura 13 ilustra o fluxograma das etapas da pesquisa. \n\n \n\n \n\n      * Endoscopia digestiva n\u00e3o foi realizada no grupo controle \n\nFigura 13. \u2013 Fluxograma das etapas da pesquisa \n\n \n\n \n\n \n\n\n\n53 \n \n\n3.2.Local e Popula\u00e7\u00e3o do Estudo \n\nA amostra do estudo caracterizou-se por ser uma amostra por conveni\u00eancia, composta por \n\npacientes com esquistossomose mans\u00f4nica forma hepatoespl\u00eanica acompanhados nos \n\nambulat\u00f3rios de Esquistossomose e Hepatologia do Hospital das Cl\u00ednicas da Universidade \n\nFederal de Pernambuco (HC-UFPE). Para o grupo controle foram selecionados pacientes \n\nprovenientes dos ambulat\u00f3rios de Cl\u00ednica M\u00e9dica e Cardiologia do mesmo hospital com \n\ndiagn\u00f3stico de hipertens\u00e3o arterial prim\u00e1ria bem controlada com anti-hipertensivos, \n\nvalvulopatia reum\u00e1tica n\u00e3o-complicada e hipotireoidismo controlado com levotiroxina. \n\n \n\n3.2.1. Crit\u00e9rios de Inclus\u00e3o \n\n? Diagn\u00f3stico de esquistossomose hepatoespl\u00eanica atrav\u00e9s da epidemiologia positiva, \n\nparasitol\u00f3gico de fezes positivo ou hist\u00f3ria de tratamento pr\u00e9vio para S. mansoni; \n\n? Exame ultrassonogr\u00e1fico, feito por profissional habilitado, com evid\u00eancia de fibrose \n\nperiportal graduada segundo o protocolo de Niamey-Belo Horizonte, presen\u00e7a de \n\nesplenomegalia ou outro sinal de hipertens\u00e3o portal, com ou sem epis\u00f3dios pr\u00e9vios de \n\nhemorragia digestiva alta; \n\n? Pacientes com faixa et\u00e1ria acima de 18 anos de ambos os sexos; \n\n? Controles \n\no Indiv\u00edduos sem doen\u00e7a hep\u00e1tica documentada por ultrassonografia normal, \n\naminotransferases, bilirrubinas, albumina e tempo de protrombina normais. \n\n \n\n3.2.2. Crit\u00e9rios de Exclus\u00e3o \n\n? Pacientes com doen\u00e7a hep\u00e1tica mista (esquistossomose associada \u00e0 doen\u00e7a hep\u00e1tica \n\nalco\u00f3lica ou hepatites virais cr\u00f4nicas B e/ou C), caracterizada pela positividade das \n\nsorologias Anti-HBc, Anti-HCV ou hist\u00f3ria de ingest\u00e3o de mais de 60g/dia de etanol; \n\n? Evid\u00eancia ultrassonogr\u00e1fica de esteatose hep\u00e1tica ou fibrose fina difusa associada fibrose \n\nperiportal; \n\n? Pacientes esplenectomizados; \n\n? Evid\u00eancia ultrassonogr\u00e1fica de Trombose de veia porta; \n\n? Antecedente de hemorragia digestiva 30 dias antes do exame cintilogr\u00e1fico; \n\n? Insufici\u00eancia renal (definida como creatinina s\u00e9rica >2,0mg/dL); \n\n? Gestantes e Pu\u00e9rperas; \n\n\n\n54 \n \n\n \n\n3.3.Defini\u00e7\u00e3o e categoriza\u00e7\u00e3o das vari\u00e1veis \n\n? Os pacientes esquistossom\u00f3ticos inclu\u00eddos foram submetidos \u00e0 anamnese detalhada em \n\nbusca de antecedentes de hemorragia digestiva e exame cl\u00ednico. Pun\u00e7\u00e3o venosa perif\u00e9rica \n\nfoi realizada para colher exames laboratoriais: bilirrubinas, albumina, tempo e atividade de \n\nprotrombina, INR, fosfatase alcalina, gama-glutamil transferase, creatinina s\u00e9rica e \n\nplaquetas.  \n\n \n\n? Inicialmente, ultrassonografia abdominal com Doppler colorido utilizando um equipamento \n\nAcuson X 150, 3,5MHz, Siemens, foi realizada por examinador \u00fanico e experiente, atrav\u00e9s \n\nda qual foi confirmada a presen\u00e7a e o grau da fibrose periportal pela classifica\u00e7\u00e3o de Niamey \n\n(variando de Padr\u00e3o A \u2013 normal \u2013 a Padr\u00e3o F \u2013 fibrose hep\u00e1tica muito avan\u00e7ada) e aferidos \n\no maior di\u00e2metro espl\u00eanico (em cent\u00edmetros) com ponto de corte de normal inferior a 13cm, \n\no calibre das veias porta e espl\u00eanica (em cent\u00edmetros) com ponto de corte normal inferior a \n\n1,3cm e 1,0cm, respectivamente.  \n\n \n\n? Exame de endoscopia digestiva alta foi realizado naqueles pacientes esquistossom\u00f3ticos \n\ncom \u00faltima avalia\u00e7\u00e3o endosc\u00f3pica h\u00e1 mais de seis meses da inclus\u00e3o no estudo. Neste \n\nexame foi observada a presen\u00e7a de varizes esofagog\u00e1stricas, segundo a classifica\u00e7\u00e3o de \n\nPalmer e Brick (F1 \u2013 fino calibre; F2 \u2013 m\u00e9dio calibre e F3 \u2013 grosso calibre) (PALMER; \n\nBRICK, 1956). \n\n \n\n? Os pacientes selecionados foram, posteriormente, encaminhados ao setor de Medicina \n\nNuclear do Hospital das Cl\u00ednicas \u2013 UFPE onde, ap\u00f3s jejum noturno de oito horas, se \n\nsubmeteram \u00e0 cintilografia de perfus\u00e3o hep\u00e1tica. Esta, por sua vez, foi realizada com o \n\nposicionamento do paciente na gama-c\u00e2mara em dec\u00fabito dorsal, sendo infundido um bolus \n\nintravenoso em m\u00e9dia de 135 MBq de 99mTc ligado a enxofre coloidal num volume de 2 mL \n\nem veia da fossa antecubital. Imagens do abdome concentradas no f\u00edgado e rins foram \n\nobtidas a cada dois segundos, durante dois minutos, conforme o protocolo descrito por \n\nWarren et al. (WARREN et al., 1998) \u2013 Ap\u00eandice 1.  \n\n \n\nAs imagens geradas foram analisadas por um \u00fanico examinador, o qual demarcava um ROI \n\n(Region Of Interest) na topografia do rim esquerdo para gerar a curva de capta\u00e7\u00e3o tempo\u2013\n\natividade renal e demarcar o pico de capta\u00e7\u00e3o renal. Nos indiv\u00edduos com grandes \n\n\n\n55 \n \n\nesplenomegalias, que dificultavam a demarca\u00e7\u00e3o do rim esquerdo, foi utilizado o rim direito \n\npara os c\u00e1lculos. Em seguida foram demarcados ROIs sobre o f\u00edgado para, assim, gerar as \n\ncurvas de capta\u00e7\u00e3o tempo\u2013atividade hep\u00e1tica. \n\n \n\nO pico de capta\u00e7\u00e3o na art\u00e9ria renal esquerda foi utilizado para demarcar os componentes \n\narterial e portal do fluxo sangu\u00edneo hep\u00e1tico nas curvas de tempo\u2013atividade hep\u00e1ticas. A \n\npartir da curva de tempo-atividade hep\u00e1tica, as \u00e1reas sob a curva dos dez segundos \n\nimediatamente antes (G1) \u2013 componente arterial \u2013 e nos dez segundos imediatamente depois \n\n(G2) \u2013 componente arterial e portal \u2013 do pico de capta\u00e7\u00e3o da art\u00e9ria renal esquerda foram \n\ncalculados atrav\u00e9s da an\u00e1lise de regress\u00e3o quadrada utilizando o Microsoft Excel\u2122 2010. \n\nO \u00cdndice de Perfus\u00e3o Hep\u00e1tico (IPH) foi expresso como o quociente entre gradiente arterial \n\nhep\u00e1tico (G1) e a soma dos gradientes arterial e venoso portal (G2): IPH = (G1)/ (G1 + G2) \n\nx 100. O observador desconhecia a identidade e os resultados ultrassonogr\u00e1ficos dos \n\npacientes. O limite superior aceito como normal para o IPH foi de 40% (LEVESON et al., \n\n1983; WARREN et al., 1998; DRAGOTEANU et al., 2008). Dessa forma, resultados \n\nsuperiores a este ponto de corte indicaram haver maior \u201carterializa\u00e7\u00e3o\u201d do fluxo sangu\u00edneo \n\nhep\u00e1tico. A Figura 14 ilustra as etapas da angiocintilografia hep\u00e1tica. Esta medida do IPH \n\nfoi, concomitantemente, realizada nos indiv\u00edduos sem doen\u00e7a hep\u00e1tica a fim de se obter um \n\nvalor de normalidade para o tipo de popula\u00e7\u00e3o estudada e confirmar se este valor de \n\nnormalidade estava de acordo com os referidos em estudos anteriores (LEVESON et al., \n\n1983; WARREN et al., 1998; DRAGOTEANU et al., 2008). \n\n \n\n? Tabula\u00e7\u00e3o e verifica\u00e7\u00e3o dos dados \n\n \n\n3.4.An\u00e1lise Estat\u00edstica \n\nOs dados obtidos foram devidamente tabulados usando o Microsoft Excel\u2122 2010 e os testes \n\nestat\u00edsticos e descritos abaixo realizados empregando o software SPSS 20.0 vers\u00e3o em \n\nportugu\u00eas. Inicialmente, os resultados do IPH, tanto dos pacientes esquistossom\u00f3ticos, quanto \n\ndos normais foram categorizados em normais (com IPH ? 40%) e alterados (com IPH > 40%) \n\ne, assim, submetidos aos testes de normalidade de Shapiro-Wilk e de homogeneidade de \n\nvari\u00e2ncia de Bartlett, evidenciando-se distribui\u00e7\u00e3o normal, por\u00e9m heterog\u00eanea. Dessa forma foi \n\nutilizado para a avalia\u00e7\u00e3o estat\u00edstica o teste exato de Fisher para a compara\u00e7\u00e3o de frequ\u00eancias \n\n\n\n56 \n \n\nentre os pacientes com exame cintilogr\u00e1ficos normais e alterados. Um valor de p&lt;0,05 foi \n\nutilizado para avaliar o n\u00edvel de signific\u00e2ncia dos resultados obtidos. \n\n \n\nA an\u00e1lise comparativa intergrupos do padr\u00e3o de fibrose hep\u00e1tica, presen\u00e7a de colaterais, varizes \n\nesofagog\u00e1stricas e antecedentes de hemorragia digestiva alta tamb\u00e9m foi realizada usando o \n\nteste estat\u00edstico exato de Fisher, por se tratarem de dados categ\u00f3ricos. Um valor de p&lt;0,05 foi \n\nutilizado para avaliar o n\u00edvel de signific\u00e2ncia dos resultados obtidos. Entre os pacientes \n\nesquistossom\u00f3ticos para a compara\u00e7\u00e3o dos grupos com IPH ? 40% e IPH > 40% no que se \n\nrefere \u00e0s medidas do comprimento do ba\u00e7o e di\u00e2metros das veias porta foi utilizado o teste t \n\nindependente por se tratarem de dados num\u00e9ricos de distribui\u00e7\u00e3o normal. J\u00e1 para a compara\u00e7\u00e3o \n\nentre os di\u00e2metros da veia espl\u00eanica e a contagem de plaquetas foi utilizado o teste de Mann-\n\nWhitney devido \u00e0 distribui\u00e7\u00e3o n\u00e3o normal dessas duas \u00faltimas vari\u00e1veis.  \n\n \n\nPara o c\u00e1lculo das correla\u00e7\u00f5es entre o IPH e o di\u00e2metro do ba\u00e7o, di\u00e2metro das veias porta e \n\nespl\u00eanica e quantifica\u00e7\u00e3o de plaquetas foi utilizado o coeficiente de correla\u00e7\u00e3o de Pearson (?). \n\nValores maiores ou iguais a 0,7 indicam forte correla\u00e7\u00e3o, entre 0,3 e 0,7, correla\u00e7\u00e3o moderada \n\ne entre 0 e 0,3 fraca correla\u00e7\u00e3o. Uma curva ROC foi desenvolvida utilizando o di\u00e2metro \n\nlongitudinal do ba\u00e7o em rela\u00e7\u00e3o aos resultados do IPH \u00e0 angiocintilografia. Assim, foi avaliado \n\no ponto de corte do comprimento do ba\u00e7o que melhor definia o IPH como alterado ou n\u00e3o. \n\nOutra curva ROC foi criada utilizando os valores do IPH em rela\u00e7\u00e3o \u00e0 presen\u00e7a de varizes \n\nesof\u00e1gicas de grosso calibre (F3), para avaliar a sensibilidade e especificidade do teste \n\ncintilogr\u00e1fico em prever a presen\u00e7a de varizes mais calibrosas. \n\n \n\n \n\n3.5.Aspectos \u00c9ticos \n\nO presente trabalho, devidamente aprovado pelo Comit\u00ea de \u00c9tica e Pesquisa da Universidade \n\nFederal de Pernambuco (CEP-UFPE) - CAAE 27612814.9.0000.5208 (Anexo 1.). Todos os \n\npacientes autorizaram a participa\u00e7\u00e3o no estudo por meio da assinatura do Termo de \n\nConsentimento Livre e Esclarecido (Ap\u00eandice 2.). \n\n \n\n  \n\n\n\n57 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 14. \u2013 Passo a passo da angiocintilografia hep\u00e1tica. (A) Demarca\u00e7\u00e3o do ROI sobre \n\no rim na imagem cintilogr\u00e1fica din\u00e2mica. (B) Obten\u00e7\u00e3o da curva de tempo\u2013atividade renal \n\ncom a defini\u00e7\u00e3o do pico de capta\u00e7\u00e3o renal em 21 segundos. (C) Demarca\u00e7\u00e3o de ROIs sobre \n\no f\u00edgado e ba\u00e7o, inicialmente em imagem cintilogr\u00e1fica est\u00e1tica e posteriormente (D) em \n\nimagem din\u00e2mica. (E) Obten\u00e7\u00e3o da curva de tempo\u2013atividade hep\u00e1tica com defini\u00e7\u00e3o do \n\nponto coincidente com o pico de capta\u00e7\u00e3o renal. (F) Obten\u00e7\u00e3o das \u201c\u00e1reas sobre a curva\u201d \n\n10 segundos antes \u2013 G1 \u2013 e 10 segundos ap\u00f3s \u2013 G2 \u2013 o pico de capta\u00e7\u00e3o renal para o c\u00e1lculo \n\ndo \u00cdndice de Perfus\u00e3o Hep\u00e1tico. \n\n  \n\nB \n\nE \n\nF \n\nA \n\nC \n\nD \n\n\n\n58 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nIncreased Hepatic Arterial Blood Flow \n\nMeasured by Hepatic \n\nPerfusion Index in Hepatosplenic \n\nSchistosomiasis: New Concepts \n\nfor an Old Disease \n\n \n\n \n\n\n\n59 \n \n\nABSTRACT \n\nBackground: Portal vein obstructive lesions associated with hypertrophy of the hepatic artery \n\nterritory are observed in mansoni schistosomiasis. Liver perfusion scintigraphy is a method \n\nused in the evaluation of hepatic perfusion changes in liver diseases. It has been suggested that, \n\nlikely in cirrhosis, where the compensatory increase in perfusion through the hepatic artery is \n\ndocumented, perfusion changes occur in hepatosplenic schistosomiasis (HSS). Aims: This \n\nstudy was aimed to determine changes in liver hemodynamics of hepatosplenic schistosomiasis \n\nthrough hepatic perfusion scintigraphy. It also tried to correlate these changes with clinical and \n\nlaboratory variables and ultrasound findings on HSS. Methods: Nineteen patients with \n\nschistosomiasis underwent ultrasound evaluation of the degree of liver fibrosis, splenic length, \n\nsplenic and portal vein diameters, digestive endoscopy and quantification of platelets. \n\nSubsequently, perfusion scintigraphy with measurement of hepatic perfusion index (HPI) was \n\nperformed. Results: It was observed that patients with hepatosplenic schistosomiasis had \n\nsignificant increase in HPI compared to normal individuals (p = 0.0029) and that this increase \n\ncorrelates with splenic length (p = 0.038) and esophageal varices diameter (p = 0.0060), and \n\nangioscintigraphy has high accuracy in predicting the presence of large esophageal varices. \n\nConclusion: It was concluded that angioscintigraphy was able to show that patients with HSS \n\nhad increased HPI, featuring greater liver \"arterialization\", as previously described for cirrhotic \n\npatients. The correlation between HPI and the longitudinal splenic length, caliber of esophageal \n\nvarices, caliber of the portal vein and blood platelet count was also observed. Angioscintigraphy \n\nis a promising field in the evaluation of hepatosplenic schistosomiasis. \n\nKey words: Hepatosplenic schistosomiasis; scintigraphy; angioscintigraphy; hepatic \n\nperfusion  \n\n\n\n60 \n \n\nINTRODUCTION \n\nSchistosomiasis infection is a parasitic disease caused by Schistosoma worms being the \n\nSchistosoma mansoni the only species described in Brazil [1]. It is considered endemic in 78 \n\ncountries in Africa, Asia, Central and South America, occuring in places with inadequate \n\nsanitation [2]. The hepatosplenic form (HSS) is the most serious and more typical stage on the \n\ndisease evolution [3,4]. The dominant changes observed are obstructive lesions of the portal \n\nvein. Studies on plastic models have shown that  portal vein is the least prominent of the three \n\nvascular sectors [5,6]. Changes in the hepatic artery vascular bed can be considered \n\ncompensatory to the decrease in portal vein flow [7,8]. However, changes in arterial \n\nvascularization are still object of controversy, with angiographic studies showing reduction in \n\narterial perfusion in HSS [9\u201311]. \n\nHepatic perfusion scintigraphy or angioscintigraphy is a radioisotopic method used in \n\nstudies of liver perfusion and their changes in various liver diseases, especially cirrhosis and \n\nintrahepatic colorectal metastasis [12,13]. It measures the fractions of arterial and portal flows \n\nof the total hepatic blood flow. The scintigraphic assessment of hepatic blood flow is done by \n\ncalculating the hepatic perfusion index (HPI), a ratio between the hepatic artery flow and the \n\ntotal hepatic flow [14,15]. Thus, when there is an increase in the hepatic artery perfusion, an \n\nincrease in HPI is observed. In chronic liver disease, HPI exceeding 40% suggests \n\n\u201carterialization\u201d of the liver perfusion, guiding the diagnosis of portal hypoperfusion [16]. \n\nSo far, studies using liver scintigraphy in schistosomiasis were limited to morphological \n\nevaluation, with no assessment of perfusion characteristics [17\u201319]. There are no in vivo \n\nevaluations of the hepatic hemodynamics effects caused by occlusions of portal branches and \n\nassociated hypertrophy of intra-hepatic arterial sector in HSS. Once schistosomiasis courses \n\nwith changes in the portal perfusion physiology, secondary to reduced intrahepatic portal \n\n\n\n61 \n \n\nvasculature, it may be suggested that changes similar to cirrhosis could occur and would be \n\ndetected by angioscintigraphy. \n\nThe purpose of this study was to fill in this gap by assessing abnormal liver \n\nhemodynamics in HSS using hepatic perfusion scintigraphy, and to correlate these changes with \n\nclinical and sonographic variables. So, there will be more elements to expand the knowledge \n\nabout this very heterogeneous and multifactorial disease, and may add new perspectives in the \n\nmanagement of patients with severe forms of schistosomiasis.  \n\n\n\n62 \n \n\nMATERIALS AND METHODS \n\nThis is a cross-sectional analytical study where liver hemodynamic changes were \n\nassessed by liver perfusion scintigraphy. Liver radioisotope uptake measurements were made \n\nin patients with HSS compared to individuals without liver disease. The study has been \n\napproved by the local Ethics Research Committee and all subjects signed the informed consent \n\nform. \n\nPatients \n\nThe study subjects were chosen as a convenience sample composed of patients with \n\nHSS followed at the outpatient clinics of the General Hospital, Federal University of \n\nPernambuco (HC-UFPE). For the control group, patients with well controlled essential \n\nhypertension, uncomplicated rheumatic cardiopathy and hypothyroidism controlled with \n\nlevothyroxine were selected. \n\nInclusion criteria \n\n? Hepatosplenic schistosomiasis diagnosed by positive epidemiology, positive parasitological \n\nstool test or history of previous treatment for S. mansoni; \n\n? Ultrasound examination, done by qualified professional, with evidence of periportal fibrosis \n\n[20,21] graduated according to the Niamey-Belo Horizonte protocol [22,23], splenomegaly \n\nor other sign of portal hypertension, with or without previous episodes of upper \n\ngastrointestinal bleeding; \n\n? Patients over 18 years of both sexes; \n\nControls \n\nThe control group was composed of individuals without liver disease, documented by normal \n\nultrasound, aminotransferases, bilirubin, albumin and prothrombin time. The control group was \n\nage-matched according to the average age of the study group. \n\n \n\n\n\n63 \n \n\nExclusion criteria \n\n? Patients with mixed liver disease (schistosomiasis associated with alcoholic liver disease or \n\nchronic viral hepatitis B and / or C), characterized by the positivity of anti-HBc serology, \n\nAnti-HCV or history of ingestion of more than 60 g/day of ethanol; \n\n? Sonographic evidence of hepatic steatosis or diffuse thin fibrosis associated periportal \n\nfibrosis; \n\n?  Splenectomy; \n\n? Sonographic evidence of portal vein thrombosis, defined by identification of intraluminal \n\nthrombus, absence of portal flow or portal vein cavernomatous transformation; \n\n? Antecedent of digestive bleeding 30 days before scintigraphic examination; \n\n? Renal impairment (defined as serum creatinine > 2.0 mg/dL); \n\n? Pregnant and postpartum women; \n\nMethods \n\nPatients underwent detailed clinical history and clinical examination. Peripheral venous \n\npuncture was performed for the following laboratory tests: bilirubin, albumin, prothrombin \n\ntime, INR, alkaline phosphatase, gamma-glutamyl transferase, serum creatinine and platelets. \n\nInitially, abdominal color Doppler ultrasonography using Acuson X 150 equipment, \n\n3,5MHz Siemens, was carried out by a single and experienced examiner, through which the \n\npresence and degree of periportal fibrosis were confirmed by Niamey classification (ranging \n\nfrom Pattern A - Normal - to Pattern F - very advanced liver fibrosis), the splenic diameter was \n\nmeasured (in centimeters) with normal cutoff of less than 13cm and the caliber of the portal and \n\nsplenic veins (in centimeters) with normal lower cutoff of 1.3 cm and 1.0 cm, respectively.   \n\nUpper digestive endoscopy was performed in patients with HSS whose last endoscopic \n\nevaluation was carried out more than six months before the present study. The presence of \n\n\n\n64 \n \n\nesophageal varices was graduated according to Palmer and Brick classification (F1: &lt;3mm; \n\nF2: 3 \u2013 6mm and F3: > 6mm) [24]. \n\nSelected patients subsequently underwent liver perfusion scintigraphy after an overnight \n\nfasting period of eight hours. They were positioned in the gamma camera in supine decubitus. \n\nAn intravenous bolus of average 135 MBq (3.5 mCi) Tc-99m sulfur colloid bonded in a 2 ml \n\nvolume was infused in the antecubital fossa vein. Abdomen images, concentrated in the liver \n\nand kidney, were obtained every two seconds for a total of two minutes, according to protocol \n\ndescribed by Warren et al [12]. \n\nAfter the acquisition of images, a ROI (Region Of Interest) was marked in the left kidney \n\ntopography to generate the kidney curve uptake and mark the renal uptake peak. In individuals \n\nwith large splenomegaly, which hindered the left kidney demarcation, right kidney was used \n\nfor calculations. Then, ROIs were marked on the liver to generate the liver curve uptake. \n\nThe left renal artery uptake peak was used to demarcate the arterial and portal \n\ncomponents of the hepatic blood flow in hepatic time-activity curves. The areas under the curve \n\nof ten seconds immediately before - arterial component (G1) - and ten seconds immediately \n\nafter - portal component (G2) - the peak of the left renal artery uptake was calculated by \n\nregression analysis. Hepatic Perfusion Index (HPI) was expressed as the quotient between \n\nhepatic arterial gradient (G1) and the sum of arterial and portal venous gradients (G2): HPI = \n\n(G1) / (G1 + G2) x 100. The observer was blinded about the identity and sonographic results of \n\npatients. The upper limit accepted as normal for HPI was 40% [12,16,25]. Thus, results above \n\nthis cutoff point indicated that there was more \"arterialization\" of the hepatic blood flow. HPI \n\nmeasure has been concurrently carried out in individuals without liver disease in order to obtain \n\na normal value for the study population and confirm that this normal value was in accordance \n\nwith those shown in previous studies [12,16,25]. \n\nStatistical Analysis \n\n\n\n65 \n \n\nStatistical tests were performed using the SPSS software version 20. Initially, the HPI \n\nresults in both schistosomal and normal groups were categorized as normal (HPI ? 40%) and \n\nincreased (HPI> 40%) and then submitted to the Shapiro-Wilk normality test and Bartlett's \n\nhomogeneity of variances test, results seem to be normal, but with heterogeneous distribution. \n\nThus, the Fisher's exact test was used to compare frequencies among patients with normal and \n\nabnormal scintigraphic examination. Value of p&lt;0.05 was used to assess the significance level \n\nof results. \n\nThe inter-group comparative analysis of the liver fibrosis pattern, presence of collateral \n\ncirculation, esophageal varices and history of upper gastrointestinal bleeding was also \n\nperformed using Fisher's exact test, since they were categorical data. Among patients with \n\nschistosomiasis, for comparison between groups with HPI ? 40% and those with HPI > 40%, \n\nin relation to spleen length and diameters of portal veins, the independent t-test was used, since \n\nnumerical data were normally distributed. Comparison between splenic vein diameters and \n\nplatelet count was performed using Mann-Whitney test due to the non-normal distribution of \n\nthese last two variables. \n\nTo calculate the correlation between HPI and spleen diameter, portal and splenic veins \n\ndiameter and platelets count, the Pearson's correlation coefficient (?) was used. Values greater \n\nthan or equal to 0.7 indicate strong correlation, values between 0.3 and 0.7, moderate correlation \n\nand between 0 and 0.3 weak correlation. A ROC curve was developed using the spleen \n\nlongitudinal diameter in relation to the angioscintigraphic results of HPI, control group and \n\ngroup of schistosomiasis patients. Thus, the splenic length cutoff that would best define the HPI \n\nas increased or not was evaluated. Another ROC curve was designed using HPI values and the \n\npresence of large esophageal varices. The sensitivity and specificity of the scintigraphic method \n\nin predicting presence of risky esophageal varices was evaluated. \n\n  \n\n\n\n66 \n \n\nRESULTS  \n\nA total of 34 patients were initially included in the study, and eight patients were later \n\nexcluded due to the presence of fine diffuse fibrosis in the liver parenchyma associated with \n\nperiportal fibrosis, six to the presence of portal vein thrombosis and one to impossibility of \n\nacquiring a reliable renal curve on the scintigraphy study. Therefore, 19 patients with \n\nschistosomiasis completed the study protocol. Five patients without liver disease were \n\nsubmitted to the study protocol as a control group.  \n\nAmong the features of the study population, of the 19 patients included, 58% were \n\nfemale, with average age of 56 years (ranging from 25 to 77 years). All had preserved hepatic \n\nsynthetic function, characterized by normal levels of direct bilirubin, albumin, and prothrombin \n\ntime / INR and normal creatinine levels. None of them were taking non-selective beta-blockers.  \n\nRegarding the angioscintigraphy study, all five control patients without liver disease had \n\nHPI values considered normal, i.e. below 40% (respectively 30; 32; 35; 35; 36). In the \n\nschistosomiasis population, five of 19 patients (26.3%) had normal results, with the remaining \n\n14 (73.7%) showing increased HPI, higher than the 40% the cutoff point. This frequency \n\ndifference was statistically significant, with p = 0.0029. Figure 1 shows the comparison between \n\nthree hepatic uptake curves of two patients with schistosomiasis and one of an individual \n\nbelonging to the control group.  \n\nUltrasonographic analysis showed splenomegaly in 89.5% of patients, with a \n\nstatistically significant frequency among those with elevated HPI (p = 0.038). The other \n\nsonographic findings are shown in Table 1. Laboratory analysis evidenced that 84.2% had \n\nplatelet count less than 100,000/mm3. Regarding the endoscopic study, 84.2% had esophageal \n\nvarices, which were of large caliber in 62.5%, all from the group of patients with increased HPI. \n\nWhen patients with large esophageal varices (F3) were analyzed separately, the frequency of \n\n\n\n67 \n \n\npatients with increased HPI was statistically significant, with p = 0.0060. History of upper \n\ngastrointestinal bleeding was documented in 71.4%. Table 2 summarizes the main results. \n\nPearson correlation test for numerical variables showed strong positive correlation \n\nbetween increased HPI and longitudinal splenic length, with correlation coefficient (?) of \n\n0.7853. Analyzing the portal vein diameter and total platelets count, the correlation test resulted \n\nin moderate correlation between increased HPI and the increase of portal vein diameter, with a \n\nratio (?) of 0.3829, and decreased platelet count with correlation coefficient (?) of -0.4901. \n\nFigure 2 shows the scatterplots graphics for these three variables with their respective trend \n\nlines. Regarding the splenic vein diameter, although there is positive correlation between \n\nincreased HPI and increased vein caliber, this correlation was weak, with coefficient (?) of \n\n0.1391.  \n\nThe first designed ROC curve showed that cutoff for the splenic length of 14.4cm \n\ncorrelates well with increased HPI. The AUC (Area Under the Curve) of 0.9 with significant p-\n\nvalue of 0.001 demonstrates good accuracy of the splenic diameter in evaluating increased HPI, \n\nwith sensibility of 0.78 and specificity of 0.9. The second ROC curve correlates increased HPI \n\nwith the prediction of large esophageal varices on endoscopic findings. It also shows that cutoff \n\nvalue of 45% for HPI predicted the presence of large esophageal varices with sensitivity of 1.0, \n\nspecificity of 0.929 and AUC of 0.96 with significant p-value of 0.001 (Figure 3). \n\n \n\n  \n\n\n\n68 \n \n\nDISCUSSION \n\nThis study showed that the hepatic perfusion index (HPI), measured by \n\nangioscintigraphy with colloidal sulfur, is unusually high in patients with the hepatosplenic \n\nform of schistosomiasis, when compared to normal individuals. Thus, it could be inferred that \n\nin HSS, there is increased perfusion through the hepatic artery, increasing HPI. This suggests \n\nthat intra-hepatic changes related to the portal venous system distortion and the arterial system \n\nproliferation are responsible, not only for anatomical changes, but also for changes in the in \n\nvivo circulatory dynamics. \n\nTo date, no studies using nuclear medicine techniques have evaluated the perfusion \n\ncharacteristics of the liver in patients with HSS. Razzak, by calculating the hepatic uptake of \n\nradioactive gold Au-198m, suggested that the hepatic blood flow was reduced in patients with \n\nHSS, and this reduction was related to the severity of the liver disease [17]. However, these \n\ndata contradict the current knowledge based on experimental, ultrasound and hemodynamic \n\nstudies that despite the presence of liver fibrosis and portal hypertension, in schistosomiasis, \n\nthe total liver flow is normal [26-29]. Other scintigraphic studies in HSS population are \n\nrestricted to morphological features, such as Iio et al and Mustafa et al, which showed lower \n\nliver uptake of radioactive gold, atrophy of the right hepatic lobe, irregular liver surface and \n\nincreased splenic uptake of the radiotracer [18,19]. Our study extends previous observations \n\nfrom the perspective of perfusion alterations, previously described only in cirrhosis and liver \n\ncolorectal metastases. \n\nIn cirrhosis, the hepatic lobular architecture distortion causes a decrease in portal vein \n\nflow. This reduction, through multifactorial mechanism, provides an increase in the hepatic \n\narterial flow [30-35]. The most accepted theory involves the washout of adenosine described \n\nby Lautt [36-38]. Adenosine is released at a constant rate within the Mall space and is primarily \n\n\n\n69 \n \n\ncleared by the portal flow. In situations of portal hypoperfusion, the amount of accumulated \n\nadenosine, acting as a vasodilator, increases the hepatic artery inflow [39,40]. \n\nSchistosomal hepatopathy presents unique characteristics that differentiate it from those \n\nfound in cirrhosis [5]. The extensive hepatic fibrosis has a high dependence on parasitic load \n\ndue to massive egg embolization to the portal system [5,6,41]. Obliteration of small caliber \n\nportal vessels and the inflammatory and fibrovascular reactions in the host are the main factors \n\nresponsible for portal venous flow obstructions [5,6,42]. In HSS, despite obliterative changes \n\nin the portal venous system, the total hepatic blood flow remains preserved [41,43]. It is still \n\ncontroversial if its preservation is simply due to portal blood hyperflow secondary to \n\nsplenomegaly or if there would be a compensatory mechanism increasing the arterial flow \n\n[5,9,10,44-49]. \n\nSome angiographic studies reported small participation of the arterial sector in the \n\nhemodynamics of HSS, which demonstrated reduction in the hepatic artery diameter and poor \n\nintra-hepatic arterial vasculature [9-11,43]. The authors suggested that, as a result of massive \n\nsplenomegaly, the splenic artery hypertrophy would deviate the hepatic artery flow. Mies et al \n\nhave demonstrated reduced flow through the hepatic artery, which increased after treatment \n\nwith propranolol accompanied by a reduction in flow through the portal vein [47]. Lacerda [50] \n\nand Pereira [51] evaluated the hemodynamic effects of splenectomy, respectively associated \n\nwith esophagogastric devascularization and left gastric vein ligation. They showed that there is \n\nan increase in the caliber and in the hepatic artery flow just after surgery, when there was a \n\nreduction in the portal vein diameter and flow. Lacerda [51] suggested that the absence of \n\nincreased participation of the arterial sector is justified by the portal blood flow, which maintain \n\nnormal liver perfusion, diverting only the excess of blood by collateral circulation. \n\nOther studies, however, suggest the opposite. Coutinho [52] analyzing the hepatic \n\ncirculation pressures in HSS, associated with an angiographic evaluation proposed the \n\n\n\n70 \n \n\npossibility of compensatory increase in the arterial system in maintaining the total hepatic flow \n\nin HSS. Alves et al [46] highlighted the importance of the arterial sector in maintaining \n\nsinusoidal pressure in individuals with HSS when, after transient hepatic artery ligation, \n\ndocumented a drop of more than 15 mmHg in sinusoidal pressure. Some animal models of HSS \n\n[48,53] also showed that there is an increased flow through the hepatic artery in animals with \n\nHSS and reduced portal flow. \n\nIn addition to in vivo studies, pathological studies of HSS vascularization using plastic \n\nmodels [6,8,44] clearly demonstrate that the portal sector is the least prominent of the three \n\nvascular sectors. Unlike cirrhosis, vascular changes of schistosomiasis involve larger portal \n\nbranches with considerable distortion and reduction of small peripheral branches. Portal \n\nbranches of medium and large calibers often show dilatation, tortuous and sudden diameter \n\nreduction without formation of small terminal branches [5-8,44,54]. The hepatic vein sector \n\nremains unchanged; however, the hepatic artery sector shows considerable hyperplasia and \n\nhypertrophy with denser and tortuous vascular network. These arterial vascular bed alterations \n\ncould be considered compensatory to decreased portal perfusion [7]. \n\nUpper gastrointestinal bleeding represents an evolutionary event on advanced forms of \n\nschistosomiasis, which is associated with liver disease decompensation and occurrence of \n\njaundice, ascites and hepatic encephalopathy, usually transient. Furthermore, there may be a \n\nprogressive evolution to end-stage liver disease indistinguishable of cirrhosis after repeated \n\nepisodes of gastrointestinal bleeding. Therefore, this characteristic is the result of arterial blood \n\nflow dependence in severe schistosomiasis. The scintigraphy results confirm this \n\npathophysiological aspect and corroborates, in vivo, anatomopathological findings of plastic \n\nmodels describing remarkable increase in the arterial sector in HSS. Thus, increased HPI \n\nevidenced in scintigraphic studies shows that changes in the intrahepatic arterial bed are not \n\njust pathological, in fact, taking its place in circulatory dynamics of schistosomal liver. \n\n\n\n71 \n \n\nThe results shown in this study raise some questions about the possible mechanisms \n\ninvolved in the arterial response of HSS. Based on well-established findings [10,11,41,55,56], \n\nthe increased hepatic arterial flow with reduced portal blood flow cannot be justified, as it is \n\nwell documented that in HSS, there is portal overflow. It can be suggested that the total hepatic \n\nflow in HSS would actually be increased with increasing flows of both vascular beds. Another \n\nhypothesis is that high resistance to intrahepatic portal flow and the formation of intrahepatic \n\narterio-portal shunts, like in cirrhosis, could cause intrahepatic portal hypoperfusion, despite \n\nthe overflow of the extra-hepatic portal system, which is responsible for stimulating \n\ncompensatory response of the hepatic artery. Rocheleau et al [57] studied the separate vascular \n\nresponse of liver lobes after selective ligation of the left portal vein branch and showed that due \n\nto low portal flow, the left lobe had an increase in arterial flow, while the right lobe showed \n\nexactly the opposite, reduced arterial flow due to a portal overflow. Based on this study, we \n\nsuggest a more interesting theory. Due to the spleno-portal laminar flow, the portal blood flow \n\npreferably directs to the left lobe, which undergo hypertrophy, while the right lobe, least \n\nperfused, undergo atrophy [47]. Based on the study by Rocheleau, it could be suggested that in \n\nHSS, even in portal overflow situation, there would be increased compensatory hepatic arterial \n\nflow in hypoperfused right lobe, justifying the scintigraphic findings. \n\nRegarding clinical aspects, the increase in HPI did not correlate with the severity of \n\nhepatic fibrosis evaluated by ultrasonography. However, increased frequencies of \n\nsplenomegaly and large esophageal varices were found in the schistosomiasis group with \n\nincreased HPI. The design of the ROC curve demonstrating high accuracy of angioscintigraphy \n\nin predicting the presence of large varices denotes the ability of the method to characterize more \n\nsevere stages of HSS. Correlation between the longitudinal length of the spleen, portal vein \n\ndiameter and platelet count with HPI were also demonstrated. All of these clinical variables are \n\nindirect markers of severity of schistosomal liver disease and portal hypertension. Thus, \n\n\n\n72 \n \n\nangioscintigraphy with HPI measurement contributes to assess patients with HSS, being a non-\n\ninvasive method with minimal complications, technically easy to perform and correlate with \n\nthe severity of portal hypertension, the major complication of this liver disease. \n\nThis study is pioneer in assessing schistosomiasis patients using angioscintigraphy and \n\nHPI calculation. The use of this method in clinical practice seems promising because it \n\ncorrelates with clinical and laboratory characteristics of high risk schistosomiasis, particularly \n\nesophageal varices. Since gastrointestinal bleeding is the most feared event on the clinical \n\ncourse of HSS, the ability of scintigraphy in predicting the presence of large varices can identify \n\npatients with increased risk of gastrointestinal bleeding. In addition, scintigraphy was able to \n\ndemonstrate a new clinical aspect in the HSS study: the liver dependence of the arterial flow. \n\nThis method not only relates to serious forms of HSS, but was also able to identify patients \n\nwhose livers are more dependent on the hepatic artery, in which the upper gastrointestinal \n\nbleeding event would be potentially more catastrophic. In clinical practice, therefore, these \n\npatients should receive more aggressive treatment for portal hypertension and maintain a more \n\nrigid surveillance to prevent bleeding complications. \n\nThe main limitation of the study, however, refers to the small number of study subjects, \n\nrestricting the power of generalization of results. Another limiting factor is related to the sample \n\nheterogeneity. Studies with schistosomal population often have difficulties due to the large \n\nvariability in patients\u2019 characteristics and forms of clinical presentation. It could be speculated \n\nthat HPI changes would be due to higher proportion of severe forms in the sample studied, \n\ncharacterized by patterns D, E and F, especially the last two. However, this fact does not \n\nconstitute a study weakness, since individuals with more advanced disease are those that have \n\nhigher risk of complications and need for medical attention. \n\nIn conclusion, this study was able to evaluate changes in the circulatory dynamics of \n\npatients with the hepatosplenic form of schistosomiasis through angioscintigraphy and correlate \n\n\n\n73 \n \n\nwith severity variables. It was able to confirm changes demonstrated in previous studies with \n\nrespect to increased arterial perfusion in HSS, and to show correlation with the severity of portal \n\nhypertension. It seems to be a promising field of nuclear medicine in schistosomiasis in view \n\nof the preliminary results achieved in this research. Further studies with larger population will \n\nbe useful to confirm and validate our findings. \n\n \n\n \n\n \n\n \n\nACKNOWLEDGEMENTS \n\nSpecial thanks to Socrates Times de Carvalho for the mathematical assistance on the regression \n\nanalysis of the graphic data. \n\n \n\n \n\n.  \n\n\n\n74 \n \n\nREFERENCES \n\n[1] Pereira GJM, Torres MEG. Epidemiologia. In: Malta J, editor. Esquistossomose \n\nMans\u00f4nica. Primeira. Recife: Editora Universit\u00e1ria da UFPE; 1994. p. 47\u20138.  \n\n[2] Who WHO. Sustaining the drive to overcome the global impact of neglected tropical \n\ndiseases. Second WHO Rep neglected Trop Dis. 2013;3.9:67\u201371.  \n\n[3] Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. \n\n2006;368:1106\u201318.  \n\n[4] Ross AG., Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, et al. Schistosomiasis. \n\nN Engl J Med. 2002;346(16):1212\u201320.  \n\n[5] Andrade ZA. Schistosomal hepatopathy. Mem Inst Oswaldo Cruz. 2004;99:51\u20137.  \n\n[6] Andrade ZA. Schistosomiasis and liver fibrosis. Parasite Immunol. 2009;31:656\u201363.  \n\n[7] Hidayat M, Wahid H. A study of the vascular changes in bilharzic hepatic fibrosis and \n\ntheir significance. Surgery, Gynecol Obstet. 1971;997\u20131004.  \n\n[8] Magalh\u00e3es-Filho A, Menezes H, Coelho R de B. Patog\u00eanese da fibrose hep\u00e1tica na \n\nesquistossomose mansoni (Estudo das altera\u00e7\u00f5es vasculares portais mediante modelo \n\npl\u00e1stico). Rev Assoc Med Bras. 1960;6(4):284\u201394.  \n\n[9] Mies S, Larsson E, Mori T, Williams GM. Sistema porta e as art\u00e9rias hepatica, espl\u00eanica \n\ne mesent\u00e9rica superior na esquistossomose hepatoespl\u00eanica. Estudo angiogr\u00e1fico. Rev \n\ndo Hosp das Cl\u00ednicas Fac Med S\u00e3o Paulo. 1980;35:121\u201331.  \n\n\n\n75 \n \n\n[10] Cleva R, Pugliese V, Zilberstein B, Saad WA, Pinotti W, Laudanna AA. Systemic \n\nhemodynamic changes in mansonic schistosomiasis with portal hypertension treated by \n\nazygoportal disconnection and splenectomy. Am J Gastroenterol. 1999;94(6):1632\u20137.  \n\n[11] Cleva R, Herman P, D\u2019albuquerque LA, Pugliese V, Santarem OL, Saad WA. Pre- and \n\npostoperative systemic hemodynamic evaluation in patients subjected to esophagogastric \n\ndevascularization plus splenectomy and distal splenorenal shunt: A comparative study in \n\nschistosomal portal hypertension. World J Gastroenterol. 2007;13(41):5471\u20135.  \n\n[12] Warren HW, Gallagher H, Hemingway DM, Angerson WJ, Bessent RG, Wotherspoon \n\nH, et al. Prospective assessment of the hepatic perfusion index in patients with colorectal \n\ncancer. Br J Surg. 1998;85(12):1708\u201312.  \n\n[13] Koranda P, Myslivecek M, Erban J, Seidlov\u00e1 V, Hus\u00e1k V. Hepatic perfusion changes in \n\npatients with cirrhosis indices of hepatic arterial blood flow. Clin Nucl Med. \n\n1999;24(7):507\u201310.  \n\n[14] O\u2019Connor MK, Krom RF, Carton EG, Sanchez-Urdazpal L, Juni JE, Ferguson DM, et \n\nal. Ratio of hepatic arterial-to-portal venous blood flow--validation of radionuclide \n\ntechniques in an animal model. J Nucl Med. 1992;33:239\u201345.  \n\n[15] Pandharipande P V, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: \n\ncurrent challenges and future goals. Radiology. Radiological Society of North America; \n\n2005;234(3):661\u201373.  \n\n[16] Dragoteanu M, Balea I a, Dina L a, Piglesan CD, Grigorescu I, Tamas S, et al. Staging \n\nof portal hypertension and portosystemic shunts using dynamic nuclear medicine \n\ninvestigations. World J Gastroenterol. 2008;14(6):3841\u20138.  \n\n\n\n76 \n \n\n[17] Razzak M a. The Use of Radioactive Isotopes To Study the Hemodynamic Pattern, \n\nFunction and Morphology of the Liver in Hepato-Splenic Bilharziasis (Schistosomiasis). \n\nJ Nucl Med. 1964;5:125\u201333.  \n\n[18] Mustafa a G, Razzak M a, Mahfouz M, Guirgis B. Radioisotope photoscanning of the \n\nliver in bilharzial hepatic fibrosis. J Nucl Med. 1966;7:909\u201316.  \n\n[19] Iio M, Iuchi M, Kitani K, Yamada H, Ishiwa M. Scintigraphic evaluation of the liver \n\nwith schistosomiasis japonica. J Nucl Med. 1971;12:655\u20139.  \n\n[20] Homeida M, Abdel-Gradir AF, Cheever AW, Bennett JL, Arbab BM, Ibrahium SZ et al. \n\nDiagnosis of pathologically confirmed Symmers' periportal fibrosis by ultrasonography: \n\na prospective blinded study. Am J Trop Med Hyg. 1988 Jan;38(1):86-91. \n\n[21] Abdel-Wahab MF, Esmat G, Milad M, Abdel-Razek S, Strickland GT. Characteristic \n\nsonographic pattern of schistosomal hepatic fibrosis. Am J Trop Med Hyg. 1989;40:72\u2013\n\n76. \n\n[22] Richter J, Hatz C, Campangne G, Bergquist N, Jenkins J. Ultrasound in schistosomiasis: \n\nA Practical Guide to the Standardized Use of Ultrasonography for the Assessment of \n\nSchistosomiasis-related Morbidity. World Health Organ Tech Rep Ser. 2000;1\u201355.  \n\n[23] Richter J, Coutinho Domingues AL, Barata CH, Prata AR, Lambertucci JR. Report of \n\nthe Second Satellite Symposium on Ultrasound in Schistosomiasis. Mem Inst Oswaldo \n\nCruz. 2001;96(May):151\u20136.  \n\n[24] Palmer E, Brick I. Correlation between the severity of esophageal varices in cirrhosis \n\nand their propensity toward hemorrhage. Gastroenterology. 1956;30:85\u201390.  \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/3124648\n\n\n77 \n \n\n[25] Leveson SH, Wiggins P a, Nasiru T a, Giles GR, Robinson PJ, Parkin A. Improving the \n\ndetection of hepatic metastases by the use of dynamic flow scintigraphy. Br J Cancer. \n\n1983;47:719\u201321.  \n\n[26] Sarin S, Mosca P, Sabba C, Groszmann R. Hyperdynamic ciculation in a chronic murine \n\nschistosomiasis model of portal hypertension. Hepatology. 1991;13(3):581\u20134.  \n\n[27] Deni\u00e9 C, Vachiery F, Elman A, Soupison T, Gadano A, Moreau R, et al. Systemic and \n\nsplanchnic hemodynamic changes in patients with hepatic schistosomiasis. Liver. \n\n1996;16(5):309\u201312.  \n\n[28] Azeredo LM, Queiroz LC de, Marinho CC, Esp\u00edrito Santo MCC do, Chammas MC, \n\nRuiz-Guevara R, et al. Aspectos ultrassonogr\u00e1ficos e hemodin\u00e2micos da \n\nesquistossomose mans\u00f4nica: avalia\u00e7\u00e3o pela ultrassonografia Doppler em \u00e1reas \n\nend\u00eamicas. Radiol Bras. 2010;43(2):69\u201376.  \n\n[29] De Arruda SMB, Barreto VST, Do Amaral FJ. Duplex sonography study in \n\nschistosomiasis portal hypertension: Characterization of patients with and without a \n\nhistory of variceal bleeding. Arq Gastroenterol. 2008;45(1):11\u20136.  \n\n[30] Zipprich A, Steudel N, Behrmann C, Meiss F, Sziegoleit U, Fleig WE, et al. Functional \n\nsignificance of hepatic arterial flow reserve in patients with cirrhosis. Hepatology. \n\n2003;37(2):385\u201392. \n\n[31] Kleber G, Steudel N, Behrmann C, Zipprich A, H\u00fcbner G, Lotterer E, et al. Hepatic \n\narterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler \n\nand adenosine infusion. Gastroenterology. 1999;116(4):906\u201314.  \n\n\n\n78 \n \n\n[32] Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: \n\nhepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol. \n\n1985;249(5):G549\u201356.  \n\n[33] Lautt WW. Hepatic Circulation Physiology and Pathophysiology. 1st ed. Colloquium \n\nSeries on Integrated Systems Physiology: From Molecule to Function. San Rafael: \n\nMorgan &amp; Claypool Life Sciences; 2009  \n\n[34] Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD. Portal branch \n\nligation induces a hepatic arterial buffer response, microvascular remodeling, \n\nnormoxygenation, and cell proliferation in portal blood-deprived liver tissue. Am J \n\nPhysiol Gastrointest Liver Physiol. 2007;292:G1534\u201342.  \n\n[35] Moeller M, Thonig A, Pohl S, Ripoll C, Zipprich A. Hepatic Arterial Vasodilation Is \n\nIndependent of Portal Hypertension in Early Stages of Cirrhosis. PLoS One. \n\n2015;10(3):e0121229.  \n\n[36] Ezzat WR, Lautt WW. Hepatic arterial pressure-flow autoregulation is adenosine \n\nmediated. Am J Physiol. 1987;252(4):H836\u201345.  \n\n[37] Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: \n\nhepatic arterial buffer response. Am J Physiol. 1985;249(5):549\u201356.  \n\n[38] Lautt WW. Control of hepatic arterial blood flow: independence from liver metabolic \n\nactivity. Am J Physiol. 1980;239:H559\u201364.  \n\n[39] Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and \n\ntherapeutic targets in liver injury and repair. Physiol Rev. 2009;89:1269\u2013339.  \n\n\n\n79 \n \n\n[40] Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: The hepatic arterial \n\nbuffer response revisited. World Journal of Gastroenterology. 2010.  \n\n[41] Strauss E. Hepatosplenic schistosomiasis: a model for the study of portal hypertension. \n\nAnn Hepatol. 2002;1(1):6\u201311.  \n\n[42] Warren KS. Hepatosplenic schistosomiasis mansoni: an immunologic disease. Bull N Y \n\nAcad Med. 1975;51(4):545\u201350.  \n\n[43] Da Silva LC. Portal hypertension in schistosomiasis: pathophysiology and treatment. \n\nMem Inst Oswaldo Cruz. 1992;87(suppl IV):183\u20136.  \n\n[44] Jorge PAR, Carvalhal S dos S. Sobre a rede vascular intra-hep\u00e1tica na esquistossomose \n\nmansonica, forma de Symmers: Estudo com modelos pl\u00e1sticos. Rev Assoc Med Bras. \n\n1967;13(12):435\u201341.  \n\n[45] Widman A, Speranzini MB, de Lima JT, Wierman P, de Oliveira MR, Raia A. Arterial \n\nand operative portography in patients with portal hypertension caused by hepato-splenic \n\nschistosomiasis and those with spleno-renal anastomosis (comparative study). Rev do \n\nHosp das Cl\u00ednicas Fac Med S\u00e3o Paulo. 1973;28(4):177\u201387.  \n\n[46] Alves C, Alves A, Abreu W, Andrade ZA. Hepatic artery hypertrophy and sinusoidal \n\nhypertension in advanced schistosomiasis. Gastroenterology. 1977;72(1):126\u20138.  \n\n[47] Mies S, Braghirolli-Neto O, Beer A, Baia C, Alfieri F, Pereira L, et al. Systemic and \n\nhepatic hemodynamics in hepatosplenic manson\u2019s schistosomiasis with and without \n\npropranolol. Dig Dis Sci. 1997;42(4):751\u201361.  \n\n\n\n80 \n \n\n[48] SK S, P M, C S, Groszmann R. Hyperdynamic circulation in a chronic murine \n\nschistosomiasis model of portal hypertension. Hepatology. 1991;13(3):581\u20134.  \n\n[49] Baptista AP, Andrade ZA. Angiogenesis and schistosomal granuloma formation. Mem \n\nInst Oswaldo Cruz. 2005;100(April):183\u20135.  \n\n[50] Lacerda CM, Ramos H, Raia S, Kelner S. Fisiopatologia da hipertens\u00e3o portal \n\nesquistossom\u00f3tica e efeitos da esplenectomia com ligadura de varizes de es\u00f4fago. Acta \n\nCir Bras. 1993;8:113\u20137.  \n\n[51] Pereira FM, Evangelista-Neto J, Brito N, Amaral F, da Fonseca-Neto OC, Lacerda CM. \n\nAngiografic and pressoric changes determined by splenectomy with left gastric vein \n\nligature in mansoni schistosomiasis. Arq Bras Cir Dig. 2013;26(4):302\u20138.  \n\n[52] Coutinho A. Hypertension Studies of Portal in Schistosomiasis. Am J Med. \n\n1968;44:547\u201355.  \n\n[53] Morgan J, Groszmann R, Rojkind M, Enriquez R. Hemodynamic mechanism of \n\nemerging portal hypertension caused by schistosomiasis in the hamster. Hepatology. \n\n1990;11(1):98\u2013104.  \n\n[54] Andrade ZA. A double and paradoxical role for angiogenesis. Rev Patol Trop. \n\n2013;42(3):259\u201364.  \n\n[55] Coutinho A. Hemodynamic studies of portal hypertension in schistosomiasis. Am J Med. \n\n1968;44:547\u201355.  \n\n\n\n81 \n \n\n[56] Azeredo LM, Queiroz LC De, Marinho CC, Carvalho C, Chammas MC, Ruiz-guevara \n\nR, et al. Sonographic and hemodynamic findings of schistosomiasis mansoni?: Doppler \n\nsonography assessment in endemic areas. Radiol Bras. 2010;43(2):69\u201376.  \n\n[57] Rocheleau B, Ethier C, Houle R, Huet PM, Bilodeau M. Hepatic artery buffer response \n\nfollowing left portal vein ligation: its role in liver tissue homeostasis. Am J Physiol. \n\n1999;277(5):G1000\u20137.  \n\n \n\n  \n\n\n\n82 \n \n\nSonographic Findings N (%) \n\n    \n\nSpleen   \n\n? 13 cm 2 (10,5%) \n\n> 13 cm 17 (89,5%) \n\n    \n\nPortal Vein   \n\n? 1,2 cm 9 (47,4%) \n\n> 1,2 cm 10 (52,6%) \n\n    \n\nSplenic Vein   \n\n? 1,0 cm 8 (42,1%) \n\n> 1,0 cm 11 (57,9%) \n\n    \n\nFibrosis Pattern   \n\nD 6 (31,5%) \n\nE 7 (37,0%) \n\nF 6 (31,5%) \n\nCollaterals   \n\nPresent 14 (73,6%) \n\nAbsent 5 (26,4%) \n\n    \n\n    Table 1. Sonographic findings \n\n  \n\n\n\n83 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFig 1. Comparison of three time-activity curves (A) control patient with a HPI of 35% (B \n\nand C) patients with HSS with a HPI of 47% and 48%, respectively. The dashed line \n\nindicates the moment of the renal artery capture peak, used to delimit the hepatic artery \n\nand portal phases of liver perfusion. It is observed a greater total liver uptake and a more \n\npronounced arterial inflow.  \n\n \n\n \n\n \n\n \n\n \n \n\n \n\n0\n\n200\n\n400\n\n600\n\n800\n\n1000\n\n1200\n\n1 5 9\n1\n\n3\n1\n\n7\n2\n\n1\n2\n\n5\n2\n\n9\n3\n\n3\n3\n\n7\n4\n\n1\n4\n\n5\n4\n\n9\n5\n\n3\n5\n\n7\n6\n\n1\n6\n\n5\n6\n\n9\n7\n\n3\n7\n\n7\n8\n\n1\n8\n\n5\n8\n\n9\n9\n\n3\n9\n\n7\n1\n\n0\n1\n\n1\n0\n\n5\n1\n\n0\n9\n\n1\n1\n\n3\n1\n\n1\n7\n\nT\nim\n\ne\n -\n\nA\nct\n\niv\nit\n\ny\n\nC\n\nB\n\nA\n\n\n\n84 \n \n\n  HPI % Spleen (cm) Portal Vein (cm)  Splenic Vein (cm) Collaterals Esophageal Varices UDB \u00a7 Platelets x 10\u00b3 Fibrosis Pattern \n\n          \n\nNormal HPI 35 13,64 1,4 1,04 Present F1 Present 83 D \n\n(N=5) 36 13,15 1,16 0,9 Absent Absent Absent 141 F \n\n 40 10,34 1,17 0,59 Present Absent Present 165 E \n 40 14,4 1,24 1,18 Present F1 Absent 31 D \n\n 40 16,84 1,29 1,54 Present F1 Absent 32 E \n\n                    \n\nMean 38,2 13,60 1,25 1,05      90,4  \n\nSD \u2021 2,50 2,34 0,09 0,35      61  \n\nCI 95% \u2020 35,1 - 41,3 10,8 - 16,6 1,13 - 1,37 0,61 - 1,48      36,93 - 143,87  \n                    \n\nAbnormal HPI 42 13,6 1,31 0,98 Absent F1 Present 72 E \n(N=14) 42 15,12 0,97 0,85 Present F2 Absent 86 F \n\n 45 17,48 1,12 0,95 Present F2 Present 51 E \n\n 46 14,06 0,8 0,71 Absent F3 Present 53 D \n\n 47 15,33 1,68 2,2 Present F3 Absent 56 F \n 47 16,44 1,66 0,84 Present F3 Absent 58 E \n\n 47 15,63 1,31 1,04 Present F3 Absent 53 E \n\n 47 20,1 1,16 1,73 Present F3 Absent 79 E \n\n 48 17,84 1,39 0,73 Absent Absent Present 86 F \n 48 11,15 0,83 0,76 Present F3 Absent 117 D \n\n 51 19,29 1,07 0,92 Present F3 Absent 76 D \n\n 52 17,05 1,16 1,1 Present F3 Absent 64 F \n\n 55 19,29 1,26 0,64 Present F3 Absent 46 F \n 66 27,16 1,98 1,51 Absent F3 Absent 30 D \n\n                    \n\nMean 48,80 17,1 1,26 1,06       66   \nSD \u2021 6,0 3,80 0,33 0,44    22   \n\nCI 95% \u2020 45,3 - 52,3 14,9 - 19,3 1,07 - 1,45 0,81 - 1,32    54,48 - 77,52   \n           \n\n  p=0,0029* p= 0,038 p=0,46 p=0,29 p=0,88 p=0,006 p=0,75 p=0,11 p=0,75 \n                    \n\nTable 2. \u2013 Results of Hepatic Perfusion Index (HPI) obtained by angioscintigraphy in patients with hepatosplenic schistosomiasis. These \n\npatients were divided into two groups with respectively normal and increased HPI. Differences between variables were analyzed, with \n\nstatistical significance of the HPI compared with normal individuals, the presence of large varices (F3) and the length of the spleen \n\u00a7 Upper Digestive Bleeding \n\u2021 Standard Deviation  \n\u2020 Confidence Interval 95% \n* This p-value refers to the comparison between the 19 schistosomal patients and the control group.\n\n\n\n85 \n \n\n  \n\n \n\n \n\nFig 2. \u2013 Scatterplot graphic showing positive correlations through their respective trend \n\nlines and Pearson's correlation coefficient (?) between increased HPI and increased \n\nlongitudinal spleen length (A) and diameter of the portal vein (B) and a negative \n\ncorrelation between the increase in HPI and the total platelet count (C).  \n\ny = 1,4959x + 21,758\nR\u00b2 = 0,6167\n\n0\n\n10\n\n20\n\n30\n\n40\n\n50\n\n60\n\n70\n\n0 5 10 15 20 25 30\n\nH\ne\n\np\na\n\nti\nc \n\nP\ne\n\nrf\nu\n\nsi\no\n\nn\n I\n\nn\nd\n\ne\nx\n\n (\nH\n\nP\nI)\n\nSplenic Lenght (cm)\n\ny = 9,5518x + 33,955\nR\u00b2 = 0,1466\n\n0\n\n10\n\n20\n\n30\n\n40\n\n50\n\n60\n\n70\n\n0 0,5 1 1,5 2 2,5\n\nH\ne\n\np\na\n\nti\nc \n\nP\ne\n\nrf\nu\n\nsi\no\n\nn\n I\n\nn\nd\n\ne\nx\n\n (\nH\n\nP\nI)\n\nPortal Vein Diameter (cm)\n\ny = -0,1008x + 53,525\nR\u00b2 = 0,2402\n\n0\n\n10\n\n20\n\n30\n\n40\n\n50\n\n60\n\n70\n\n0 50 100 150 200\n\nH\ne\n\np\na\n\nti\nc \n\nP\ne\n\nrf\nu\n\nsi\no\n\nn\n I\n\nn\nd\n\ne\nx\n\n (\nH\n\nP\nI)\n\nPlatelet Count x 103\n\nA \n\nB \n\nC \n\n? = 0,785 \n\n? = 0,382 \n\n? = - 0,490 \n\n\n\n86 \n \n\n \n\n \nFig 3. ROC curves (A) Spleen ROC curve showing the best splenic longitudinal length to \n\npredict an increased HPI at the cutoff point (?), corresponding to 14,4cm with a sensibility \n\nof 0,78 and specificity of 0,90 and an AUC of 0,90 (B) HPI ROC curve showing the good \n\naccuracy of the HPI in predicting occurrence of large esophageal varices. Using the cutoff \n\npoint (?), corresponding to a HPI of 45%, it is possible to predict the presence of large \n\nvarices with a sensibility of 1,0 and a specificity of 0,92, with an AUC of 0,96. \n\n \n\n \n\n \n\n \n\n \n\n0\n\n0,1\n\n0,2\n\n0,3\n\n0,4\n\n0,5\n\n0,6\n\n0,7\n\n0,8\n\n0,9\n\n1\n\n0 0,2 0,4 0,6 0,8 1\n\nT\nru\n\ne\n P\n\no\nsi\n\nti\nv\n\ne\ns \n\n(S\ne\n\nn\nsi\n\nb\nil\n\nit\ny\n\n)\n\nFalse Positives (1- Specificity)\n\nROC Curve / Spleen \n\n0\n\n0,1\n\n0,2\n\n0,3\n\n0,4\n\n0,5\n\n0,6\n\n0,7\n\n0,8\n\n0,9\n\n1\n\n0 0,2 0,4 0,6 0,8 1\n\nT\nru\n\ne\n P\n\no\nsi\n\nti\nv\n\ne\ns \n\n(S\ne\n\nn\nsi\n\nb\nil\n\nit\ny\n\n)\n\nFalse Positives (1 - Specificity)\n\nROC Curve / HPI \n\n? ? \n\nB A \n\n\n\n87 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nHemodynamic changes in the intra-hepatic \n\ncirculation of hepatosplenic schistosomiasis: \n\nthe role of hepatic artery \n \n\n \n\n\n\n88 \n \n\nABSTRACT \n\nSchistosomal liver disease represents a particular type of chronic liver disease, which presents \n\nunique characteristics that differentiate it from those found in cirrhosis, especially in the \n\nvascular bed. Changes in the vascular territory of the hepatic artery are still controversial in the \n\nliterature, with some authors advocating no change, while others reporting a greater \n\nparticipation of this sector in hepatosplenic schistosomiasis (HSS). The purpose of this \n\nanalytical review is to describe the pathophysiology of schistosomal liver disease, with special \n\nattention to intra-hepatic vascular alterations and the hepatic artery. In conclusion, the literature, \n\nto date, has divided opinions in respect to the role of the hepatic artery in advanced schistosomal \n\nliver disease. We believe this is an interesting field for future research in order to solve the \n\nintriguing pathophysiology of hepatic schistosomiasis and use this knowledge for the patients \n\nbenefit. \n\nKeywords: \n\nSchistosomiasis; hepatopathy; hepatic circulation \n\n  \n\n\n\n89 \n \n\nINTRODUCTION \n\n \n\nSchistosomiasis is a parasitic infectious disease caused by worms of Schistosoma genus. \n\nIn 78 countries of Africa, Asia, Central and South America, it is considered an endemic \n\ninfection, occurring in places without sanitation or with inadequate sanitation [1]. Although \n\nthere are no specific global survey for schistosomiasis, it is estimated that about 200 million \n\npeople are infected with Schistosoma in Africa, Asia and South America, 20 million with severe \n\ndisease and other 600 million people are at risk of contracting it [2,3]. \n\nSchistosomal liver disease represents a particular type of chronic liver disease, which \n\npresents unique characteristics that differentiate it from those found in cirrhosis, especially in \n\nthe vascular bed [4]. Advanced schistosomiasis produces one of the most characteristic \n\npresentations of liver diseases: fibrosis of Symmers. In the cut surface, whitish fibrotic plaques \n\noccupying portal spaces are observed, surrounded by a hepatic parenchyma with normal \n\nappearance, without the formation of fibrous septa and typical regenerative cirrhotic nodules \n\n[5]. \n\nVascular changes in the hepatic artery territory are still controversial in the literature, \n\nwith some authors advocating no change, while others reporting a greater participation of this \n\nsector in hepatosplenic schistosomiasis (HSS) [4,6-12]. The purpose of this analytical review \n\nis to describe the pathophysiology of schistosomal liver disease with special attention to intra-\n\nhepatic vascular and hepatic artery alterations, since, unlike the portal venous bed, there is no \n\nconsensus about the role of the hepatic artery in severe forms of schistosomiasis. \n\n \n\n \n\n \n\n \n\n\n\n90 \n \n\nINTRAHEPATIC VASCULAR CHANGES  \n\n \n\nIn S. mansoni infection, the female parasite produces daily a huge amount of eggs which \n\nare deposited on the branches of mesenteric venules, to be excreted in the host feces. Most eggs \n\nis retained in the colonic wall or is excreted in the feces. However, about one third of them falls \n\nback into the mesenteric circulation towards the liver and impact on small portal branches, \n\ncausing partial obstruction to portal blood flow. Soluble antigens produced by the larva inside \n\nthe egg stimulate a cascade of immune reactions that culminate in the formation of a periovular \n\ngranuloma. The latter determines extensive damage to the hepatoportal vascular system. Thus, \n\ninflammatory and fibrovascular reactions of the host are the main factor responsible for the \n\nobstruction of portal venous flow [13,14]. Liver fibrosis is probably not significant by itself. \n\nThe space occupied by fibrosis in chronic liver diseases is not enough to have an impact on the \n\nphysiology of an organ with such functional reserve. The significance of liver fibrosis is related \n\nto the fact that this change serve as a support for abnormal vascularization. Intrahepatic vascular \n\nderangement, venous and arterial, caused by chronic liver insults are the cause of physiological \n\nchanges [15]. \n\nThe extensive hepatic fibrosis seen in advanced schistosomiasis is dependent on a high \n\nparasitic load due to massive embolization of eggs to the portal system causing obliteration of \n\nsmall caliber vessels of the peripheral portal system and the immune response developed by the \n\nhost. In the formation of periovular granuloma, there is vascular proliferation that progressively \n\naffects the periphery of the granuloma as it grows by the formation of fibrosis. When there is \n\nfusion of granulomas, as occurs in periportal fibrosis of advanced disease, small blood vessels \n\nproliferate and exhibit a prominent aspect in the inter-granuloma tissue, assuming an \n\nangiomatoid feature. Despite this vascular proliferation, many portal vessels, in fact, are \n\ndistorted, with thickening of the muscular layer and occluded [4,5,13,16,17].  \n\n\n\n91 \n \n\nEmbolization of eggs and distal occlusion of portal branches causes an increase in \n\nintrahepatic portal venous pressure, which induces the formation of periportal collaterals in \n\nlarger diameter vessels, allowing the diversion of the blood flow. With the continuing arrival \n\nof eggs, damage to the larger caliber veins will occur, with formation of granulomatous \n\nperiportal inflammation, fibrosis inter-granuloma and vascular occlusion, which, in turn, \n\npromotes portal hypertension, increasing splenomegaly and portosystemic collateral [4 , 13,16]. \n\nThe worm itself, on the other hand, participate of the intrahepatic portal occlusive \n\nchanges. After its death, it can function as microemboli occluding branches of portal venous \n\nbed [14]. These lesions caused by dead worms, although larger in extent, causes less impact, \n\nbeing fewer in number, and therefore located. Another mechanism involved refers to soluble \n\nantigens secreted by the worm. These promote changes in the physiology of intrahepatic portal \n\nvasculature, characterized by an increased sensitivity of the portal branches to vasoconstrictors \n\nagents such as serotonin and acetylcholine [18,19]. Coupled with the increased extracellular \n\nmatrix, vascular contraction contribute to increase the portal resistance [18]. \n\nIn advanced hepatosplenic schistosomiasis, despite obliterative changes of portal \n\nvenous system, the total hepatic blood flow is maintained in the normal range [5]. This \n\nphenomenon may be due to hypertrophy/hyperplasia of hepatic arterial system [14,20,21]. \n\nStudies of vascularization in plastic models, obtained by injection in different vascular systems \n\n- portal vein, hepatic vein and hepatic artery - of plastic substance with different color could \n\ndocument the intrahepatic vascular changes of hepatosplenic schistosomiasis [12,13]. \n\nThe portal branches are reduced and the less prominent of the three vascular sectors. \n\nUnlike cirrhosis, vascular changes in schistosomiasis affect larger portal branches, with \n\nconsiderable distortion and reduction of small peripheral branches [22]. Portal branches of \n\nmedium and large calibers often have dilatation, tortuosity and sudden diameter reduction \n\nwithout emitting the terminals rami, with a network of thin newly formed vessels coming up of \n\n\n\n92 \n \n\nthe main branches and anastomosing with each other [4,12,13,22, 23]. The sector of the hepatic \n\nveins does not show changes. But the hepatic artery sector shows considerable hyperplasia and \n\nhypertrophy with a vascular network more dense and tortuous, especially in peribiliar plexus \n\n[4,13,24]. \n\nThese changes in the hepatic artery vascular bed may be considered compensatory to \n\ndecreased portal venous perfusion [23] consequent to the distortion of the portal venous system \n\nby occlusions or amputations of their branches. An intense arterial network is formed that grows \n\nthrough the venous anastomotic and distorted branches around the thick trunks of the portal \n\nvein, and fill the spaces that lack portal branches [22]. Thus, the total hepatic blood flow remains \n\nunchanged. However, this increase in intra-hepatic arterial flow is responsible for a rise in \n\nsinusoidal pressure causing a greater accumulation of collagen fibers within the Disse space. \n\nThese changes determine the capillarization of the hepatic sinusoids and impairs the exchange \n\nsurface between the sinusoid and the hepatocytes, contributing in episodes of bleeding, for \n\ndecompensated stage of hepatosplenic schistosomiasis [4,13,20,25]. \n\nThe main disadvantage of hypertrophy of the hepatic artery is the hepatic parenchyma \n\ndependence of the arterial flow. When there are episodes of massive gastrointestinal bleeding - \n\ncommon complication of hepatosplenic schistosomiasis \u2013 there is liver hypoperfusion, because \n\nthe blood flow is more dependent on the mean arterial pressure. As a consequence of these \n\nischemic insults, areas of necrosis appear, and become focal and peripheral post-necrotic scars \n\nwith the formation of fibrotic septa isolating nodules indistinguishable in appearance from \n\ncirrhosis, in these areas [4,13,20]. \n\nDespite these morphological aspects described above, some angiographic studies of the \n\nhepatic vascular system in hepatosplenic schistosomiasis revealed conflicting results, with a \n\ntheory of little arterial participation in the HSS abnormal liver hemodynamics. They observed \n\nreduction in the diameter of the hepatic artery, with decreased intrahepatic arterial \n\n\n\n93 \n \n\nvascularization [8,26,27]. The authors suggested that, as a result of massive splenomegaly, there \n\nwould be a hypertrophy of the splenic artery with consequent diversion of the flow of the \n\nhepatic artery, a mechanism similar to the splenic artery steal syndrome, described in vascular \n\ncomplication cases of liver transplantation [28,29]. However, the \"siphon\" mechanism \n\ndescribed to explain this steal has been questioned. The reduction in the hepatic artery inflow \n\nhas been assigned to the intrahepatic regulatory mechanism known as hepatic arterial buffer \n\nresponse (HABR) [30]. In this, the portal blood flow caused by increased splenic flow from the \n\nsplenic artery, reduce the flow of hepatic artery in a compensatory mechanism [31]. \n\nCleva et al, in angiographic evaluations of systemic hemodynamics in schistosomal \n\npatients prior to splenectomy with ligation of the left gastric vein, observed poor intrahepatic \n\narterial vascularization. Documented exuberant splenic vasculature both arterial, and splenic \n\nvein, with hemodynamic measurements suggesting systemic hyperdynamic state like in \n\ncirrhosis, with increased heart rate and cardiac work and reduction in peripheral vascular \n\nresistance. They suggested that the supporters of a systemic hyperdynamic state were \n\nsplenomegaly, along with the portosystemic collateral circulation working as arteriovenous \n\nfistula shunting hypertensive portal flow [9,32]. Another study by the same author, using \n\nthermodilution techniques showed that 56% of 16 patients with HSS had portal flow above the \n\nrange considered normal for a total hepatic flow (greater than 1500ml / min) opposing the idea \n\nof a typical normal global liver flow in these patients [33]. \n\nMies et al also studied the systemic hemodynamics in patients with HSS to assess the \n\neffects of treatment with propranolol. They observed the same findings of Cleva et al in relation \n\nto increased heart rate, decreased peripheral vascular resistance and preservation of the total \n\nliver blood flow. They have also reported increased flow through the azygos vein, indicating a \n\nhigher blood drainage through portosystemic collateral circulation, with significant reduction \n\nafter treatment with propranolol. In this study they demonstrated a reduced flow through the \n\n\n\n94 \n \n\nhepatic artery that had increased after the use of propranolol, accompanied by reduction in flow \n\nthrough the portal vein, splenic vein and superior mesenteric vein [11]. \n\nLacerda and Pereira evaluating the hemodynamic effects of splenectomy associated \n\nwith gastroesophageal devascularization and ligation of the left gastric vein, respectively, \n\nshowed an increase in the caliber and flow through the hepatic artery, just after surgery, \n\nassociated with a reduction in the diameter and flow in the portal vein accompanied of a slight \n\nincrease in sinusoidal pressure [34,35]. Lacerda suggests that, in patients with HSS, with large \n\nshunts, the absence of increased arterial sector is justified by the portal blood overflow, which \n\nmaintain normal liver perfusion, diverting only the blood in excess and dispensable by collateral \n\ncirculation. With surgery the overflow mechanism would cease, reducing the portal perfusion, \n\nwith a compensatory increase in arterial circulation [35]. \n\nOther in vivo dynamic studies, however, have documented opposite results. Coutinho in \n\n1968 conducted a hemodynamic study with measurement of intra-splenic, intrahepatic, direct \n\nportal vein, free and occluded hepatic vein pressures, associated with an angiography study \n\nwith splenoportography. He observed an increase in intra-splenic and portal pressures, normal \n\nor slightly increased sinusoidal pressure, and total liver flow maintained. In the angiographic \n\nstudy, documented dilation of the right and left branches of the portal vein with reduced venous \n\nramifications, as described as Bogliolo signal, and preservation of the arterial system. Thus, the \n\nauthor raises as the possibilities for maintenance of total liver blood flow, the arterial system \n\nconservation that would allow a compensatory increase in the flow to the liver [36]. \n\nIn another angiographic study, Ramos et al documented an intrahepatic presinusoidal \n\nblock of the portal flow, with maintained total liver blood flow, indicating a compensatory \n\nincrease in arterial blood flow [37,38]. Alves et al, studying 5 schistosomal patients during \n\nsplenectomy, positioned a catheter in the hepatic vein to measure the intrahepatic pressures. \n\nThe next step was the clamping of the hepatic artery, in its main trunk, observing a decrease in \n\n\n\n95 \n \n\nsinusoidal pressure over 15 mmHg. Then, individuals in control group, with splenomegaly \n\nsecondary to a cavernous hemangioma, the same pressures were measured during splenectomy \n\nwith normal sinusoidal pressures findings and unchanged sinusoidal pressures after clamping \n\nthe hepatic artery. With these findings the authors highlight the importance of the arterial sector \n\nin HSS [10].  \n\nDynamic studies in animal models also describe changes in arterial circulation of mice \n\nlivers. Morgan et al studying a HSS model in hamsters showed that, with progression of liver \n\ndisease, there was a significant decline in portal blood flow partially compensated by an \n\nincrease in arterial flow [39]. Sarin et al, in a murine model of HSS, using radioactive \n\nmicrospheres technique, demonstrated that the decline in portal flow of infected animals was \n\n61% greater than in healthy animals and observed an increase of two times in the arterial inflow \n\nof animals with HSS compared to controls. In addition to these observations, highlighted \n\nmeasures consistent with hyperdynamic circulatory state like described by Cleva et al, with \n\nincreased heart rate, decreased peripheral vascular resistance and splanchnic [7]. \n\nThese observations can be explained by the double hepatic blood supply and a unique \n\nmechanism that allows an intimate relationship between these two vascular systems, \n\ndetermining an intrinsic regulation of the blood flow. This inter-relationship is the so-called \n\nhepatic arterial buffer response (HABR), described initially by Lautt [40], in which the hepatic \n\nartery can produce compensatory changes in its flow in response to changes of portal blood \n\nflow, to maintain a constant total liver flow [41]. In association with classic mechanism of \n\narterial auto-regulation, in which there is a myogenic contraction of the vessel in response to \n\nincreases in blood pressure and, in the case of the hepatic artery is considered low, there is a \n\nsecond mechanism in which the hepatic artery dilates when the portal flow decreases and \n\ncontracts when the portal flow increases [42,43,41,44]. This HABR mechanism has been \n\ndemonstrated not only in physiological conditions, but also in fetuses, liver cirrhosis and liver \n\n\n\n96 \n \n\ntransplant [43,45-51]. The increased arterial flow can compensate 25 to 60% of the decrease in \n\nportal flow. Kollmar et al showed that 14 days after the ligature of the left branch of the portal \n\nvein of rats there was an increase in the flow through hepatic artery so significant that reached \n\nlevels close to the initial arterial and portal flow [52]. Since the portal vein is unable to control \n\nits flow, which is the sum of outflows of splanchnic organs, there is no reciprocity of HABR, \n\ni.e. changes in the perfusion of the hepatic artery does not induce compensatory changes within \n\nthe portal vein [42,43]. \n\nSeveral studies have demonstrated the maintenance of HABR in cirrhotic livers. Moeller \n\net al in an animal model of cirrhosis have demonstrated reduced resistance and increased hepatic \n\nartery flow in cirrhotic rats even without portal hypertension, i.e. with normal portal vein \n\nresistance [51]. Richter et al, also in rodent models of cirrhosis, showed decrease in total hepatic \n\nblood flow with marked decrease of portal blood flow and compensatory increased flow \n\nthrough the hepatic artery.  He demonstrated that the ratio of the total hepatic flow changed of \n\n79.8% via the portal vein and 20.2% via hepatic artery before the chemical induction of \n\ncirrhosis to 59.2% through the vein and40.8% through the hepatic artery in the cirrhotic \n\nanimals. The author mentions also that, although the absolute value of the blood flow is similar \n\nto control animals, the proportion of increase was much higher [47]. Aoki et al, in a study using \n\nhuman clamping of the portal vein in cirrhotics during transplantation surgery, demonstrated \n\nthat portal vein flow was reduced while the flow of the hepatic artery was increased and the \n\nclamping of the portal vein induced an additional increase the arterial flow [48]. Gulberg et al, \n\nevaluating the HABR in cirrhotic patients undergoing TIPS (Transjugular intrahepatic portal \n\nshunt) placement, showed that the hepatic artery resistance index was decreased in cirrhotic \n\npatients, with further reduction after the fall of the portal perfusion induced by TIPS placement \n\n[45]. \n\n\n\n97 \n \n\nThe most accepted theory, however, involves intrahepatic adenosine washout [40,44,53-\n\n55]. This hypothesis discloses that adenosine, a potent arterial vasodilator, is released at a \n\nconstant rate in the space of Mall fluid that surrounds the portal vessels. This space is limited \n\nby a limiting plate that separates it from the other compartments. The concentration of \n\nadenosine is regulated by its clearance through the portal vein and hepatic artery. When there \n\nis a reduction on portal blood flow, less adenosine is cleared from the space of Mall and its \n\naccumulation leads to dilation of the hepatic artery and increase arterial flow. Likewise, when \n\nthe portal blood flow increases, a larger amount of adenosine is cleared causing contraction of \n\nthe hepatic artery and decreasing its flow, demonstrating the inverse relationship between the \n\narterial and portal flows [42,43,48-50]. In association with adenosine, other vasoactive \n\nmediators have been described in the participation of HABR, such as nitric oxide, carbon \n\nmonoxide, adenosine triphosphate (ATP) and hydrogen sulfide [42,43]. \n\nHepatic arterioles ramifies around the portal venules, sending small branches to the \n\ncapillaries of peribiliar plexus and to the venules that will form arteriolo-portal shunts. The \n\nthinner arterioles branches will supply the venular portal walls as a vasa- vasorum [43]. Under \n\nnormal conditions, about 30% of the flow through the hepatic artery is shunted to the portal \n\ncirculation [50]. This deviation was demonstrated to guarantee the nutrient supply and oxygen \n\nsupply by the HABR in rats, with authors suggesting no change in vascular diameter, but the \n\nproportion of flow through the shunts [56]. Under normal conditions, most of the sinusoids are \n\nperfused by portal blood with small portion further supplied directly by hepatic arterioles \n\nterminals. Conditions of reduced portal flow induces the HABR, with preferred inflow through \n\nthe shunts leading to a disproportionate increase in the contribution of the hepatic artery to the \n\nsinusoidal perfusion [43,56]. \n\nPreliminary study conducted by our group, with not yet published data, used the \n\nangioscintigraphy in the evaluation of hepatic perfusion with findings similar to those described \n\n\n\n98 \n \n\nin cirrhotic patients [57-60]. We observed a rise of radioisotope uptake in the arterial phase of \n\nhepatic perfusion of patients with HSS. Thus, it is suggested that, in fact, there is an increased \n\narterial component in the total hepatic flow of schistosomal liver, similar to what occurs in \n\ncirrhosis. This increase would be secondary to the difficulty of intrahepatic portal flow caused \n\nby vascular distortion of this sector as a result of fibrocicatricial phenomena of schistosomal \n\nhepatopathy. \n\nIn conclusion, the literature to date has divided opinions in respect to the role of the \n\nhepatic artery in advanced schistosomal liver disease. Various studies indicate a direct \n\ninvolvement of the hepatic artery to maintain the total flow of the liver, while others show little \n\narterial involvement, assigning the maintenance of hepatic blood flow exclusively through to \n\nportal overflow. We believe this is an interesting field for future research in order to solve the \n\nintriguing pathophysiology of hepatic schistosomiasis and use this knowledge for the patients \n\nbenefit. \n\n \n\n \n\n  \n\n\n\n99 \n \n\nREFERENCES \n\n[1].  Who WHO. Sustaining the drive to overcome the global impact of neglected tropical \n\ndiseases. Second WHO Rep neglected Trop Dis. 2013;3.9:67\u201371.  \n\n[2].  Ross AG., Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, et al. Schistosomiasis. \n\nN Engl J Med. 2002;346(16):1212\u201320.  \n\n[3].  Steinmann P, Steinmann P, Keiser J, Keiser J, Bos R, Bos R, et al. Schistosomiasis and \n\nwater resources development: systematic review, meta-analysis, and estimates of people \n\nat risk. Lancet Infect Dis. 2006;6:411\u201325.  \n\n[4].  Andrade ZA. Schistosomal hepatopathy. Mem Inst Oswaldo Cruz. 2004;99:51\u20137.  \n\n[5].  Strauss E. Hepatosplenic schistosomiasis: a model for the study of portal hypertension. \n\nAnn Hepatol. 2002;1(1):6\u201311.  \n\n[6].  Widman A, Speranzini MB, de Lima JT, Wierman P, de Oliveira MR, Raia A. Arterial \n\nand operative portography in patients with portal hypertension caused by hepato-splenic \n\nschistosomiasis and those with spleno-renal anastomosis (comparative study). Rev do \n\nHosp das Cl\u00ednicas Fac Med S\u00e3o Paulo. 1973;28(4):177\u201387.  \n\n[7].  Sarin S, Mosca P, Sabba C, Groszmann R. Hyperdynamic ciculation in a chronic murine \n\nschistosomiasis model of portal hypertension. Hepatology. 1991;13(3):581\u20134.  \n\n[8].  Mies S, Larsson E, Mori T, Williams GM. Sistema porta e as art\u00e9rias hepatica, espl\u00eanica \n\ne mesent\u00e9rica superior na esquistossomose hepatoespl\u00eanica. Estudo angiogr\u00e1fico. Rev \n\ndo Hosp das Cl\u00ednicas Fac Med S\u00e3o Paulo. 1980;35:121\u201331.  \n\n\n\n100 \n \n\n[9].  Cleva R, Pugliese V, Zilberstein B, Saad WA, Pinotti W, Laudanna AA. Systemic \n\nhemodynamic changes in mansonic schistosomiasis with portal hypertension treated by \n\nazygoportal disconnection and splenectomy. Am J Gastroenterol. 1999;94(6):1632\u20137.  \n\n[10].  Alves C, Alves A, Abreu W, Andrade ZA. Hepatic artery hypertrophy and sinusoidal \n\nhypertension in advanced schistosomiasis. Gastroenterology. 1977;72(1):126\u20138.  \n\n[11].  Mies S, Braghirolli-Neto O, Beer A, Baia C, Alfieri F, Pereira L, et al. Systemic and \n\nhepatic hemodynamics in hepatosplenic manson\u2019s schistosomiasis with and without \n\npropranolol. Dig Dis Sci. 1997;42(4):751\u201361.  \n\n[12].  Jorge PAR, Carvalhal S dos S. Sobre a rede vascular intra-hep\u00e1tica na esquistossomose \n\nmansonica, forma de Symmers: Estudo com modelos pl\u00e1sticos. Rev Assoc Med Bras. \n\n1967;13(12):435\u201341.  \n\n[13].  Andrade ZA. Schistosomiasis and liver fibrosis. Parasite Immunol. 2009;31:656\u201363.  \n\n[14].  Warren KS. Hepatosplenic schistosomiasis mansoni: an immunologic disease. Bull N Y \n\nAcad Med. 1975;51(4):545\u201350.  \n\n[15].  Andrade ZA, Baptista AP, Santana TS. Remodeling of hepatic vascular changes after \n\nspecific chemotherapy of schistosomal periportal fibrosis. Mem Inst Oswaldo Cruz. \n\n2006;101:267\u201372.  \n\n[16].  Andrade ZA, Santana TS. Angiogenesis and schistosomiasis. Mem Inst Oswaldo Cruz. \n\n2010;105(July):436\u20139.  \n\n\n\n101 \n \n\n[17].  Magalh\u00e3es-Filho A, Silva JF. Patologia e patogenia da esquistossomose mans\u00f4nica. In: \n\nMalta J, editor. Esquistossomose Mans\u00f4nica. Primeira. Recife: Editora Universit\u00e1ria da \n\nUFPE; 1994. p. 61\u20139.  \n\n[18].  Silva CLM, Lenzi HL, Silva VFM, Paulo FO, No\u00ebl F. Cellular mechanisms involved in \n\nthe increased contraction of portal veins from Schistosoma mansoni-infected mice. \n\nParasitol Res. 2003;89:16\u201322.  \n\n[19].  Araujo FP, Quintas LEM, No\u00ebl F, Silva CLM. Schistosoma mansoni infection enhances \n\nhost portal vein contraction: role of potassium channels and p38 MAP kinase. Microbes \n\nInfect. 2007;9:1020\u20135.  \n\n[20].  Andrade ZA. Pathology of human schistosomiasis. Mem Inst Oswaldo Cruz. \n\n1987;82(4):17\u201323.  \n\n[21].  De Cock K. Hepatosplenic schistosomiasis: a clinical review. Gut. 1986;27:734\u201345.  \n\n[22].  Magalh\u00e3es-Filho A, Menezes H, Coelho R de B. Patog\u00eanese da fibrose hep\u00e1tica na \n\nesquistossomose mansoni (Estudo das altera\u00e7\u00f5es vasculares portais mediante modelo \n\npl\u00e1stico). Rev Assoc Med Bras. 1960;6(4):284\u201394.  \n\n[23].  Hidayat M, Wahid H. A study of the vascular changes in bilharzic hepatic fibrosis and \n\ntheir significance. Surgery, Gynecol Obstet. 1971;997\u20131004.  \n\n[24].  Andrade ZA. A double and paradoxical role for angiogenesis. Rev Patol Trop. \n\n2013;42(3):259\u201364.  \n\n\n\n102 \n \n\n[25].  Domingues ALC, Domingues LAW. Forma intestinal, hepatointestinal e \n\nhepatoespl\u00eanica. In: Malta J, editor. Esquistossomose Mans\u00f4nica. Primeira. Recife: \n\nEditora Universit\u00e1ria da UFPE; 1994. p. 95\u2013105.  \n\n[26].  Da Silva LC, Chieffi PP, Carrilho FJ. Schistosomiasis mansoni -- clinical features. \n\nGastroenterol Hepatol. 2005;28(1):30\u20139.  \n\n[27].  Da Silva LC. Portal hypertension in schistosomiasis: pathophysiology and treatment. \n\nMem Inst Oswaldo Cruz. 1992;87(suppl IV):183\u20136.  \n\n[28].  N\u00fcssler NC, Settmacher U, Haase R, Stange B, Heise M, Neuhaus P. Diagnosis and \n\ntreatment of arterial steal syndromes in liver transplant recipients. Liver Transpl. \n\n2003;9:596\u2013602.  \n\n[29].  Akamatsu N, Sugawara Y, Satou S, Mitsui T, Ninomiya R, Komagome M, et al. \n\nHemodynamic changes in the hepatic circulation after the modulation of the splenic \n\ncirculation in an in vivo human experimental model. Liver Transplant. 2014;20:116\u201321.  \n\n[30].  Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: \n\nhepatic arterial buffer response. Am J Physiol. 1985;249(5):549\u201356.  \n\n[31].  Quintini C, Hirose K, Hashimoto K, Diago T, Aucejo F, Eghtesad B, et al. \u201cSplenic \n\nartery steal syndrome\u201d: Is a misnomer: The cause is portal hyperperfusion, not arterial \n\nsiphon. Liver Transplant. 2008;14:374\u20139.  \n\n[32].  Cleva R, Herman P, D\u2019albuquerque LA, Pugliese V, Santarem OL, Saad WA. Pre- and \n\npostoperative systemic hemodynamic evaluation in patients subjected to esophagogastric \n\ndevascularization plus splenectomy and distal splenorenal shunt: A comparative study in \n\nschistosomal portal hypertension. World J Gastroenterol. 2007;13(41):5471\u20135.  \n\n\n\n103 \n \n\n[33].  Cleva R, Saad WA, Herman P, Pugliese V, Zilberstein B, Laudanna AA, et al. Portal \n\nhyperflow in patients with hepatosplenic mansonic schistosomiasis. Rev do Hosp das \n\nCl\u00ednicas Fac Med S\u00e3o Paulo. 2004;59(1):10\u20134.  \n\n34.  Pereira FM, Evangelista-Neto J, Brito N, Amaral F, da Fonseca-Neto OC, Lacerda CM. \n\nAngiografic and pressoric changes determined by splenectomy with left gastric vein \n\nligature in mansoni schistosomiasis. Arq Bras Cir Dig. 2013;26(4):302\u20138.  \n\n[35].  Lacerda CM, Ramos H, Raia S, Kelner S. Fisiopatologia da hipertens\u00e3o portal \n\nesquistossom\u00f3tica e efeitos da esplenectomia com ligadura de varizes de es\u00f4fago. Acta \n\nCir Bras. 1993;8:113\u20137.  \n\n[36].  Coutinho A. Hemodynamic studies of portal hypertension in schistosomiasis. Am J Med. \n\n1968;44:547\u201355.  \n\n[37].  Warren KS. Pathophysiology and pathogenesis of hepatosplenic schistosomiasis \n\nmansoni. Bull N Y Acad Med. 1968;44(3):280\u201394.  \n\n[38].  Ramos OL, Saad F, Leser WP. Portal hemodynamics and liver cell function in hepatic \n\nschistosomiasis. Gastroenterology. 1964;47:241\u20137.  \n\n[39].  Morgan J, Groszmann R, Rojkind M, Enriquez R. Hemodynamic mechanism of \n\nemerging portal hypertension caused by schistosomiasis in the hamster. Hepatology. \n\n1990;11(1):98\u2013104.  \n\n[40].  Lautt WW. Control of hepatic arterial blood flow: independence from liver metabolic \n\nactivity. Am J Physiol. 1980;239:H559\u201364.  \n\n\n\n104 \n \n\n[41].  Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: \n\nhepatic arterial buffer response. Am J Physiol. 1985;  \n\n[42].  Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: The hepatic arterial \n\nbuffer response revisited. World Journal of Gastroenterology. 2010.  \n\n[43].  Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and \n\ntherapeutic targets in liver injury and repair. Physiol Rev. 2009;89:1269\u2013339.  \n\n[44].  Lautt WW. Hepatic Circulation Physiology and Pathophysiology [Internet]. 1st ed. \n\nColloquium Series on Integrated Systems Physiology: From Molecule to Function. San \n\nRafael: Morgan &amp; Claypool Life Sciences; 2009.  \n\n[45].  G\u00fclberg V, Haag K, R\u00f6ssle M, Gerbes AL. Hepatic arterial buffer response in patients \n\nwith advanced cirrhosis. Hepatology. 2002;35(3):630\u20134.  \n\n[46].  Zipprich A, Steudel N, Behrmann C, Meiss F, Sziegoleit U, Fleig WE, et al. Functional \n\nsignificance of hepatic arterial flow reserve in patients with cirrhosis. Hepatology. 2003 \n\nFeb;37(2):385\u201392.  \n\n[47].  Richter S, M\u00fccke I, Menger MD, Vollmar B. Impact of intrinsic blood flow regulation \n\nin cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol Gastrointest \n\nLiver Physiol. 2000;  \n\n[48].  Aoki T, Imamura H, Kaneko J, Sakamoto Y, Matsuyama Y, Kokudo N, et al. \n\nIntraoperative direct measurement of hepatic arterial buffer response in patients with or \n\nwithout cirrhosis. Liver Transplant. 2005;11(6):684\u201391.  \n\n\n\n105 \n \n\n[49].  Kelly DM, Zhu X, Shiba H, Irefin S, Trenti L, Cocieru A, et al. Adenosine restores the \n\nhepatic artery buffer response and improves survival in a porcine model of small-for-\n\nsize syndrome. Liver Transplant. 2009;15:1448\u201357.  \n\n[50].  Saad WEA. Nonocclusive hepatic artery hypoperfusion syndrome (splenic steal \n\nsyndrome) in liver transplant recipients. Semin Intervent Radiol. 2012;29:140\u20136.  \n\n[51].  Moeller M, Thonig A, Pohl S, Ripoll C, Zipprich A. Hepatic Arterial Vasodilation Is \n\nIndependent of Portal Hypertension in Early Stages of Cirrhosis. PLoS One. \n\n2015;10(3):e0121229.  \n\n[52].  Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD. Portal branch \n\nligation induces a hepatic arterial buffer response, microvascular remodeling, \n\nnormoxygenation, and cell proliferation in portal blood-deprived liver tissue. Am J \n\nPhysiol Gastrointest Liver Physiol. 2007;292:G1534\u201342.  \n\n[53].  Kleber G, Steudel N, Behrmann C, Zipprich A, H\u00fcbner G, Lotterer E, et al. Hepatic \n\narterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler \n\nand adenosine infusion. Gastroenterology. 1999;116(4):906\u201314.  \n\n[54].  Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: \n\nhepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol. \n\n1985;249(5):G549\u201356.  \n\n[55].  Ezzat WR, Lautt WW. Hepatic arterial pressure-flow autoregulation is adenosine \n\nmediated. Am J Physiol. 1987;252(4):H836\u201345.  \n\n\n\n106 \n \n\n[56].  Richter S, Vollmar B, M\u00fccke I, Post S, Menger MD. Hepatic arteriolo-portal venular \n\nshunting guarantees maintenance of nutritional microvascular supply in hepatic arterial \n\nbuffer response of rat livers. J Physiol. 2001;531(1):193\u2013201.  \n\n[57].  Pandharipande P V, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: \n\ncurrent challenges and future goals. Radiology. Radiological Society of North America; \n\n2005;234(3):661\u201373.  \n\n[58].  Dragoteanu M, Balea I a, Dina L a, Piglesan CD, Grigorescu I, Tamas S, et al. Staging \n\nof portal hypertension and portosystemic shunts using dynamic nuclear medicine \n\ninvestigations. World J Gastroenterol. 2008;14(6):3841\u20138.  \n\n[59].  Dragoteanu M, Cotul S, Piglesan C, Tamas S. Liver angioscintigraphy: clinical \n\napplications. Rom J Gastroenterol. 2004;13(1):55\u201363.  \n\n[60].  Dragoteanu M, Cotul S, Tamas S, Piglesan C. Nuclear medicine dynamic investigations \n\nof diffuse chronic liver diseases and portal hypertension. Rom J Gastroenterol. \n\n2004;13(4):351\u20137.  \n\n \n\n \n\n\n\n107 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCONCLUS\u00d5ES E \n\nCONSIDERA\u00c7\u00d5ES FINAIS \n\n  \n\n\n\n108 \n \n\n6. CONCLUS\u00d5ES E CONSIDERA\u00c7\u00d5ES FINAIS \n\n \n\nO presente estudo foi capaz de avaliar as altera\u00e7\u00f5es hemodin\u00e2micas in vivo de pacientes \n\ncom a forma hepatoespl\u00eanica da esquistossomose mansoni utilizando a medida do \u00cdndice \n\nde Perfus\u00e3o Hep\u00e1tica (IPH) atrav\u00e9s da angiocintilografia. Foi poss\u00edvel demonstrar que \n\nesses pacientes apresentavam aumento significativo do IPH, caracterizando uma maior \n\npropor\u00e7\u00e3o do fluxo hep\u00e1tico proveniente da art\u00e9ria hep\u00e1tica, \u00e0 semelhan\u00e7a do descrito \n\npreviamente nos cirr\u00f3ticos. A medida do IPH na EHE apresenta relev\u00e2ncia cl\u00ednica, tendo \n\nem vista sua correla\u00e7\u00e3o estatisticamente significativa com o comprimento longitudinal do \n\nespl\u00eanico e com o calibre das varizes esof\u00e1gicas, bem como, correla\u00e7\u00e3o com o calibre da \n\nveia porta e com a contagem global de plaquetas. \n\n \n\nApesar das controv\u00e9rsias e diverg\u00eancias na literatura, diante dos resultados da pesquisa, \n\npode-se documentar haver, de fato, uma maior propor\u00e7\u00e3o de fluxo arterial na perfus\u00e3o \n\nhep\u00e1tica. Deve-se acreditar que na EHE as altera\u00e7\u00f5es intra-hep\u00e1ticas do territ\u00f3rio da veia \n\nporta realmente induzem um aumento da perfus\u00e3o arterial. Ademais, as correla\u00e7\u00f5es \n\ncl\u00ednicas observadas, revestem-se de import\u00e2ncia pr\u00e1tica, especialmente quando se \n\nobserva a correla\u00e7\u00e3o entre o IPH e o calibre das varizes esof\u00e1gicas, bem como a acur\u00e1cia \n\ndo m\u00e9todo cintilogr\u00e1fico em predizer seu surgimento.  \n\n \n\nA EHE por se tratar de uma enfermidade bastante heterog\u00eanea, na qual as altera\u00e7\u00f5es da \n\nanatomia hep\u00e1tica e da sua hemodin\u00e2mica s\u00e3o multifatoriais e vari\u00e1veis deve ser estudada \n\ncom extremo crit\u00e9rio. Portanto, novas pesquisas com uma maior popula\u00e7\u00e3o, com a \n\nassocia\u00e7\u00e3o de outros m\u00e9todos diagn\u00f3sticos para a avalia\u00e7\u00e3o da perfus\u00e3o hep\u00e1tica e a \n\nutiliza\u00e7\u00e3o de um grupo cirr\u00f3tico como par\u00e2metro de compara\u00e7\u00e3o possam trazer \n\ninforma\u00e7\u00f5es adicionais e complementares ao estudo dessa enfermidade ainda muito \n\nprevalente, por\u00e9m com diversos pontos de controv\u00e9rsias na sua fisiopatologia. \n\n \n\n  \n\n\n\n109 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nREFER\u00caNCIAS \n\n \n\n  \n\n\n\n110 \n \n\nREFER\u00caNCIAS \n\n \n\nABDEL-WAHAB, M. et al. Characteristic sonographic pattern of schistosomal hepatic \n\nfibrosis. Am J Trop Med Hyg, v. 40, n. 1, p. 72\u201376, 1989.  \n\nABDEL-WAHAB, M. et al. Grading of hepatic schistosomiasis by the use of \n\nultrasonography. Am J Trop Med Hyg, v. 46, n. 4, p. 403\u2013408, 1992a.  \n\nABDEL-WAHAB, M. et al. The use of diagnostic ultrasound in schistosomiasis \u2014 \n\nAttempts at standardization of methodology. Acta Tropica, v. 51, n. 1, p. 45\u201363, 1992b.  \n\nABDEL-WAHAB, M. et al. Ultrasonographic prediction of esophageal varices in \n\nSchistosomiasis mansoni. The American Journal of Gastroenterology, v. 88, n. 4, p. \n\n560\u2013563, 1993.  \n\nABDEL-WAHAB, M.; ESMAT, G. The value of ultrasonography in assessment of portal \n\nhypertension in hepatosplenic schistosomiasis. Mem\u00f3rias do Instituto Oswaldo Cruz, \n\nv. 87, n. 4, p. 143\u2013147, 1992.  \n\nAKAMATSU, N. et al. Hemodynamic changes in the hepatic circulation after the \n\nmodulation of the splenic circulation in an in vivo human experimental model. Liver \n\nTransplantation, v. 20, p. 116\u2013121, 2014.  \n\nALVES, C. et al. Hepatic artery hypertrophy and sinusoidal hypertension in advanced \n\nschistosomiasis. Gastroenterology, v. 72, n. 1, p. 126\u2013128, 1977.  \n\nANDRADE, Z. A. Pathology of human schistosomiasis. Memorias do Instituto \n\nOswaldo Cruz, v. 82, n. 4, p. 17\u201323, 1987.  \n\nANDRADE, Z. A. Schistosomal hepatopathy. Mem\u00f3rias do Instituto Oswaldo Cruz, \n\nv. 99, p. 51\u201357, 2004.  \n\nANDRADE, Z. A. Regression of hepatic fibrosis. Revista da Sociedade Brasileira de \n\nMedicina Tropical, v. 38, n. 6, p. 514\u2013520, 2005.  \n\nANDRADE, Z. A. Schistosomiasis and liver fibrosis. Parasite immunology, v. 31, p. \n\n656\u2013663, 2009.  \n\nANDRADE, Z. A. A double and paradoxical role for angiogenesis. Rev Patol Trop, v. \n\n42, n. 3, p. 259\u2013264, 2013.  \n\nANDRADE, Z. A.; BAPTISTA, A. P.; SANTANA, T. S. Remodeling of hepatic vascular \n\nchanges after specific chemotherapy of schistosomal periportal fibrosis. Memorias do \n\nInstituto Oswaldo Cruz, v. 101, p. 267\u2013272, 2006.  \n\nANDRADE, Z. A.; BINA, J. The changing pattern of pathology due to Schistosoma \n\nmansoni infection. Memorias do Instituto Oswaldo Cruz, v. 80, n. 3, p. 363\u2013366, 1985.  \n\n\n\n111 \n \n\nANDRADE, Z. A.; SANTANA, T. S. Angiogenesis and schistosomiasis. Memorias do \n\nInstituto Oswaldo Cruz, v. 105, n. July, p. 436\u2013439, 2010.  \n\nAOKI, T. et al. Intraoperative direct measurement of hepatic arterial buffer response in \n\npatients with or without cirrhosis. Liver Transplantation, v. 11, n. 6, p. 684\u2013691, 2005.  \n\nARAUJO, F. P. et al. Schistosoma mansoni infection enhances host portal vein \n\ncontraction: role of potassium channels and p38 MAP kinase. Microbes and Infection, \n\nv. 9, p. 1020\u20131025, 2007.  \n\nAZEREDO, L. M. Avalia\u00e7\u00e3o ultrassonogr\u00e1fica e dopplervelocim\u00e9trica da \n\nesquistossomose mans\u00f4nica: estudo de campo em \u00e1reas de baixa, m\u00e9dia e alta \n\nendemicidades. [tese] Faculdade de Medicina da Universidade de S\u00e3o Paulo, 2009. \n\nAZEREDO, L. M. et al. Aspectos ultrassonogr\u00e1ficos e hemodin\u00e2micos da \n\nesquistossomose mans\u00f4nica: avalia\u00e7\u00e3o pela ultrassonografia Doppler em \u00e1reas \n\nend\u00eamicas. Radiologia Brasileira, v. 43, n. 2, p. 69\u201376, 2010.  \n\nBARBOSA, C. S. et al. Epidemiologia da esquistossomose no litoral de pernambuco. Rev \n\nPatol Trop, v. 43, n. 4, p. 436\u2013445, 2014.  \n\nBARBOSA, C. S.; DA SILVA, C. B.; BARBOSA, F. S. Esquistossomose: Reprodu\u00e7\u00e3o \n\ne expans\u00e3o da endemia no Estado de Pernambuco no Brasil. Revista de Saude Publica, \n\nv. 30, n. 6, p. 609\u2013616, 1996.  \n\nBARBOSA, C. S.; SILVA, C. B. DA. Epidemiologia da Esquistossomose Mans\u00f4nica no \n\nEngenho Bela Rosa, munic\u00edpio de S\u00e3o Louren\u00e7o da Mata, Pernambuco, Brasil. Cadernos \n\nde Sa\u00fade P\u00fablica, v. 8, n. 1950, p. 83\u201387, 1992.  \n\nBRANT, P. E. et al. Anicteric cholangiopathy in schistosomiasis patients. Acta Tropica, \n\nv. 108, p. 218\u2013221, 2008.  \n\nBRASIL. MINIST\u00c9RIO DA SA\u00daDE. Plano integrado de a\u00e7\u00f5es estrat\u00e9gicas. \n\nDispon\u00edvel em: http: //bvsms. saude. gov.br /bvs /publicacoes /plano_ integrado _acoes_ \n\nestrategicas_2011_2015.pdf. Acesso em: 4 abr. 2015.  \n\nCERRI, G. G. Contribui\u00e7\u00e3o da ultra-sonografia no diagn\u00f3stico da forma \n\nhepatoespl\u00eanica da esquistossomose mans\u00f4nica. [tese] Faculdade de Medicina da \n\nUniversidade de S\u00e3o Paulo, 1984. \n\nCHAWLA, Y.; DHIMAN, R. K. Intrahepatic portal venopathy and related disorders of \n\nthe liver. Seminars in Liver Disease, v. 28, p. 270\u2013281, 2008.  \n\nCLEVA, R. et al. Systemic hemodynamic changes in mansonic schistosomiasis with \n\nportal hypertension treated by azygoportal disconnection and splenectomy. The \n\nAmerican Journal of Gastroenterology, v. 94, n. 6, p. 1632\u20131637, 1999.  \n\nCLEVA, R. et al. Portal hyperflow in patients with hepatosplenic mansonic \n\nschistosomiasis. Revista do Hospital das Cl\u00ednicas Faculdade de Medicina de S\u00e3o \n\nPaulo, v. 59, n. 1, p. 10\u201314, 2004.  \n\n\n\n112 \n \n\nCLEVA, R. et al. Pre- and postoperative systemic hemodynamic evaluation in patients \n\nsubjected to esophagogastric devascularization plus splenectomy and distal splenorenal \n\nshunt: A comparative study in schistosomal portal hypertension. World journal of \n\ngastroenterology, v. 13, n. 41, p. 5471\u20135475, 2007.  \n\nCOUTINHO, A. Hemodynamic studies of portal hypertension in schistosomiasis. \n\nAmerican Journal of Medicine, v. 44, p. 547\u2013555, 1968.  \n\nDA SILVA, L. C. Portal hypertension in schistosomiasis: pathophysiology and treatment. \n\nMemorias do Instituto Oswaldo Cruz, v. 87, n. suppl IV, p. 183\u2013186, 1992.  \n\nDA SILVA, L. C.; CHIEFFI, P. P.; CARRILHO, F. J. Schistosomiasis mansoni -- clinical \n\nfeatures. Gastroenterologia y hepatologia, v. 28, n. 1, p. 30\u201339, 2005.  \n\nDE ARRUDA, S. M. B.; BARRETO, V. S. T.; DO AMARAL, F. J. Duplex sonography \n\nstudy in schistosomiasis portal hypertension: Characterization of patients with and \n\nwithout a history of variceal bleeding. Arquivos de Gastroenterologia, v. 45, n. 1, p. \n\n11\u201316, 2008.  \n\nDE COCK, K. Hepatosplenic schistosomiasis: a clinical review. Gut, v. 27, p. 734\u2013745, \n\n1986.  \n\nDOMINGUES, A. et al. An ultrasonographic study of liver fibrosis in patients infected \n\nwith Schistosoma mansoni in north-east Brazil. Trans R Soc Trop Med Hyg, v. 87, n. \n\n5, p. 555\u2013558, 1993.  \n\nDOMINGUES, A. L. C. Esquistossomose mans\u00f4nica. In: MATTOS, A. A.; DANTAS-\n\nCORR\u00caA, E. B. (Eds.). . Tratado de Hepatologia. Rio de Janeiro: Editora Rubio, 2010. \n\np. 301\u2013310.  \n\nDOMINGUES, A. L. C.; DOMINGUES, L. A. W. Forma intestinal, hepatointestinal e \n\nhepatoespl\u00eanica. In: MALTA, J. (Ed.). . Esquistossomose Mans\u00f4nica. Primeira \n\ned.Recife: Editora Universit\u00e1ria da UFPE, 1994. p. 95\u2013105.  \n\nDRAGOTEANU, M. et al. Nuclear medicine dynamic investigations of diffuse chronic \n\nliver diseases and portal hypertension. Rom J Gastroenterol, v. 13, n. 4, p. 351\u2013357, \n\n2004a.  \n\nDRAGOTEANU, M. et al. Liver angioscintigraphy: clinical applications. Rom J \n\nGastroenterol, v. 13, n. 1, p. 55\u201363, 2004b.  \n\nDRAGOTEANU, M. et al. Staging of portal hypertension and portosystemic shunts using \n\ndynamic nuclear medicine investigations. World Journal of Gastroenterology, v. 14, n. \n\n6, p. 3841\u20133848, 2008.  \n\nEIPEL, C.; ABSHAGEN, K.; VOLLMAR, B. Regulation of hepatic blood flow: The \n\nhepatic arterial buffer response revisited. World Journal of Gastroenterology, v. 16, n. \n\n48, p. 6046-6057, 2010.  \n\n\n\n113 \n \n\nEZZAT, W. R.; LAUTT, W. W. Hepatic arterial pressure-flow autoregulation is \n\nadenosine mediated. The American journal of physiology, v. 252, n. 4, p. H836\u2013H845, \n\n1987.  \n\nFERREIRA, F. G. et al. Doppler ultrasound could predict varices progression and \n\nrebleeding after portal hypertension surgery: Lessons from 146 EGDS and 10 years of \n\nfollow-up. World Journal of Surgery, v. 33, p. 2136\u20132143, 2009.  \n\nFI\u00daZA, MATEUS PONTES, VILAS-BOAS, LIVIA, LYRA, A. C. Esquistossomose. In: \n\nZATERKA, S.; EISIG, J. N. (Eds.). . Tratado de Gastroenterologia da Gradua\u00e7\u00e3o \u00e0 \n\nP\u00f3s-gradua\u00e7\u00e3o. Primeira ed.S\u00e3o Paulo: Editora Atheneu, 2011. p. 973\u2013976.  \n\nFROOMES, P. et al. Comparative effects of oxygen supplementation on theophylline and \n\nacetaminophen clearance in human cirrhosis. Gastroenterology, v. 116, n. 4, p. 915\u2013920, \n\n1999.  \n\nGON\u00c7ALVES, F. et al. Esquistossomose aguda, de car\u00e1ter epis\u00f3dico, na ilha de \n\nItamarac\u00e1, estado de Pernambuco. Cadernos de Sa\u00fade P\u00fablica, v. 7, n. 3, p. 424\u2013425, \n\n1991.  \n\nGRYSEELS, B. The relevance of schistosomiasis for public health. Tropical Medicine \n\nand Parasitology, v. 40, n. 2, p. 134\u2013142, 1989.  \n\nGRYSEELS, B. et al. Human schistosomiasis. Lancet, v. 368, p. 1106\u20131118, 2006.  \n\nG\u00dcLBERG, V. et al. Hepatic arterial buffer response in patients with advanced cirrhosis. \n\nHepatology, v. 35, n. 3, p. 630\u2013634, 2002.  \n\nHARVEY, P. J. et al. Acute oxygen supplementation restores markers of hepatocyte \n\nenergy status and hypoxia in cirrhotic rats. The Journal of pharmacology and \n\nexperimental therapeutics, v. 293, n. 2, p. 641\u2013645, 2000.  \n\nHAYANO, K. Computed tomography perfusion imaging as a potential imaging \n\nbiomarker of colorectal cancer. World Journal of Gastroenterology, v. 20, n. 46, p. \n\n17345, 2014.  \n\nHIDAYAT, M.; WAHID, H. A study of the vascular changes in bilharzic hepatic fibrosis \n\nand their significance. Surgery, Gynecology and Obstetrics, p. 997\u20131004, 1971.  \n\nIIO, M. et al. Scintigraphic evaluation of the liver with schistosomiasis japonica. Journal \n\nof nuclear medicine, v. 12, p. 655\u2013659, 1971.  \n\nJORGE, P. A. R.; CARVALHAL, S. DOS S. Sobre a rede vascular intra-hep\u00e1tica na \n\nesquistossomose mansonica, forma de Symmers: Estudo com modelos pl\u00e1sticos. Revista \n\nda Associa\u00e7\u00e3o M\u00e9dica Brasileira, v. 13, n. 12, p. 435\u2013441, 1967.  \n\nKELLY, D. M. et al. Adenosine restores the hepatic artery buffer response and improves \n\nsurvival in a porcine model of small-for-size syndrome. Liver Transplantation, v. 15, \n\np. 1448\u20131457, 2009.  \n\n\n\n114 \n \n\nKING, C. H. et al. Measuring morbidity in schistosomiasis mansoni: Relationship \n\nbetween image pattern, portal vein diameter and portal branch thickness in large-scale \n\nsurveys using new WHO coding guidelines for ultrasound in schistosomiasis. Tropical \n\nMedicine and International Health, v. 8, n. 2, p. 109\u2013117, 2003.  \n\nKING, C. H.; DANGERFIELD-CHA, M. The unacknowledged impact of chronic \n\nschistosomiasis. Chronic illness, v. 4, p. 65\u201379, 2008.  \n\nKLEBER, G. et al. Hepatic arterial flow volume and reserve in patients with cirrhosis: \n\nuse of intra-arterial Doppler and adenosine infusion. Gastroenterology, v. 116, n. 4, p. \n\n906\u2013914, 1999.  \n\nKOLLMAR, O. et al. Portal branch ligation induces a hepatic arterial buffer response, \n\nmicrovascular remodeling, normoxygenation, and cell proliferation in portal blood-\n\ndeprived liver tissue. American journal of physiology. Gastrointestinal and liver \n\nphysiology, v. 292, p. G1534\u2013G1542, 2007.  \n\nKORANDA, P. et al. Hepatic perfusion changes in patients with cirrhosis indices of \n\nhepatic arterial blood flow. Clinical nuclear medicine, v. 24, n. 7, p. 507\u201310, jul. 1999.  \n\nLACERDA, C. M. et al. Fisiopatologia da hipertens\u00e3o portal esquistossom\u00f3tica e efeitos \n\nda esplenectomia com ligadura de varizes de es\u00f4fago. Acta Cirurgica Brasileira, v. 8, \n\np. 113\u2013117, 1993.  \n\nLAUTT, W. W. Control of hepatic arterial blood flow: independence from liver metabolic \n\nactivity. The American journal of physiology, v. 239, p. H559\u2013H564, 1980.  \n\nLAUTT, W. W. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: \n\nhepatic arterial buffer response. The American journal of physiology, v. 249, n. 5, p. \n\n549\u2013556, 1985.  \n\nLAUTT, W. W. Hepatic Circulation Physiology and Pathophysiology. 1st. ed. San \n\nRafael: Morgan &amp; Claypool Life Sciences, 2009. v. 1p. 1\u2013174 \n\nLEEN, E. et al. The use of duplex sonography in the detection of colorectal hepatic \n\nmetastases. British journal of cancer, v. 63, p. 323\u2013325, 1991.  \n\nLEEN, E. et al. Hepatic perfusion changes in patients with liver metastases: comparison \n\nwith those patients with cirrhosis. Gut, v. 34, n. 4, p. 554\u2013557, 1993.  \n\nLEEN, E. et al. Prognostic power of Doppler perfusion index in colorectal cancer. \n\nCorrelation with survival. Annals of surgery, v. 223, n. 2, p. 199\u2013203, 1996.  \n\nLEITE, L. A. C. et al. Relationship between splenomegaly and hematologic findings in \n\npatients with hepatosplenic schistosomiasis. Revista brasileira de hematologia e \n\nhemoterapia, v. 35, p. 332\u2013336, 2013.  \n\nLEVESON, S. H. et al. Improving the detection of hepatic metastases by the use of \n\ndynamic flow scintigraphy. British journal of cancer, v. 47, p. 719\u2013721, 1983.  \n\n\n\n115 \n \n\nMAGALH\u00c3ES-FILHO, A.; MENEZES, H.; COELHO, R. DE B. Patog\u00eanese da fibrose \n\nhep\u00e1tica na esquistossomose mansoni (Estudo das altera\u00e7\u00f5es vasculares portais mediante \n\nmodelo pl\u00e1stico). Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira, v. 6, n. 4, p. 284\u2013294, 1960.  \n\nMAGALH\u00c3ES-FILHO, A.; SILVA, J. F. Patologia e patogenia da esquistossomose \n\nmans\u00f4nica. In: MALTA, J. (Ed.). . Esquistossomose Mans\u00f4nica. Primeira ed.Recife: \n\nEditora Universit\u00e1ria da UFPE, 1994. p. 61\u201369.  \n\nMARTINS, R. D. et al. Endoscopic, ultrasonographic, and US-doppler parameters as \n\nindicators of variceal bleeding in patients with Schistosomiasis. Digestive Diseases and \n\nSciences, 2000.  \n\nMARTINS-MELO, F. R. et al. Trends in schistosomiasis-related mortality in Brazil, \n\n2000\u20132011. International Journal for Parasitology, v. 44, p. 1055\u20131062, 2014.  \n\nMCCUSKEY, R. Anatomy of the Liver. In: BOYER, T. D.; MANNS, M. P.; SANYAL, \n\nA. J. (Eds.). . Zakim and Boyer\u00b4s HEPATOLOGY: A textbook of liver disease. sixth \n\ned.Philadelphia: Elsevier Saunders, 2012. p. 3\u201319.  \n\nMEDEIROS, T. B. et al. Correlation between platelet count and both liver fibrosis and \n\nspleen diameter in patients with schistosomiasis mansoni. Arquivos de \n\nGastroenterologia, v. 51, n. 1, p. 34\u201338, 2014.  \n\nMIES, S. et al. Sistema porta e as art\u00e9rias hepatica, espl\u00eanica e mesent\u00e9rica superior na \n\nesquistossomose hepatoespl\u00eanica. Estudo angiogr\u00e1fico. Revista do Hospital das \n\nCl\u00ednicas Faculdade de Medicina de S\u00e3o Paulo, v. 35, p. 121\u2013131, 1980.  \n\nMIES, S. et al. Systemic and hepatic hemodynamics in hepatosplenic manson\u2019s \n\nschistosomiasis with and without propranolol. Digestive Diseases and Sciences, v. 42, n. \n\n4, p. 751\u2013761, 1997.  \n\nMOELLER, M. et al. Hepatic Arterial Vasodilation Is Independent of Portal \n\nHypertension in Early Stages of Cirrhosis. PLOS ONE, v. 10, n. 3, p. e0121229, 2015.  \n\nMORGAN, J. et al. Hemodynamic mechanism of emerging portal hypertension caused \n\nby schistosomiasis in the hamster. Hepatology, v. 11, n. 1, p. 98\u2013104, 1990.  \n\nMUSTAFA, A G. et al. Radioisotope photoscanning of the liver in bilharzial hepatic \n\nfibrosis. Journal of nuclear medicine, v. 7, p. 909\u2013916, 1966.  \n\nN\u00dcSSLER, N. C. et al. Diagnosis and treatment of arterial steal syndromes in liver \n\ntransplant recipients. Liver transplantation, v. 9, p. 596\u2013602, 2003.  \n\nO\u2019CONNOR, M. K. et al. Ratio of hepatic arterial-to-portal venous blood flow--\n\nvalidation of radionuclide techniques in an animal model. Journal of nuclear medicine, \n\nv. 33, p. 239\u2013245, 1992.  \n\nO\u2019CONNOR, M. K.; MACMATHUNA, P.; KEELING, P. W. Hepatic arterial and portal \n\nvenous components of liver blood flow: a dynamic scintigraphic study. Journal of \n\nnuclear medicine, v. 29, p. 466\u2013472, 1988.  \n\n\n\n116 \n \n\nOLIVEIRA, L.; ANDRADE, Z. A. Significance of bile-duct changes in schistosomiasis \n\nSignificado das les\u00f5es dos ductos biliares na esquistossomose. Revista da Sociedade \n\nBrasileira de Medicina Tropical, v. 38, n. 6, p. 464\u2013468, 2005.  \n\nPALMER, E.; BRICK, I. Correlation between the severity of esophageal varices in \n\ncirrhosis and their propensity toward hemorrhage. Gastroenterology, v. 30, p. 85\u201390, \n\n1956.  \n\nPANDHARIPANDE, P. V et al. Perfusion imaging of the liver: current challenges and \n\nfuture goals. Radiology, v. 234, n. 3, p. 661\u201373, 1 mar. 2005.  \n\nPEREIRA, F. M. et al. Angiografic and pressoric changes determined by splenectomy \n\nwith left gastric vein ligature in mansoni schistosomiasis. Arq Bras Cir Dig, v. 26, n. 4, \n\np. 302\u2013308, 2013.  \n\nPEREIRA, G. J. M.; TORRES, M. E. G. Epidemiologia. In: MALTA, J. (Ed.). . \n\nEsquistossomose Mans\u00f4nica. Primeira ed.Recife: Editora Universit\u00e1ria da UFPE, 1994. \n\np. 47\u201348.  \n\nPINTO-SILVA, R. A. et al. Ultrasound in schistosomiasis mansoni. Memorias do \n\nInstituto Oswaldo Cruz, v. 105, n. 7, p. 479\u2013484, 2010.  \n\nQUINTINI, C. et al. \u201cSplenic artery steal syndrome\u201d: Is a misnomer: The cause is portal \n\nhyperperfusion, not arterial siphon. Liver Transplantation, v. 14, p. 374\u2013379, 2008.  \n\nRAMOS, O. L.; SAAD, F.; LESER, W. P. Portal hemodynamics and liver cell function \n\nin hepatic schistosomiasis. Gastroenterology, v. 47, p. 241\u2013247, 1964.  \n\nRAZZAK, M. A. The Use of Radioactive Isotopes To Study the Hemodynamic Pattern, \n\nFunction and Morphology of the Liver in Hepato-Splenic Bilharziasis (Schistosomiasis). \n\nJournal of nuclear medicine, v. 5, p. 125\u2013133, 1964.  \n\nRICHTER, J. et al. ULTRASOUND IN SCHISTOSOMIASIS: A Practical Guide to the \n\nStandardized Use of Ultrasonography for the Assessment of Schistosomiasis-related \n\nMorbidity. WHO, 2000.  \n\nRICHTER, J. Evolution of schistosomiasia-induced pathology after therapy and \n\ninterruption of exposure to schistosomes: a review of ultrasonographic studies. Acta \n\ntropica, v. 77, p. 111\u2013131, 2000.  \n\nRICHTER, S. et al. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of \n\nhepatic arterial buffer response. American journal of physiology. Gastrointestinal and \n\nliver physiology, 2000b.  \n\nRICHTER, S. et al. Hepatic arteriolo-portal venular shunting guarantees maintenance of \n\nnutritional microvascular supply in hepatic arterial buffer response of rat livers. Journal \n\nof Physiology, v. 531, n. 1, p. 193\u2013201, 2001.  \n\nROSS, A. G. . et al. Schistosomiasis. New England Journal of Medicine, v. 346, n. 16, \n\np. 1212\u20131220, 2002.  \n\n\n\n117 \n \n\nSAAD, W. E. A. Nonocclusive hepatic artery hypoperfusion syndrome (splenic steal \n\nsyndrome) in liver transplant recipients. Seminars in Interventional Radiology, v. 29, \n\np. 140\u2013146, 2012.  \n\nSARIN, S. et al. Hyperdynamic ciculation in a chronic murine schistosomiasis model of \n\nportal hypertension. Hepatology, v. 13, n. 3, p. 581\u2013584, 1991.  \n\nSEBASTIANES, P. M. et al. Interobserver variability of ultrasound parameters in portal \n\nhypertension. Memorias do Instituto Oswaldo Cruz, v. 105, n. July, p. 409\u2013413, 2010.  \n\nSHIKARE, S. et al. Hepatic perfusion index in portal hypertension of cirrhotic and non-\n\ncirrhotic aetiologies. Nucl Med Commun, v. 17, n. 6, p. 520\u2013522, 1996.  \n\nSILVA, C. L. M. et al. Cellular mechanisms involved in the increased contraction of \n\nportal veins from Schistosoma mansoni-infected mice. Parasitology Research, v. 89, p. \n\n16\u201322, 2003.  \n\nSILVA, P. C. V.; DOMINGUES, A. L. C. Aspectos epidemiol\u00f3gicos da esquistossomose \n\nhepatoespl\u00eanica no Estado de Pernambuco, Brasil. Epidemiologia e Servi\u00e7os de Sa\u00fade, \n\nv. 20, n. 3, p. 327\u2013336, 2011.  \n\nSKELLY, P. J. The use of imaging to detect schistosomes and diagnose schistosomiasis. \n\nParasite immunology, v. 35, n. 0, p. 295\u2013301, 2013.  \n\nSOUZA, F. et al. Esquistossomose mans\u00f4nica?: aspectos gerais , imunologia , patog\u00eanese \n\ne hist\u00f3ria natural. Rev Bras Clin Med, v. 9, n. 4, p. 300\u2013307, 2011.  \n\nSTEINMANN, P. et al. Schistosomiasis and water resources development: systematic \n\nreview, meta-analysis, and estimates of people at risk. The Lancet infectious diseases, \n\nv. 6, p. 411\u201325, 2006.  \n\nSTRAUSS, E. Hepatosplenic schistosomiasis: a model for the study of portal \n\nhypertension. Annals of Hepatology, v. 1, n. 1, p. 6\u201311, 2002.  \n\nVEZOZZO, D. C. P. et al. Assessment of portal hemodynamics by Doppler ultrasound \n\nand of liver morphology in the hepatosplenic and hepatointestinal forms of \n\nschistosomiasis mansoni. Digestive Diseases and Sciences, v. 51, p. 1413\u20131419, 2006.  \n\nVOLLMAR, B.; MENGER, M. D. The hepatic microcirculation: mechanistic \n\ncontributions and therapeutic targets in liver injury and repair. Physiological reviews, \n\n2009.  \n\nWARREN, H. W. et al. Prospective assessment of the hepatic perfusion index in patients \n\nwith colorectal cancer. The British journal of surgery, v. 85, n. 12, p. 1708\u201312, dez. \n\n1998.  \n\nWARREN, K. S. Pathophysiology and pathogenesis of hepatosplenic schistosomiasis \n\nmansoni. Bull N Y Acad Med, v. 44, n. 3, p. 280\u2013294, 1968.  \n\n\n\n118 \n \n\nWARREN, K. S. Hepatosplenic schistosomiasis mansoni: an immunologic disease. Bull \n\nN Y Acad Med, v. 51, n. 4, p. 545\u2013550, 1975.  \n\nWARREN, K. S. Hepatosplenic schistosomiasis: a great neglected disease of the liver. \n\nGut, v. 19, p. 572\u2013577, 1978.  \n\nWHO, W. H. O. Prevention and control of schistosomiasis and soil-transmitted \n\nhelminthiasis. World Health Organization technical report series, v. 912, 2002.  \n\nWHO, W. H. O. Sustaining the drive to overcome the global impact of neglected tropical \n\ndiseases. Second WHO report on neglected tropical diseases, v. 3.9, p. 67\u201371, 2013.  \n\nWIDMAN, A. et al. Arterial and operative portography in patients with portal \n\nhypertension caused by hepato-splenic schistosomiasis and those with spleno-renal \n\nanastomosis (comparative study). Revista do Hospital das Cl\u00ednicas Faculdade de \n\nMedicina de S\u00e3o Paulo, v. 28, n. 4, p. 177\u2013187, 1973.  \n\nWILSON, M. S. et al. Immunopathology of schistosomiasis. Immunology and cell \n\nbiology, v. 85, p. 148\u2013154, 2007.  \n\nZIPPRICH, A. et al. Functional significance of hepatic arterial flow reserve in patients \n\nwith cirrhosis. Hepatology, v. 37, n. 2, p. 385\u201392, fev. 2003.  \n\n \n\n  \n\n\n\n119 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAP\u00caNDICES \n\n \n\n  \n\n\n\n120 \n \n\nAp\u00eandice A \u2013 Protocolo de cintilografia de perfus\u00e3o de f\u00edgado e ba\u00e7o com enxofre \n\ncoloidal. \n\n \n\n1. Preparo: jejum de 12 horas. \n\n2. Radiof\u00e1rmaco e dose usual (adulto): 3 \u2013 5 mCi (111 \u2013 185 MBq) de 99mTc-\n\nenxofre coloidal. \n\n3. Cuidados durante ou ap\u00f3s a administra\u00e7\u00e3o:  \n\n? Inje\u00e7\u00e3o em bolus na c\u00e2mara para avalia\u00e7\u00e3o da fase de fluxo com volume \n\nde 2 mL \u2013 injetar em veia da fossa ante-cubital do bra\u00e7o; \n\n? Orientar retorno para imagens ap\u00f3s 20min. \n\n4. T\u00e9cnica de aquisi\u00e7\u00e3o:  \n\n? Colimador alta resolu\u00e7\u00e3o ou LEAP, janela de 20% em 140 keV; \n\n? Paciente em dec\u00fabito dorsal horizontal, bra\u00e7os para cima; \n\n? Incluir t\u00f3rax inferior e abdome superior (colimador centralizado no \n\nap\u00eandice xifoide); \n\n? Fluxo: Posterior de abdome, 1 imagem/2 segundos por 2 minutos, matriz \n\n128 e zoom 1,33; \n\n? Equil\u00edbrio: A + P de abdome, 500 kcont, matriz 128 e zoom  1,33; \n\n? Est\u00e1ticas de 20 minutos: Anterior, posterior, laterais, obliquas anteriores \n\ne posteriores de abdome (mini-tomo com passo de 45\u00ba). Imagem com \n\n1.000 kcont na anterior e mesmo tempo nas demais (m\u00e1ximo 7 minutos), \n\nmatriz 128 e zoom 1. \n\n \n\n  \n\n\n\n121 \n \n\nAp\u00eandice B. \u2013 Termo de Consentimento Livre e Esclarecido \n\n             \n\nConvidamos o (a) Sr. (a) para participar como volunt\u00e1rio (a) da pesquisa Cintilografia de perfus\u00e3o \n\nhep\u00e1tica na avalia\u00e7\u00e3o da hemodin\u00e2mica venosa portal na esquistossomose hepatoespl\u00eanica, que est\u00e1 \n\nsob a responsabilidade do pesquisador Bernardo Times de Carvalho. Endere\u00e7o: Av. Prof. Moraes Rego, \n\ns/n, Campus da UFPE, Cidade Universit\u00e1ria, Recife-PE, 50670-420. Tel: 21263700, 21263723, 99289364, \n\ne-mail b.times@yahoo.com.br (inclusive liga\u00e7\u00f5es a cobrar) e est\u00e1 sob a orienta\u00e7\u00e3o de Dra Ana L\u00facia \n\nCoutinho Domingues Av. Prof. Moraes Rego, s/n, Campus da UFPE, Cidade Universit\u00e1ria, Recife-PE, \n\n50670-420. Tel: 21263700, 21263723. \n\n \n\nEste Termo de Consentimento pode conter alguns t\u00f3picos que o/a senhor/a n\u00e3o entenda. Caso haja \n\nalguma d\u00favida, pergunte \u00e0 pessoa a quem est\u00e1 lhe entrevistando, para que o/a senhor/a esteja bem \n\nesclarecido (a) sobre tudo que est\u00e1 respondendo. Ap\u00f3s ser esclarecido (a) sobre as informa\u00e7\u00f5es a seguir, \n\ncaso aceite em fazer parte do estudo, rubrique as folhas e assine ao final deste documento, que est\u00e1 em \n\nduas vias. Uma delas \u00e9 sua e a outra \u00e9 do pesquisador respons\u00e1vel. Em caso de recusa o (a) Sr. (a) n\u00e3o \n\nser\u00e1 penalizado (a) de forma alguma. Tamb\u00e9m garantimos que o (a) Senhor (a) tem o direito de retirar o \n\nconsentimento da sua participa\u00e7\u00e3o em qualquer fase da pesquisa, sem qualquer penalidade. \n\n \n\nINFORMA\u00c7\u00d5ES SOBRE A PESQUISA: \n\n? Esse estudo tem por objetivo determinar as altera\u00e7\u00f5es hemodin\u00e2micas passiveis de serem \navaliadas pela cintilografia hep\u00e1tica e sua rela\u00e7\u00e3o com os resultados dos exames diagn\u00f3sticos \natualmente utilizados. \n\n? Os procedimentos os quais os participantes ser\u00e3o submetidos s\u00e3o: exames de cintilografia \nhep\u00e1tica, ultrassonografia e endoscopia digestiva alta. \n\n? Os riscos os quais os participantes poder\u00e3o ser expostos s\u00e3o:  \n1. Risco de constrangimento  \n\n2. Riscos m\u00ednimos de rea\u00e7\u00e3o al\u00e9rgica ao radiocontraste venoso \n\n3. Risco de dor e pequenos hematomas em s\u00edtio de venopun\u00e7\u00e3o \n\n4. Risco relacionado \u00e0 seda\u00e7\u00e3o para endoscopia digestiva alta \n\n? O benef\u00edcio gerado aos sujeitos da pesquisa uma prov\u00e1vel melhor estratifica\u00e7\u00e3o de sua doen\u00e7a, \ncom prov\u00e1vel interfer\u00eancia no tratamento disponibilizado aos mesmos. A avalia\u00e7\u00e3o de um \nm\u00e9todo objetivo que possa ser utilizado no acompanhamento e estratifica\u00e7\u00e3o da doen\u00e7a \nesquistossom\u00f3tica \u00e9 de grande valia haja vista a endemicidade da esquistossomose \nhepatoespl\u00eanica no Brasil. \n\n? O per\u00edodo de acompanhamento dos volunt\u00e1rios do estudo ser\u00e1 de junho/2014 a \nnovembro/2014. \n\n \n\nAs informa\u00e7\u00f5es desta pesquisa ser\u00e3o confidencias e ser\u00e3o divulgadas apenas em eventos ou publica\u00e7\u00f5es \n\ncient\u00edficas, n\u00e3o havendo identifica\u00e7\u00e3o dos volunt\u00e1rios, a n\u00e3o ser entre os respons\u00e1veis pelo estudo, sendo \n\nassegurado o sigilo sobre a sua participa\u00e7\u00e3o. Os dados coletados nesta pesquisa sob a forma dos \n\nresultados dos exames diagn\u00f3sticos realizados, bem como dados cl\u00ednicos, ficar\u00e3o armazenados em \n\ncomputador pessoal, sob a responsabilidade do pesquisador, no endere\u00e7o acima informado, pelo per\u00edodo \n\nde (m\u00ednimo 5 anos).  \n\nTERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO \n\n(PARA MAIORES DE 18 ANOS OU EMANCIPADOS - Resolu\u00e7\u00e3o 466/12) \n\nmailto:b.times@yahoo.com.br\n\n\n122 \n \n\nO (a) senhor (a) n\u00e3o pagar\u00e1 nada para participar desta pesquisa. Se houver necessidade, as despesas para \n\na sua participa\u00e7\u00e3o ser\u00e3o assumidos pelos pesquisadores (ressarcimento de transporte e alimenta\u00e7\u00e3o). \n\nFica tamb\u00e9m garantida indeniza\u00e7\u00e3o em casos de danos, comprovadamente decorrentes da participa\u00e7\u00e3o \n\nna pesquisa, conforme decis\u00e3o judicial ou extrajudicial.  \n\nEm caso de d\u00favidas relacionadas aos aspectos \u00e9ticos deste estudo, voc\u00ea poder\u00e1 consultar o Comit\u00ea de \n\n\u00c9tica em Pesquisa Envolvendo Seres Humanos da UFPE no endere\u00e7o: (Avenida da Engenharia s/n \u2013 1\u00ba \n\nAndar, sala 4 - Cidade Universit\u00e1ria, Recife-PE, CEP: 50740-600, Tel.: (81) 2126.8588 \u2013 e-mail: \n\ncepccs@ufpe.br).  \n\n \n\n \n\n___________________________________________________ \n\n(Assinatura do pesquisador) \n\n \n\n \n\nCONSENTIMENTO DA PARTICIPA\u00c7\u00c3O DA PESSOA COMO VOLUNT\u00c1RIO (A) \n\nEu, _____________________________________, CPF _________________, abaixo assinado, ap\u00f3s a \n\nleitura (ou a escuta da leitura) deste documento e de ter tido a oportunidade de conversar e ter \n\nesclarecido as minhas d\u00favidas com o pesquisador respons\u00e1vel, concordo em participar do estudo \n\nCintilografia de perfus\u00e3o hep\u00e1tica na avalia\u00e7\u00e3o da hemodin\u00e2mica venosa portal na esquistossomose \n\nhepatoespl\u00eanica, como volunt\u00e1rio(a). Fui devidamente informado(a) e esclarecido(a) pelo(a) pesquisador \n\nsobre a pesquisa, os procedimentos nela envolvidos, assim como os poss\u00edveis riscos e benef\u00edcios \n\ndecorrentes de minha participa\u00e7\u00e3o. Foi-me garantido que posso retirar o meu consentimento a qualquer \n\nmomento, sem que isto leve a qualquer penalidade (ou interrup\u00e7\u00e3o de meu acompanhamento/ \n\nassist\u00eancia/tratamento).  \n\n \n\n Local e data __________________   Assinatura do participante: \n\n______________________________________ \n\n \n\nPresenciamos a solicita\u00e7\u00e3o de consentimento, esclarecimentos sobre a pesquisa e o aceite do \n\nvolunt\u00e1rio em participar. (02 testemunhas n\u00e3o ligadas \u00e0 equipe de pesquisadores): \n\n \n\nNome: Nome: \n\nAssinatura: Assinatura: \n\n \n\n  \n\n\n\n123 \n \n\nAp\u00eandice C \u2013 Cover Letter e comprovante de submiss\u00e3o ao Digestive Disease and Sciences \n\ndo artigo de revis\u00e3o  \n\n \n\na. Article Title: \n\nHemodynamic changes in the intra-hepatic circulation of hepatosplenic \n\nschistosomiasis: the role of hepatic artery \n\nb. Authors: \n\nBernardo Times de Carvalho, MD1 \n\n E-mail: b.timesc@gmail.com \n\nPostal address: Av. Agamenon Magalhaes 4760 Paissandu \u2013 Recife/PE. Ed \n\nJoao de Deus 1\u00ba andar sala 3. Zip Code 52050-902 \n\nAna L\u00facia Coutinho Domingues, PhD2 \n\n E-mail: alcoutinho@superig.com.br  \n\nPostal address: Av. Agamenon Magalhaes 4760 Paissandu \u2013 Recife/PE. Ed \n\nJoao de Deus 1\u00ba andar sala 3. Zip Code 52050-902 \n\nc. Institution  \n\nHospital of Clinics, Pernambuco Federal University \n\nd. Correspondence: \n\nBernardo Times de Carvalho \n\nFax: +55 81 3184 1484 \n\nPhone: +55 81 3184 1630/ +55 81 99928 9364 \n\nE-mail: b.timesc@gmail.com \n\nPostal address: Av. Agamenon Magalhaes 4760 Paissandu \u2013 Recife/PE. Ed Joao de \n\nDeus 1\u00ba andar sala 3. Zip Code 52050-902 \n\ne. Word count \n\n4.751 words   \n\nmailto:b.timesc@gmail.com\nmailto:alcoutinho@superig.com.br\nmailto:b.timesc@gmail.com\n\n\n124 \n \n\nf. Conflict of interest: \n\nNo conflict of interest \n\ng. Financial support \n\nNo financial support \n\nh. Author\u2019s contributions \n\n1 study concept and design, acquisition of data, and drafting of the manuscript  \n\n2 study concept and design and critical revision of the manuscript for important \n\nintellectual concept \n\n \n\n \n\n  \n\n\n\n125 \n \n\nAp\u00eandice D \u2013 Cover Letter e Artigo publicado na Digestive Disease and Sciences \n\n \n\na. Article Title: \n\nIncreased hepatic arterial blood flow measured by hepatic perfusion index in \n\nhepatosplenic schistosomiasis: new concepts of an old disease. \n\na. Authors: \n\nBernardo Times de Carvalho, MD1 \n\n E-mail: b.timesc@gmail.com \n\nPostal address: Av. Agamenon Magalhaes 4760 Paissandu \u2013 Recife/PE. Ed \n\nJoao de Deus 1\u00ba andar sala 3. Zip Code 52050-902 \n\nAna L\u00facia Coutinho Domingues, PhD2 \n\n E-mail: alcoutinho@superig.com.brmailto:b.timesc@gmail.com \n\nPostal address: Av. Agamenon Magalhaes 4760 Paissandu \u2013 Recife/PE. Ed \n\nJoao de Deus 1\u00ba andar sala 3. Zip Code 52050-902 \n\nEdmundo Pessoa de Almeida Lopes, PhD3 \n\n E-mail: epalopes@uol.com.brmailto:b.timesc@gmail.com \n\nPostal address:Av. Moraes Rego, 1235 - Cidade Universitaria, Recife, \n\nPernambuco, 50670-901 \n\nSimone Cristina Soares Brand\u00e3o, PhD4 \n\n E-mail: simonecordis@yahoo.com.brmailto:b.timesc@gmail.com \n\nPostal address:Av. Moraes Rego, 1235 - Cidade Universitaria, Recife, \n\nPernambuco, 50670-901 \n\n \n\nb. Institution \n\nGeneral Hospital, Federal University of Pernambuco \n\nc. Correspondence: \n\nmailto:b.timesc@gmail.com\nmailto:alcoutinho@superig.com.br\nmailto:alcoutinho@superig.com.br\nmailto:epalopes@uol.com.br\nmailto:epalopes@uol.com.br\nmailto:simonecordis@yahoo.com.br\nmailto:simonecordis@yahoo.com.br\n\n\n126 \n \n\nBernardo Times de Carvalho \n\nFax: +55 81 3184 1484 \n\nPhone: +55 81 3184 1630/ +55 81 99928 9364 \n\nE-mail: b.timesc@gmail.com \n\nPostal address: Av. Agamenon Magalhaes 4760 Paissandu \u2013 Recife/PE. Ed Joao de \n\nDeus 1\u00ba andar sala 3. Zip Code 52050-902 \n\n \n\nd. Word count \n\n5789 words  \n\n \n\ne. Conflict of interest: \n\nNo conflict of interest \n\n \n\nf. Financial support \n\nNo financial support \n\n \n\ng. Author\u2019s contributions \n\n1 study concept and design, data acquisition, statistical analysis, data interpretation \n\nand manuscript writing    \n\n2 study concept and design and critical manuscript review for important \n\nintellectual concept \n\n3 critical manuscript review for important intellectual concept \n\n4 study concept and design, data acquisition \n\n \n\nmailto:b.timesc@gmail.com\n\n\n1 23\n\nDigestive Diseases and Sciences\n \nISSN 0163-2116\n \nDig Dis Sci\nDOI 10.1007/s10620-016-4080-y\n\nIncreased Hepatic Arterial Blood Flow\nMeasured by Hepatic Perfusion Index\nin Hepatosplenic Schistosomiasis: New\nConcepts for an Old Disease\n\nBernardo Times de Carvalho, Ana L\u00facia\nCoutinho Domingues, Edmundo Pessoa\nde Almeida Lopes &amp; Simone Cristina\nSoares Brand\u00e3o\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\n1 23\n\nYour article is protected by copyright and all\n\nrights are held exclusively by Springer Science\n\n+Business Media New York. This e-offprint is\n\nfor personal use only and shall not be self-\n\narchived in electronic repositories. If you wish\n\nto self-archive your article, please use the\n\naccepted manuscript version for posting on\n\nyour own website. You may further deposit\n\nthe accepted manuscript version in any\n\nrepository, provided it is only made publicly\n\navailable 12 months after official publication\n\nor later and provided acknowledgement is\n\ngiven to the original source of publication\n\nand a link is inserted to the published article\n\non Springer's website. The link must be\n\naccompanied by the following text: \"The final\n\npublication is available at link.springer.com\u201d.\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\nORIGINAL ARTICLE\n\nIncreased Hepatic Arterial Blood Flow Measured by Hepatic\nPerfusion Index in Hepatosplenic Schistosomiasis: New Concepts\nfor an Old Disease\n\nBernardo Times de Carvalho1 \u2022 Ana Lu?cia Coutinho Domingues1 \u2022\n\nEdmundo Pessoa de Almeida Lopes2 \u2022 Simone Cristina Soares Branda?o2\n\nReceived: 21 August 2015 / Accepted: 5 February 2016\n\n? Springer Science+Business Media New York 2016\n\nAbstract\n\nBackground Portal vein obstructive lesions associated\n\nwith hypertrophy of the hepatic artery territory are observed\n\nin Schistosoma mansoni schistosomiasis. Liver perfusion\n\nscintigraphy is a method used for evaluation of hepatic\n\nperfusion changes in liver diseases. It has been suggested\n\nthat, like in cirrhosis, where compensatory increase in per-\n\nfusion through the hepatic artery is documented, perfusion\n\nchanges occur in hepatosplenic schistosomiasis (HSS).\n\nAims This study aims to determine changes in liver\n\nhemodynamics using hepatic perfusion scintigraphy and\n\ncorrelate them with clinical and laboratory variables and\n\nultrasound findings in HSS.\n\nMethods Nineteen patients with schistosomiasis under-\n\nwent ultrasound evaluation of degree of liver fibrosis,\n\nsplenic length, and splenic and portal vein diameter,\n\ndigestive endoscopy, and quantification of platelets. Sub-\n\nsequently, perfusion scintigraphy with measurement of\n\nhepatic perfusion index (HPI) was performed.\n\nResults It was observed that patients with hepatosplenic\n\nschistosomiasis had significantly higher HPI compared\n\nwith normal individuals (p = 0.0029) and that this increase\n\ncorrelated with splenic length (p = 0.038) and diameter of\n\nesophageal varices (p = 0.0060). Angioscintigraphy showed\n\nhigh accuracy for predicting presence of large esophageal\n\nvarices.\n\nConclusions Angioscintigraphy could show that patients\n\nwith HSS had increased HPI, featuring greater liver \u2018\u2018ar-\n\nterialization,\u2019\u2019 as previously described for cirrhotic\n\npatients. Correlations were also observed between HPI and\n\nlongitudinal splenic length, caliber of esophageal varices,\n\ncaliber of portal vein, and blood platelet count.\n\nAngioscintigraphy is a promising technique for evaluation\n\nof hepatosplenic schistosomiasis.\n\nKeywords Hepatosplenic schistosomiasis ?\nScintigraphy ? Angioscintigraphy ? Hepatic perfusion\n\nIntroduction\n\nSchistosomiasis infection is a disease caused by parasitic\n\nSchistosoma worms, of which Schistosoma mansoni is the\n\nonly species described in Brazil [1]. It is considered endemic\n\nin 78 countries in Africa, Asia, and Central and South\n\nAmerica, occurring in places with inadequate sanitation [2].\n\nThe hepatosplenic form (HSS) is the most serious and more\n\ntypical stage of the disease [3, 4]. The dominant changes\n\nobserved are obstructive lesions of the portal vein. Studies\n\non plastic models have shown that the portal vein is the least\n\nprominent of the three vascular sectors [5, 6]. Changes in the\n\nhepatic artery vascular bed can be considered compensatory\n\nto the decrease in portal vein flow [7, 8]. However, changes\n\nin arterial vascularization are still the subject of controversy,\n\n&amp; Bernardo Times de Carvalho\nb.timesc@gmail.com\n\nAna Lu?cia Coutinho Domingues\n\nalcoutinho@superig.com.br\n\nEdmundo Pessoa de Almeida Lopes\n\nepalopes@uol.com.br\n\nSimone Cristina Soares Branda?o\n\nsimonecordis@yahoo.com.br\n\n1\nGeneral Hospital, Federal University of Pernambuco, Av.\n\nAgamenon Magalhaes 4760 Paissandu \u2013 Recife/PE. Ed Joao\n\nde Deus 18 andar sala 3, Recife 52050-902, Brazil\n2\n\nGeneral Hospital, Federal University of Pernambuco, Av.\n\nMoraes Rego, 1235 - Cidade Universitaria, Recife,\n\nPernambuco 50670-901, Brazil\n\n123\n\nDig Dis Sci\n\nDOI 10.1007/s10620-016-4080-y\n\nAuthor's personal copy\n\nhttp://crossmark.crossref.org/dialog/?doi=10.1007/s10620-016-4080-y&amp;amp;domain=pdf\nhttp://crossmark.crossref.org/dialog/?doi=10.1007/s10620-016-4080-y&amp;amp;domain=pdf\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\nwith angiographic studies showing reduction in arterial\n\nperfusion in HSS [9\u201311].\n\nHepatic perfusion scintigraphy or angioscintigraphy is a\n\nradioisotopic method used to study liver perfusion and its\n\nchanges in various liver diseases, especially cirrhosis and\n\nintrahepatic colorectal metastasis [12, 13]. It measures the\n\narterial and portal flows as fractions of the total hepatic\n\nblood flow. Scintigraphic assessment of hepatic blood flow\n\nis carried out by calculating the hepatic perfusion index\n\n(HPI), the ratio between the hepatic artery flow and total\n\nhepatic flow [14, 15]. Thus, when there is an increase in\n\nhepatic artery perfusion, an increase in HPI is observed. In\n\nchronic liver disease, HPI exceeding 40 % suggests \u2018\u2018ar-\n\nterialization\u2019\u2019 of liver perfusion, guiding the diagnosis of\n\nportal hypoperfusion [16].\n\nTo date, studies using liver scintigraphy in schistosomi-\n\nasis have been limited to morphological evaluation, with no\n\nassessment of perfusion characteristics [17\u201319]. There have\n\nbeen no in vivo evaluations of hepatic hemodynamic effects\n\ncaused by occlusion of portal branches and associated\n\nhypertrophy of the intrahepatic arterial sector in HSS. Once\n\nschistosomiasis results in changes in portal perfusion phys-\n\niology, secondary to reduced intrahepatic portal vasculature,\n\nit may be suggested that changes similar to cirrhosis could\n\noccur and would be detected by angioscintigraphy.\n\nThe purpose of this study is to fill this knowledge gap by\n\nassessing abnormal liver hemodynamics in HSS using\n\nhepatic perfusion scintigraphy, and to correlate these\n\nchanges with clinical and sonographic variables. This may\n\nexpand knowledge regarding this heterogeneous, multi-\n\nfactorial disease and add new management perspectives for\n\npatients with severe forms of schistosomiasis.\n\nPatients and Methods\n\nThis is a cross-sectional analytical study in which liver\n\nhemodynamic changes were assessed using liver perfusion\n\nscintigraphy. Liver radioisotope uptake measurements\n\nwere carried out in patients with HSS and compared with\n\nthose in individuals without liver disease. The study was\n\napproved by the local Ethics Research Committee, and all\n\nsubjects signed an informed consent form.\n\nPatients\n\nThe study subjects were chosen as a convenience sample\n\ncomposed of patients with HSS followed at the outpatient\n\nclinics of the General Hospital, Federal University of\n\nPernambuco (HC-UFPE). For the control group, patients\n\nwith well-controlled essential hypertension, uncomplicated\n\nrheumatic cardiopathy, and hypothyroidism controlled with\n\nlevothyroxine were selected.\n\nInclusion Criteria\n\n\u2022 Hepatosplenic schistosomiasis diagnosed by positive\nepidemiology, positive parasitological stool test, or\n\nhistory of previous treatment for S. mansoni\n\n\u2022 Ultrasound examination by a qualified professional, with\nevidenceofperiportalfibrosis[20,21],graduatedaccording\n\nto the Niamey\u2013Belo Horizonte protocol [22, 23], spleno-\n\nmegaly or other sign of portal hypertension, with or without\n\nprevious episodes of upper gastrointestinal bleeding\n\n\u2022 Patients over 18 years of age of both sexes\n\nControls\n\nThe control group was composed of individuals without\n\nliver disease, documented by normal ultrasound, amino-\n\ntransferases, bilirubin, albumin, and prothrombin time. The\n\ncontrol group was age-matched according to the average\n\nage of the study group.\n\nExclusion Criteria\n\n\u2022 Patients with mixed liver disease (schistosomiasis\nassociated with alcoholic liver disease or chronic viral\n\nhepatitis B and/or C), characterized by positivity of\n\nanti-HBc serology, anti-HCV or history of ingestion of\n\nmore than 60 g/day ethanol\n\n\u2022 Sonographic evidence of hepatic steatosis or diffuse\nthin fibrosis associated with periportal fibrosis\n\n\u2022 Splenectomy\n\u2022 Sonographic evidence of portal vein thrombosis,\n\ndefined by identification of intraluminal thrombus,\n\nabsence of portal flow, or portal vein cavernomatous\n\ntransformation\n\n\u2022 Antecedent of digestive bleeding 30 days before scinti-\ngraphic examination\n\n\u2022 Renal impairment (defined as serum creatinine\n[2.0 mg/dL)\n\n\u2022 Pregnant and postpartum women\n\nMethods\n\nPatients underwent detailed clinical history recording and\n\nclinical examination. Peripheral venous puncture was per-\n\nformed for the following laboratory tests: bilirubin, albu-\n\nmin, prothrombin time, international normalized ratio\n\n(INR), alkaline phosphatase, gamma-glutamyl transferase,\n\nserum creatinine, and platelets.\n\nInitially, abdominal color Doppler ultrasonography was\n\ncarried out by a single experienced examiner using Acu-\n\nson X150 equipment (3.5 MHz, Siemens) to confirm the\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\npresence and degree of periportal fibrosis according to the\n\nNiamey classification [ranging from pattern A (normal) to\n\npattern F (very advanced liver fibrosis)] and to measure the\n\nsplenic diameter (in centimeters) with normal cutoff of less\n\nthan 13 cm and the caliber of the portal and splenic veins\n\n(in centimeters) with normal lower cutoff of 1.3 and\n\n1.0 cm, respectively.\n\nUpper digestive endoscopy was performed in patients\n\nwith HSS whose last endoscopic evaluation had been car-\n\nried out more than 6 months before the present study.\n\nPresence of esophageal varices was graduated according to\n\nthe Palmer\u2013Brick classification (F1:\\3 mm; F2: 3\u20136 mm;\nF3: [6 mm) [24].\n\nSelected patients subsequently underwent liver perfu-\n\nsion scintigraphy after an overnight fasting period of 8 h.\n\nThey were positioned in the gamma camera in supine\n\ndecubitus. An intravenous bolus of average 135 MBq\n\n(3.5 mCi) Tc-99m sulfur colloid bonded in 2 mL volume\n\nwas infused in the antecubital fossa vein. Abdominal\n\nimages, concentrating on the liver and kidney, were\n\nobtained every 2 s for a total of 2 min, according to the\n\nprotocol described by Warren et al. [12].\n\nAfter image acquisition, a region of interest (ROI) was\n\nmarked in the left kidney topography to generate the kid-\n\nney uptake curve and mark the renal uptake peak. In\n\nindividuals with large splenomegaly, which hindered left\n\nkidney demarcation, the right kidney was used for calcu-\n\nlations. Then, ROIs were marked on the liver to generate\n\nthe liver uptake curve.\n\nThe left renal artery uptake peak was used to demarcate\n\nthe arterial and portal components of the hepatic blood flow\n\nin hepatic time\u2013activity curves. The area under the curve at\n\n10 s immediately before (arterial component, G1) and 10 s\n\nimmediately after (portal component, G2) the peak of the\n\nleft renal artery uptake was calculated by regression anal-\n\nysis. The hepatic perfusion index (HPI) was calculated as\n\nthe quotient between the hepatic arterial gradient (G1) and\n\nthe sum of the arterial and portal venous gradients (G2):\n\nHPI = (G1)/(G1 ? G2) 9 100. The observer was blinded\n\nto the identity and sonographic results of the patients. The\n\nupper limit accepted as normal for HPI was 40 % [12, 16,\n\n25]. Thus, results above this cutoff point indicate greater\n\n\u2018\u2018arterialization\u2019\u2019 of hepatic blood flow. HPI measurement\n\nwas carried out concurrently in individuals without liver\n\ndisease to obtain a normal value for the study population\n\nand confirm that this normal value was in accordance with\n\nthose reported in previous studies [12, 16, 25].\n\nStatistical Analysis\n\nStatistical tests were performed using SPSS software ver-\n\nsion 20. Initially, HPI results for both schistosomal and\n\nnormal groups were categorized as normal (HPI B40 %) or\n\nincreased (HPI [40 %), then subjected to the Shapiro\u2013\nWilk normality test and Bartlett\u2019s homogeneity of vari-\n\nances test, the results appearing to be normal but with\n\nheterogeneous distribution. Thus, Fisher\u2019s exact test was\n\nused to compare frequencies among patients with normal\n\nand abnormal scintigraphic examination. p \\ 0.05 was\nused to assess the significance level of results.\n\nIntergroup comparative analysis of liver fibrosis pattern,\n\npresence of collateral circulation, esophageal varices, and\n\nhistory of upper gastrointestinal bleeding was also per-\n\nformed using Fisher\u2019s exact test, since these are categorical\n\ndata. Among patients with schistosomiasis, for comparison\n\nbetween groups with HPI B40 % versus[40 %, for spleen\nlength and diameter of portal vein, the independent t test was\n\nused, since the numerical data were normally distributed.\n\nComparison between groups for splenic vein diameter and\n\nplatelet count was performed using Mann\u2013Whitney test due\n\nto the nonnormal distribution of these two variables.\n\nTo calculate the correlation between the HPI and spleen\n\ndiameter, portal and splenic vein diameter, and platelet\n\ncount, Pearson\u2019s correlation coefficient (q) was used. Values\ngreater than or equal to 0.7 indicate strong correlation,\n\nvalues between 0.3 and 0.7 indicate moderate correlation,\n\nand values between 0 and 0.3 indicate weak correlation. A\n\nreceiver operating characteristic (ROC) curve was devel-\n\noped using the spleen longitudinal diameter in relation to the\n\nangioscintigraphic results for HPI in the control group and\n\ngroup of schistosomiasis patients to determine the splenic\n\nlength cutoff best defining increased HPI. Another ROC\n\ncurve was designed using HPI values and the presence of\n\nlarge esophageal varices. The sensitivity and specificity of\n\nthe scintigraphic method for predicting presence of large\n\nesophageal varices were evaluated.\n\nResults\n\nA total of 34patientswereinitially included inthe study,and 8\n\npatients were later excluded due to presence of fine diffuse\n\nfibrosis in liver parenchyma associated with periportal fibro-\n\nsis, 6 due to presence of portal vein thrombosis, and 1 due to\n\ninability to acquire a reliable renal curve on scintigraphy\n\nstudy. Therefore, 19 patients with schistosomiasis completed\n\nthe study protocol. Five patients without liver disease were\n\nsubmitted to the study protocol as the control group.\n\nAmong the study population of 19 included patients,\n\n58 % were female and the average age was 56 years (range\n\n25\u201377 years). All had preserved hepatic synthetic function,\n\ncharacterized by normal levels of direct bilirubin, albumin,\n\nand prothrombin time/INR and normal creatinine levels.\n\nNone of them were taking nonselective beta-blockers.\n\nOn angioscintigraphy study, all five control patients\n\nwithout liver disease had HPI values considered normal, i.e.,\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\nbelow 40 % (30, 32, 35, 35, and 36 %, respectively). In the\n\nschistosomiasis group, 5 of 19 patients (26.3 %) had normal\n\nresults, with the remaining 14 (73.7 %) showing increased\n\nHPI above the 40 % cutoff point. This frequency difference\n\nwas statistically significant (p = 0.0029). Figure 1 shows a\n\ncomparison between three hepatic uptake curves for two\n\npatients with schistosomiasis and one individual from the\n\ncontrol group.\n\nUltrasonographic analysis showed splenomegaly in\n\n89.5 % of patients, with a statistically significant frequency\n\namong those with elevated HPI (p = 0.038). The other\n\nsonographic findings are presented in Table 1. Laboratory\n\nanalysis evidenced that 84.2 % had platelet count below\n\n100,000/mm\n3\n. On endoscopic study, 84.2 % had esopha-\n\ngeal varices, which were of large caliber in 62.5 %, all\n\nfrom the group of patients with increased HPI. When\n\npatients with large esophageal varices (F3) were analyzed\n\nseparately, the frequency of patients with increased HPI\n\nwas statistically significant (p = 0.0060). History of upper\n\ngastrointestinal bleeding was documented in 71.4 %.\n\nTable 2 summarizes the main results.\n\nThe Pearson correlation tests for numerical variables\n\nshowed strong positive correlation between increased HPI\n\nand longitudinal splenic length, with correlation coefficient\n\n(q) of 0.7853. Analyzing the portal vein diameter and total\nplatelet count, the correlation test resulted in moderate\n\ncorrelation between increased HPI and increased portal\n\nvein diameter, with a ratio (q) of 0.3829, and decreased\nplatelet count with correlation coefficient (q) of -0.4901.\nFigure 2 shows scatterplots for these three variables and\n\ntheir respective trend lines. Regarding splenic vein diam-\n\neter, although there was a positive correlation between\n\nincreased HPI and increased vein caliber, this correlation\n\nwas weak with coefficient (q) of 0.1391.\nThe first ROC curve showed that a cutoff for splenic\n\nlength of 14.4 cm correlated well with increased HPI. The\n\narea under the curve (AUC) of 0.9 with significant p value\n\nof 0.001 demonstrate good accuracy of splenic diameter for\n\nevaluating increased HPI, with sensitivity of 0.78 and\n\nspecificity of 0.9. The second ROC curve examined\n\nincreased HPI for prediction of finding large esophageal\n\nvarices on endoscopy. It revealed that a cutoff value of\n\n45 % for HPI predicted the presence of large esophageal\n\nvarices with sensitivity of 1.0, specificity of 0.929, and\n\nAUC of 0.96 and significant p value of 0.001 (Fig. 3).\n\nDiscussion\n\nThis study showed that the hepatic perfusion index (HPI),\n\nmeasured by angioscintigraphy with colloidal sulfur, is\n\nunusually high in patients with the hepatosplenic form of\n\nschistosomiasis, when compared with normal individuals.\n\nFig. 1 Comparison of three\ntime\u2013activity curves: a control\n\npatient with HPI of 35 %, and\n\ntwo HSS patients with HPI of\n\nb 47 and c 48 %. The dashed\n\nline indicates the moment of the\n\nrenal artery capture peak, used\n\nto delimit the hepatic artery and\n\nportal phases of liver perfusion.\n\nGreater total liver uptake and\n\nmore pronounced arterial inflow\n\nwere observed\n\nTable 1 Sonographic findings\n\nSonographic finding N (%)\n\nSpleen\n\nB13 cm 2 (10.5 %)\n\n[13 cm 17 (89.5 %)\nPortal vein\n\nB1.2 cm 9 (47.4 %)\n\n[1.2 cm 10 (52.6 %)\nSplenic vein\n\nB1.0 cm 8 (42.1 %)\n\n[1.0 cm 11 (57.9 %)\nFibrosis pattern\n\nD 6 (31.5 %)\n\nE 7 (37.0 %)\n\nF 6 (31.5 %)\n\nCollaterals\n\nPresent 14 (73.6 %)\n\nAbsent 5 (26.4 %)\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\nThus, it can be inferred that, in HSS, there is increased\n\nperfusion through the hepatic artery, increasing the HPI.\n\nThis suggests that intrahepatic changes related to portal\n\nvenous system distortion and arterial system proliferation\n\nare responsible not only for anatomical changes but also for\n\nchanges in in vivo circulatory dynamics.\n\nTo date, no studies using nuclear medicine techniques\n\nhave evaluated liver perfusion characteristics in patients with\n\nHSS. Razzak [17], by calculating the hepatic uptake of\n\nradioactive gold Au-198m, suggested that hepatic blood flow\n\nwas reduced in patients with HSS, and this reduction was\n\nrelated to the severity of liver disease. However, these data\n\ncontradict current knowledge based on experimental, ultra-\n\nsound and hemodynamic studies that, despite presence of\n\nliver fibrosis and portal hypertension, show normal total liver\n\nflow in schistosomiasis [26\u201329]. Other scintigraphic studies\n\nin HSS population were restricted to morphological features,\n\nsuch as those of Iio et al. [19] and Mustafa et al. [18], which\n\nshowed lower liver uptake of radioactive gold, atrophy of\n\nright hepatic lobe, irregular liver surface, and increased\n\nsplenic uptake of radiotracer. Our study extends previous\n\nobservations relating to perfusion alterations, previously\n\ndescribed only in cirrhosis and liver colorectal metastasis.\n\nIn cirrhosis, hepatic lobular architecture distortion cau-\n\nses a decrease in portal vein flow. This reduction, through a\n\nmultifactorial mechanism, results in increased hepatic\n\narterial flow [30\u201335]. The most well-accepted theory\n\ninvolves washout of adenosine, as described by Lautt [36\u2013\n\n38]. Adenosine is released at a constant rate within the\n\nMall space and is primarily cleared by portal flow.\n\nTable 2 Hepatic perfusion index (HPI) obtained by angioscintigraphy in patients with hepatosplenic schistosomiasis\n\nHPI (%) Spleen\n\n(cm)\n\nPortal\n\nvein (cm)\n\nSplenic\n\nvein (cm)\n\nCollaterals Esophageal\n\nvarices\n\nUDB\n\u00a7\n\nPlatelets 9 10\n3\n\nFibrosis\n\npattern\n\nNormal HPI 35 13.64 1.4 1.04 Present F1 Present 83 D\n\n(N = 5) 36 13.15 1.16 0.9 Absent Absent Absent 141 F\n\n40 10.34 1.17 0.59 Present Absent Present 165 E\n\n40 14.4 1.24 1.18 Present F1 Absent 31 D\n\n40 16.84 1.29 1.54 Present F1 Absent 32 E\n\nMean 38.2 13.60 1.25 1.05 90.4\n\nSD\n?\n\n2.50 2.34 0.09 0.35 61\n\n95 % CI\n?\n\n35.1\u201341.3 10.8\u201316.6 1.13\u20131.37 0.61\u20131.48 36.93\u2013143.87\n\nAbnormal HPI 42 13.6 1.31 0.98 Absent F1 Present 72 E\n\n(N = 14) 42 15.12 0.97 0.85 Present F2 Absent 86 F\n\n45 17.48 1.12 0.95 Present F2 Present 51 E\n\n46 14.06 0.8 0.71 Absent F3 Present 53 D\n\n47 15.33 1.68 2.2 Present F3 Absent 56 F\n\n47 16.44 1.66 0.84 Present F3 Absent 58 E\n\n47 15.63 1.31 1.04 Present F3 Absent 53 E\n\n47 20.1 1.16 1.73 Present F3 Absent 79 E\n\n48 17.84 1.39 0.73 Absent Absent Present 86 F\n\n48 11.15 0.83 0.76 Present F3 Absent 117 D\n\n51 19.29 1.07 0.92 Present F3 Absent 76 D\n\n52 17.05 1.16 1.1 Present F3 Absent 64 F\n\n55 19.29 1.26 0.64 Present F3 Absent 46 F\n\n66 27.16 1.98 1.51 Absent F3 Absent 30 D\n\nMean 48.80 17.1 1.26 1.06 66\n\nSD\n?\n\n6.0 3.80 0.33 0.44 22\n\n95 % CI\n?\n\n45.3\u201352.3 14.9\u201319.3 1.07\u20131.45 0.81\u20131.32 54.48\u201377.52\n\np = 0.0029* p = 0.038 p = 0.46 p = 0.29 p = 0.88 p = 0.006 p = 0.75 p = 0.11 p = 0.75\n\nPatients were divided into two groups with normal and increased HPI, respectively. Differences between variables were analyzed, revealing\n\nstatistical significance for HPI, presence of large varices (F3), and length of spleen compared with normal individuals\n\u00a7\nUpper digestive bleeding\n\n?\nStandard deviation\n\n?\n95 % confidence interval\n\n* This p value refers to the comparison between the 19 patients with schistosomiasis and the control group\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\nIn situations of portal hypoperfusion, the amount of accu-\n\nmulated adenosine, acting as a vasodilator, increases the\n\nhepatic artery inflow [39, 40].\n\nSchistosomal hepatopathy presents unique characteris-\n\ntics that differentiate it from cirrhosis [5]. The extensive\n\nhepatic fibrosis has a strong dependence on parasitic load\n\ndue to massive egg embolization to the portal system [5, 6,\n\n41]. Obliteration of small-caliber portal vessels and the\n\ninflammatory and fibrovascular reactions in the host are the\n\nmain factors responsible for portal venous flow obstruc-\n\ntions [5, 6, 42]. In HSS, despite obliterative changes in the\n\nportal venous system, the total hepatic blood flow remains\n\npreserved [41, 43]. It remains controversial whether its\n\npreservation is simply due to portal blood hyperflow sec-\n\nondary to splenomegaly or whether there is a compensatory\n\nmechanism increasing arterial flow [5, 9, 10, 26, 44\u201348].\n\nSome angiographic studies have reported small partici-\n\npation of the arterial sector in the hemodynamics of HSS,\n\nFig. 2 Scatterplots with respective trend lines and Pearson\u2019s correlation coefficients (q): positive correlation for increased HPI versus increased\nlongitudinal spleen length (a) or diameter of portal vein (b), and negative correlation for increased HPI versus total platelet count (c)\n\nFig. 3 ROC curves showing a that the best longitudinal splenic\nlength to predict increased HPI occurs at the cutoff point (a)\ncorresponding to 14.4 cm with sensitivity of 0.78, specificity of 0.90,\n\nand AUC of 0.90, and b good accuracy of HPI in predicting\n\noccurrence of large esophageal varices; using the cutoff point (b),\ncorresponding to HPI of 45 %, it is possible to predict presence of\n\nlarge varices with sensitivity of 1.0, specificity of 0.92, and AUC of\n\n0.96\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\ndemonstrating reduction in hepatic artery diameter and poor\n\nintrahepatic arterial vasculature [9\u201311, 43]. Those authors\n\nsuggested that, as a result of massive splenomegaly, the\n\nsplenic artery hypertrophy would deviate the hepatic artery\n\nflow. Mies et al. [47] demonstrated reduced flow through the\n\nhepatic artery, which increased after treatment with pro-\n\npranolol accompanied by a reduction in flow through the\n\nportal vein. Lacerda et al. [49] and Pereira et al. [50] eval-\n\nuated the hemodynamic effects of splenectomy, associated\n\nwith esophagogastric devascularization and left gastric vein\n\nligation, respectively. They showed an increase in hepatic\n\nartery caliber and flow just after surgery, when there was a\n\nreduction in portal vein diameter and flow. Lacerda [50]\n\nsuggested that the absence of increased participation of the\n\narterial sector is justified by the portal blood flow, which\n\nmaintains normal liver perfusion, diverting only excess\n\nblood via collateral circulation.\n\nHowever, other studies suggest the opposite. Coutinho\n\n[51], analyzing hepatic circulation pressures in HSS,\n\nassociated with angiographic evaluation, proposed the\n\npossibility of compensatory increase in the arterial system\n\nin maintaining the total hepatic flow in HSS. Alves et al.\n\n[46] documented a drop of more than 15 mmHg in sinu-\n\nsoidal pressure after transient hepatic artery ligation,\n\nhighlighting the importance of the arterial sector in main-\n\ntaining sinusoidal pressure in individuals with HSS. Some\n\nanimal models of HSS [26, 52] have also revealed\n\nincreased flow through the hepatic artery in animals with\n\nHSS and reduced portal flow.\n\nIn addition to in vivo studies, pathological studies of HSS\n\nvascularization using plastic models [6, 8, 44] clearly\n\ndemonstrated that the portal sector is the least prominent of\n\nthe three vascular sectors. Unlike in cirrhosis, vascular\n\nchanges in schistosomiasis involve larger portal branches\n\nwith considerable distortion and reduction of small periph-\n\neral branches. Portal branches of medium and large caliber\n\noften show dilatation and tortuous and sudden diameter\n\nreduction without formation of small terminal branches [5\u2013\n\n8, 44, 53]. The hepatic vein sector remains unchanged, but\n\nthe hepatic artery sector shows considerable hyperplasia and\n\nhypertrophy with denser and tortuous vascular network.\n\nThese arterial vascular bed alterations could be considered\n\ncompensatory to decreased portal perfusion [7].\n\nUpper gastrointestinal bleeding represents an evolutionary\n\nevent in advanced forms of schistosomiasis, being associated\n\nwith liver disease decompensation and occurrence of jaun-\n\ndice, ascites, and hepatic encephalopathy, usually transient.\n\nFurthermore, there may be progressive evolution to end-\n\nstage liver disease indistinguishable from cirrhosis after\n\nrepeated episodes of gastrointestinal bleeding. Therefore, this\n\ncharacteristic is the result of arterial blood flow dependence\n\nin severe schitosomiaisis livers. The scintigraphy results\n\nconfirm this pathophysiological aspect and provide in vivo\n\ncorroboration for anatomopathological findings based on\n\nplastic models describing remarkable increase in the arterial\n\nsector in HSS. Thus, increased HPI as evidenced by scinti-\n\ngraphic study shows that changes in the intrahepatic arterial\n\nbed are not just pathological but also play a role in the cir-\n\nculatory dynamics of the schistosomal liver.\n\nThe results of this study raise various questions about the\n\npossible mechanisms involved in the arterial response in\n\nHSS. Based on well-established findings [10, 11, 28, 41, 51],\n\nincreased hepatic arterial flow with reduced portal blood\n\nflow cannot be justified, as is well documented in HSS, by\n\nportal overflow. It can be suggested that the total hepatic\n\nflow in HSS is actually increased by increasing flows in both\n\nvascular beds. Another hypothesis is that high resistance to\n\nintrahepatic portal flow and formation of intrahepatic arte-\n\nrioportal shunts, like in cirrhosis, could cause intrahepatic\n\nportal hypoperfusion, despite overflow of the extrahepatic\n\nportal system, which is responsible for stimulating the\n\ncompensatory response of the hepatic artery. Rocheleau\n\net al. [54] studied the separate vascular response of liver\n\nlobes after selective ligation of the left portal vein branch\n\nand showed that, due to low portal flow, the left lobe\n\nexhibited an increase in arterial flow, while the right lobe\n\nshowed exactly the opposite, namely reduced arterial flow\n\ndue to portal overflow. Based on this study, we suggest a\n\nmore interesting theory. Due to the splenoportal laminar\n\nflow, the portal blood flow preferably directs to the left lobe,\n\nwhich undergoes hypertrophy, while the least perfused, right\n\nlobe undergoes atrophy [47]. Based on the study by\n\nRocheleau, it could be suggested that, in HSS, even in the\n\nsituation of portal overflow, there would be increased\n\ncompensatory hepatic arterial flow in the hypoperfused right\n\nlobe, justifying the scintigraphic findings.\n\nRegarding clinical aspects, the increase in HPI did not\n\ncorrelate with severity of hepatic fibrosis as evaluated by\n\nultrasonography. However, increased frequencies of sple-\n\nnomegaly and large esophageal varices were found in the\n\nschistosomiasis group with increased HPI. The ROC curve\n\ndemonstrating high accuracy of angioscintigraphy for\n\npredicting presence of large varices indicates the ability of\n\nthis method to characterize more severe stages of HSS.\n\nCorrelations were also demonstrated between HPI and\n\nlongitudinal spleen length, portal vein diameter, and pla-\n\ntelet count. All of these clinical variables are indirect\n\nmarkers of severity of schistosomal liver disease and portal\n\nhypertension. Thus, angioscintigraphy with HPI measure-\n\nment can contribute to assessment of patients with HSS,\n\nbeing a noninvasive method with minimal complications\n\nthat is technically easy to perform and correlates with the\n\nseverity of portal hypertension, the major complication of\n\nthis liver disease.\n\nThis is a pioneering study on assessment of schistoso-\n\nmiasis patients using angioscintigraphy and HPI\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\ncalculation. This method seems promising for use in clin-\n\nical practice, because it correlates with clinical and labo-\n\nratory characteristics of high-risk schistosomiasis,\n\nparticularly esophageal varices. Since gastrointestinal\n\nbleeding is the most feared event in the clinical course of\n\nHSS, the ability of scintigraphy to predict the presence of\n\nlarge varices can identify patients at increased risk of\n\ngastrointestinal bleeding. In addition, scintigraphy could\n\ndemonstrate a new clinical aspect of HSS, namely the liver\n\ndependence of the arterial flow. This method not only\n\nrelates to serious forms of HSS, but was also able to\n\nidentify patients whose liver was more dependent on the\n\nhepatic artery, in whom upper gastrointestinal bleeding\n\nevents would be potentially more catastrophic. In clinical\n\npractice, therefore, such patients should receive more\n\naggressive treatment for portal hypertension and be sub-\n\njected to more rigid surveillance to prevent bleeding\n\ncomplications.\n\nThe main limitation of this study, however, is related to\n\nthe small number of study subjects, restricting the power to\n\ngeneralize the results. Another limiting factor is related to\n\nsample heterogeneity. Studies with schistosomal popula-\n\ntion often face difficulties due to the large variability in\n\npatient characteristics and forms of clinical presentation. It\n\ncould be speculated that HPI changes might be due to a\n\nhigher proportion of severe forms in the sample studied,\n\ncharacterized by patterns D, E, and F, especially the latter\n\ntwo. However, this fact does not constitute a study weak-\n\nness, since individuals with more advanced disease are\n\nthose with higher risk of complications and need for\n\nmedical attention.\n\nIn conclusion, this study was able to evaluate changes in\n\ncirculatory dynamics of patients with the hepatosplenic\n\nform of schistosomiasis by angioscintigraphy and correlate\n\nthem with severity variables. It was able to confirm chan-\n\nges demonstrated in previous studies with respect to\n\nincreased arterial perfusion in HSS, and to show correlation\n\nwith severity of portal hypertension. This appears to be a\n\npromising nuclear medicine technique for use in schisto-\n\nsomiasis in view of the preliminary results achieved in this\n\nresearch. Further studies with larger population will be\n\nuseful to confirm and validate our findings.\n\nAcknowledgments Special thanks go to Socrates Times de Car-\nvalho for mathematical assistance with regression analysis of graph-\n\nical data.\n\nAuthor\u2019s contributions Bernardo Times de Carvalho: study con-\ncept and design, data acquisition, statistical analysis, data interpre-\n\ntation, and manuscript writing. Ana Lu?cia Coutinho Domingues:\n\nstudy concept and design and critical manuscript review for important\n\nintellectual concepts. Edmundo Pessoa de Almeida Lopes: critical\n\nmanuscript review for important intellectual concepts. Simone Cris-\n\ntina Soares Branda?o: study concept and design, and data acquisition.\n\nCompliance with ethical standards\n\nConflict of interest The authors declare that they have no conflict\nof interest.\n\nReferences\n\n1. Pereira GJM, Torres MEG. Epidemiologia. In: Malta J, ed.\n\nEsquistossomose Manso?nica. Primeira. Recife: Editora Univer-\n\nsita?ria da UFPE; 1994:47\u201348.\n\n2. WHO. Sustaining the drive to overcome the global impact of\n\nneglected tropical diseases. Second WHO Rep Neglected Trop\n\nDis. 2013;3:67\u201371.\n\n3. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistoso-\n\nmiasis. Lancet. 2006;368:1106\u20131118.\n\n4. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J\n\nMed. 2002;346:1212\u20131220.\n\n5. Andrade ZA. Schistosomal hepatopathy. Mem Inst Oswaldo\n\nCruz. 2004;99:51\u201357.\n\n6. Andrade ZA. Schistosomiasis and liver fibrosis. Parasite Immu-\n\nnol. 2009;31:656\u2013663.\n\n7. Hidayat M, Wahid H. A study of the vascular changes in bilharzic\n\nhepatic fibrosis and their significance. Surg Gynecol Obstet.\n\n1971;132:997\u20131004.\n\n8. Magalha?es-Filho A, Menezes H, de Coelho R. B. Patoge?nese da\n\nfibrose hepa?tica na esquistossomose mansoni (Estudo das alter-\n\nac?o?es vasculares portais mediante modelo pla?stico). Rev Assoc\n\nMed Bras. 1960;6:284\u2013294.\n\n9. Mies S, Larsson E, Mori T, Williams GM. Sistema porta e as\n\narte?rias hepatica, esple?nica e mesente?rica superior na esquistos-\n\nsomose hepatoesple?nica. Estudo angiogra?fico. Rev do Hosp das\n\nCl??nicas Fac Med Sa?o Paulo. 1980;35:121\u2013131.\n\n10. Cleva R, Pugliese V, Zilberstein B, Saad WA, Pinotti W, Lau-\n\ndanna AA. Systemic hemodynamic changes in mansonic schis-\n\ntosomiasis with portal hypertension treated by azygoportal\n\ndisconnection and splenectomy. Am J Gastroenterol.\n\n1999;94:1632\u20131637.\n\n11. Cleva R, Herman P, D\u2019albuquerque LA, Pugliese V, Santarem\n\nOL, Saad WA. Pre- and postoperative systemic hemodynamic\n\nevaluation in patients subjected to esophagogastric devascular-\n\nization plus splenectomy and distal splenorenal shunt: a com-\n\nparative study in schistosomal portal hypertension. World J\n\nGastroenterol. 2007;13:5471\u20135475.\n\n12. Warren HW, Gallagher H, Hemingway DM, et al. Prospective\n\nassessment of the hepatic perfusion index in patients with col-\n\norectal cancer. Br J Surg. 1998;85:1708\u20131712.\n\n13. Koranda P, Myslivecek M, Erban J, Seidlova? V, Husa?k V.\n\nHepatic perfusion changes in patients with cirrhosis indices of\n\nhepatic arterial blood flow. Clin Nucl Med. 1999;24:507\u2013510.\n\n14. O\u2019Connor MK, Krom RF, Carton EG, et al. Ratio of hepatic\n\narterial-to-portal venous blood flow-validation of radionuclide\n\ntechniques in an animal model. J Nucl Med. 1992;33:239\u2013245.\n\n15. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion\n\nimaging of the liver: current challenges and future goals. Radi-\n\nology. 2005;234:661\u2013673.\n\n16. Dragoteanu M, Balea IA, Dina LA, et al. Staging of portal\n\nhypertension and portosystemic shunts using dynamic nuclear\n\nmedicine investigations. World J Gastroenterol. 2008;14:\n\n3841\u20133848.\n\n17. Razzak MA. The use of radioactive isotopes to study the hemo-\n\ndynamic pattern, function and morphology of the liver in hepato-\n\nsplenic bilharziasis (schistosomiasis). J Nucl Med. 1964;5:\n\n125\u2013133.\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\n18. Mustafa AG, Razzak MA, Mahfouz M, Guirgis B. Radioisotope\n\nphotoscanning of the liver in bilharzial hepatic fibrosis. J Nucl\n\nMed. 1966;7:909\u2013916.\n\n19. Iio M, Iuchi M, Kitani K, Yamada H, Ishiwa M. Scintigraphic\n\nevaluation of the liver with schistosomiasis japonica. J Nucl Med.\n\n1971;12:655\u2013659.\n\n20. Homeida M, Abdel-Gradir AF, Cheever AW, et al. Diagnosis of\n\npathologically confirmed Symmers\u2019 periportal fibrosis by ultra-\n\nsonography: a prospective blinded study. Am J Trop Med Hyg.\n\n1988;38:86\u201391.\n\n21. Abdel-Wahab MF, Esmat G, Milad M, Abdel-Razek S, Strick-\n\nland GT. Characteristic sonographic pattern of schistosomal\n\nhepatic fibrosis. Am J Trop Med Hyg. 1989;40:72\u201376.\n\n22. Richter J, Hatz C, Campagne G, Bergquist NR, Jenkins JM, eds.\n\nUltrasound in Schistosomiasis: A Practical Guide to Standard-\n\nized Use of Ultrasonography for the Assessment of Schistosomi-\n\nasis-related Morbidity. Geneva: World Health Organization,\n\nTDR/STR/SCH/00.1; 2000.\n\n23. Richter J, Coutinho Domingues AL, Barata CH, Prata AR,\n\nLambertucci JR. Report of the second satellite symposium on\n\nultrasound in schistosomiasis. Mem Inst Oswaldo Cruz.\n\n2001;96:151\u2013156.\n\n24. Palmer E, Brick I. Correlation between the severity of esophageal\n\nvarices in cirrhosis and their propensity toward hemorrhage.\n\nGastroenterology. 1956;30:85\u201390.\n\n25. Leveson SH, Wiggins PA, Nasiru TA, Giles GR, Robinson PJ,\n\nParkin A. Improving the detection of hepatic metastases by the\n\nuse of dynamic flow scintigraphy. Br J Cancer. 1983;47:\n\n719\u2013721.\n\n26. Sarin S, Mosca P, Sabba C, Groszmann R. Hyperdynamic cir-\n\nculation in a chronic murine schistosomiasis model of portal\n\nhypertension. Hepatology. 1991;13:581\u2013584.\n\n27. Denie? C, Vachiery F, Elman A, et al. Systemic and splanchnic\n\nhemodynamic changes in patients with hepatic schistosomiasis.\n\nLiver. 1996;16:309\u2013312.\n\n28. Azeredo LM, Queiroz LCD, Marinho CC, et al. Sonographic and\n\nhemodynamic findings of schistosomiasis mansoni: Doppler\n\nsonography assessment in endemic areas. Radiol Bras. 2010;43:\n\n69\u201376.\n\n29. De Arruda SMB, Barreto VST, Do Amaral FJ. Duplex sonogra-\n\nphy study in schistosomiasis portal hypertension: characterization\n\nof patients with and without a history of variceal bleeding. Arq\n\nGastroenterol. 2008;45:11\u201316.\n\n30. Zipprich A, Steudel N, Behrmann C, et al. Functional significance\n\nof hepatic arterial flow reserve in patients with cirrhosis. Hepa-\n\ntology. 2003;37:385\u2013392.\n\n31. Kleber G, Steudel N, Behrmann C, et al. Hepatic arterial flow\n\nvolume and reserve in patients with cirrhosis: use of intra-arterial\n\nDoppler and adenosine infusion. Gastroenterology. 1999;116:\n\n906\u2013914.\n\n32. Lautt WW. Mechanism and role of intrinsic regulation of hepatic\n\narterial blood flow: hepatic arterial buffer response. Am J Physiol\n\nGastrointest Liver Physiol. 1985;249:G549\u2013G556.\n\n33. Lautt WW. Hepatic circulation physiology and pathophysiology.\n\nIn: Lautt WW, ed. Colloquium Series on Integrated Systems\n\nPhysiology: From Molecule to Function. San Rafael: Morgan &amp;\n\nClaypool Life Sciences; 2009.\n\n34. Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK,\n\nMenger MD. Portal branch ligation induces a hepatic arterial\n\nbuffer response, microvascular remodeling, normoxygenation,\n\nand cell proliferation in portal blood-deprived liver tissue. Am J\n\nPhysiol Gastrointest Liver Physiol. 2007;292:G1534\u2013G1542.\n\n35. Moeller M, Thonig A, Pohl S, Ripoll C, Zipprich A. Hepatic\n\narterial vasodilation is independent of portal hypertension in early\n\nstages of cirrhosis. PLoS One. 2015;10:e0121229.\n\n36. Ezzat WR, Lautt WW. Hepatic arterial pressure-flow autoregu-\n\nlation is adenosine mediated. Am J Physiol. 1987;252:H836\u2013\n\nH845.\n\n37. Lautt WW. Mechanism and role of intrinsic regulation of hepatic\n\narterial blood flow: hepatic arterial buffer response. Am J Physiol.\n\n1985;249:549\u2013556.\n\n38. Lautt WW. Control of hepatic arterial blood flow: independence\n\nfrom liver metabolic activity. Am J Physiol. 1980;239:H559\u2013\n\nH564.\n\n39. Vollmar B, Menger MD. The hepatic microcirculation: mecha-\n\nnistic contributions and therapeutic targets in liver injury and\n\nrepair. Physiol Rev. 2009;89:1269\u20131339.\n\n40. Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood\n\nflow: the hepatic arterial buffer response revisited. World J\n\nGastroenterol. 2010;28:6046\u20136057.\n\n41. Strauss E. Hepatosplenic schistosomiasis: a model for the study\n\nof portal hypertension. Ann Hepatol. 2002;1:6\u201311.\n\n42. Warren KS. Hepatosplenic schistosomiasis mansoni: an\n\nimmunologic disease. Bull N Y Acad Med. 1975;51:545\u2013550.\n\n43. Da Silva LC. Portal hypertension in schistosomiasis: patho-\n\nphysiology and treatment. Mem Inst Oswaldo Cruz. 1992;87:\n\n183\u2013186.\n\n44. Jorge PAR, dos Carvalhal SS. Sobre a rede vascular intra-hepa?-\n\ntica na esquistossomose mansonica, forma de Symmers: Estudo\n\ncom modelos pla?sticos. Rev Assoc Med Bras. 1967;13:435\u2013441.\n\n45. Widman A, Speranzini MB, de Lima JT, Wierman P, de Oliveira\n\nMR, Raia A. Arterial and operative portography in patients with\n\nportal hypertension caused by hepato-splenic schistosomiasis and\n\nthose with spleno-renal anastomosis (comparative study). Rev do\n\nHosp das Cl??nicas Fac Med Sa?o Paulo. 1973;28:177\u2013187.\n\n46. Alves C, Alves A, Abreu W, Andrade ZA. Hepatic artery\n\nhypertrophy and sinusoidal hypertension in advanced schistoso-\n\nmiasis. Gastroenterology. 1977;72:126\u2013128.\n\n47. Mies S, Braghirolli-Neto O, Beer A, et al. Systemic and hepatic\n\nhemodynamics in hepatosplenic manson\u2019s schistosomiasis with\n\nand without propranolol. Dig Dis Sci. 1997;42:751\u2013761.\n\n48. Baptista AP, Andrade ZA. Angiogenesis and schistosomal gran-\n\nuloma formation. Mem Inst Oswaldo Cruz. 2005;100:183\u2013185.\n\n49. Lacerda CM, Ramos H, Raia S, Kelner S. Fisiopatologia da\n\nhipertensa?o portal esquistossomo?tica e efeitos da esplenectomia\n\ncom ligadura de varizes de eso?fago. Acta Cir Bras. 1993;8:\n\n113\u2013117.\n\n50. Pereira FM, Evangelista-Neto J, Brito N, Amaral F, da Fonseca-\n\nNeto OC, Lacerda CM. Angiografic and pressoric changes\n\ndetermined by splenectomy with left gastric vein ligature in\n\nmansoni schistosomiasis. Arq Bras Cir Dig. 2013;26:302\u2013308.\n\n51. Coutinho A. Hemodynamic studies of portal hypertension in\n\nschistosomiasis. Am J Med. 1968;44:547\u2013555.\n\n52. Morgan J, Groszmann R, Rojkind M, Enriquez R. Hemodynamic\n\nmechanism of emerging portal hypertension caused by schisto-\n\nsomiasis in the hamster. Hepatology. 1990;11:98\u2013104.\n\n53. Andrade ZA. A double and paradoxical role for angiogenesis. Rev\n\nPatol Trop. 2013;42:259\u2013264.\n\n54. Rocheleau B, Ethier C, Houle R, Huet PM, Bilodeau M. Hepatic\n\nartery buffer response following left portal vein ligation: its role\n\nin liver tissue homeostasis. Am J Physiol. 1999;277:G1000\u2013\n\nG1007.\n\nDig Dis Sci\n\n123\n\nAuthor's personal copy\n\nbtime_000\nCarimbo\n\nbtime_000\nCarimbo\n\n\n\n138 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nANEXOS \n\n \n\n\n\n139 \n \n\nAnexo A \u2013 Parecer do Comit\u00ea de \u00c9tica e Pesquisa \n\n \n\n \n\n \n\n \n\n \n\nT\u00edtulo da Pesquisa: Cintilografia de perfus\u00e3o hep\u00e1tica na avalia\u00e7\u00e3o da hemodin\u00e2mica \n\nvenosa portal na esquistossomose hepatoespl\u00eanica \n \n\n \n\nPesquisador Respons\u00e1vel: BERNARDO TIMES DE CARVALHO \n \n\n \n\n \u00c1rea Tem\u00e1tica:  \n \n\n \n\nVers\u00e3o: 1 \n \n\n \n\nCAAE: 27612814.9.0000.5208 \n \n\n \n\nSubmetido em: 24/02/2014 \n \n\n \n\nInstitui\u00e7\u00e3o Proponente: CENTRO DE CI\u00caNCIAS DA SA\u00daDE \n \n\n \n\nSitua\u00e7\u00e3o da Vers\u00e3o do Projeto: Aprovado \n \n\n \n\nLocaliza\u00e7\u00e3o atual da Vers\u00e3o do Projeto: Pesquisador Respons\u00e1vel \n \n\n \n\nPatrocinador Principal: Financiamento Pr\u00f3prio  \n\n \n\n  \n\n\n\n140 \n \n\nAnexo B \u2013 Instru\u00e7\u00f5es para publica\u00e7\u00e3o do Digestive Disease and Sciences \n \n\nDigestive Diseases and Sciences  \n\n \n\n \n\nCATEGORIES OF MANUSCRIPTS \n\nDigestive Diseases and Sciences publishes peer-reviewed basic and clinical studies and special \n\narticles on all aspects of gastroenterology and hepatology and related fields. The editors will \n\nconsider and publish the following categories of manuscripts: \n\n\u2022 Original Articles: basic or clinic research. \n\n\u2022 Reviews (including systematic reviews and meta-analyses): basic or clinical topics. \n\n\u2022 Special Category Articles: such as meeting reports (per approval of the editor-in-chief), \n\ncomments on medical policy, or opinion pieces. \n\n\u2022 Case Reports: in general, case reports are not encouraged; the editors will limit the number of \n\ncase reports per issue and will only consider particularly novel and important clinical \n\nobservations. \n\n\u2022 Editorials: comment on papers published elsewhere in the issue and solicited by the editor-in-\n\nchief, and occasional special topics or announcements from the editors. \n\n\u2022 Correspondence: concise opinions on papers published in Digestive Diseases and Science online \n\nwithin the past six months. In special circumstances, free-standing concise correspondence related \n\nto a unique clinical experience will be considered. \n\n\u2022 Stanford Multidisciplinary Seminars: specifically allocated for the Stanford Multidisciplinary \n\nSeminars submitted by authors from Stanford and coordinated by the editor for this series. \n\n\u2022 Industry Sponsored Articles and Reviews: provided that the relationship is clearly stated in the \n\nmanuscript, editors will consider industry sponsored articles and reviews. \n\n\u2022 DDS New Digestive Science: a forum for presenting exciting new basic science or clinical \n\nresearch findings that are important and novel, warranting early communication in brief. Findings \n\npresented in this format must be robust, innovative, and eventually important to medical practice. \n\n\u2022 Medical Education and Practice: Scientific articles that focus on medical education or on \n\ncommon facets of medical practice. \n\nManuscripts should be concise, well organized, and clearly written. Acceptance of manuscripts \n\nwill be based on originality and importance to the field of digestive diseases. Submitted \n\nmanuscripts are reviewed by the editor-in-chief and associate editors and, in the majority of cases, \n\nby two or more experts in the field. The editors can choose to reject a manuscript without peer \n\nreview if the manuscript is of insufficient quality or relevance to warrant acceptance. Manuscripts \n\nbased on or those describing the experimental or therapeutic use of complex mixtures of \n\nchemically undefined substances such as plant-derived extracts will be returned without further \n\nreview. The editors reserve the right to reject poorly written manuscripts even if their scientific \n\ncontent is potentially suitable for publication. Authors are responsible for the use of \n\ngrammatically correct English. Springer reserves the right to copy edit accepted manuscripts. \n\nProofs will be sent to the corresponding author for final approval, and must be returned within 48 \n\nhours of receipt. \n\nETHICS AND DISCLOSURE POLICIES \n\nMaterial submitted to Digestive Diseases and Sciences (DDS) must be original and not published \n\nor submitted for publication elsewhere. Meeting abstracts do not constitute prior publication. \n\nAuthors who have related material under consideration or in press elsewhere should upload a \n\n\n\n141 \n \n\nclearly marked copy at the time of their submission to DDS. If part of a contribution has appeared \n\nor will appear elsewhere in press, the author must specify the details in the covering letter \n\naccompanying the DDS submission. Duplicate publication (by the same author) and plagiarism \n\n(by a different author) must be avoided in accordance with \u201cUniform Requirements for \n\nManuscripts Submitted to Biomedical Journals\u201d developed by the International Committee of \n\nMedical Journal Editors (http://www.icmje.org). Each author must have participated substantially \n\nin the work and approve the final version of the manuscript. Where applicable, the following must \n\nbe disclosed: all financial arrangements (research support, stock ownerships, equity interest, \n\nconsultancies, or major honoraria) with a company whose product figures prominently in the \n\nmanuscript; a statement of specific funding support; and identification of third party individuals \n\nwho provided writing assistance. Reports of clinical trials with a control or comparison group \n\nshould be presented according to the CONSORT guidelines (http://www.consort-statement.org \n\nor JAMA. 2001;285:1987-1991). The clinical trial registry URL (e.g., \n\nhttp://www.clinicaltrials.gov in the United States) and clinical trial number should be included in \n\nthe body of the manuscript in the methods section. \n\n? http://dds.edmgr.com \n\nINVESTIGATIONS INVOLVING HUMAN SUBJECTS \n\nThe journal requires that investigations performed on human subjects have the prior approval of \n\nthe appropriate institutional or other independent ethics committee on human experimentation. \n\nThis attestation should appear in the methods section of the manuscript. In countries where such \n\nmechanisms for approval do not exist, authors are required to indicate that the research was \n\ncarried out in accordance with the Helsinki Declaration. A similar assurance is required to \n\ndocument that animal experimentation was performed under appropriate circumstances. \n\nSUBMISSION \n\nManuscripts should be submitted online using Springer\u2019s manuscript submission and review \n\nsystem, Editorial Manager, at http://dds.edmgr.com. Editorial Manager supports a wide range of \n\nsubmission file formats: \n\n\u2022 Manuscripts: Word, WordPerfect, RTF, TXT, and LaTeX \n\n\u2022 Figures: TIFF, GIF, JPEG, EPS, PPT, and Postscript (Color art is FREE for both online and \n\nprint publication!) \n\n(Please note that PDF is not an acceptable file format for manuscripts or figures.) \n\nManuscript submission requires the uploading of at least one manuscript file (including \n\nreferences), but a cover letter, figures, figure legends, and tables may also be uploaded as separate \n\nfiles. Files should ideally be posted in the following order (order can be changed after uploading): \n\n1. Cover letter \n\n2. Manuscript \n\n3. Tables \n\n4. Figure legends (if separate) \n\n5. Figures \n\n6. Other \n\nFor all article types except correspondence and editorials, submission also requires the suggestion \n\nof four to six peer reviewers (experts in the topic area of the manuscript and not recent \n\ncollaborators or from the same institution as the author[s]), including name, department, \n\ninstitution, and email address. \n\nOnce the manuscript is uploaded to Editorial Manager, the corresponding author will receive an \n\nemail requesting approval of the PDF created from the source files. If not done immediately \n\nfollowing upload, it is important to review and approve the PDF to initiate review by the editors. \n\nShould any difficulties arise while submitting manuscripts online, please contact the responsible \n\neditorial assistant by clicking \u201cContact Us\u201d in the Editorial Manager toolbar at the top of each \n\nhttp://dds.edmgr.com/\n\n\n142 \n \n\npage. Once submitted, a manuscript\u2019s progress through the review process may be tracked in real \n\ntime. \n\nMANUSCRIPT STYLE \n\n\u2022 Text should conform to accepted standards of American English style and usage. Before \n\nsubmitting an article to DDS, authors for whom English is a second language are encouraged to \n\nhave their manuscripts reviewed and professionally edited by an individual whose native language \n\nis English. \n\n\u2022 All manuscripts should be typed in 12-point font size and double-spaced with 1-inch margins. \n\nOne space only should be used after periods and commas. Authors should retain a copy of all \n\nmaterials. \n\n\u2022 The manuscript, if an original article, should be arranged as follows: Title Page, Abstract, \n\nKeywords, Introduction, Methods, Results, Discussion, References, Tables, Figure Legends, and \n\nFigures. \n\n\u2022The title page should include the title of the article, name(s) of author(s) and highest academic \n\ndegree(s), department and institution from which the work originated, email and postal addresses \n\nof all authors, name of the corresponding author, acknowledgment of grant support, and \n\ndisclosure of financial arrangements related to the research or assistance with manuscript \n\npreparation. Personal acknowledgments, if any, should be given in a separate section at the end \n\nof the article. \n\n\u2022 Titles should state the main findings of the article, not focus on design of the research, and \n\nshould not exceed 120 characters in length. Do not use abbreviations in titles. \n\n\u2022 Authors of original articles should submit a structured abstract of no more than 250 words \n\norganized as applicable into the following categories: Background, Aims, Methods, Results, and \n\nConclusions. Review articles should include a general abstract (i.e., the above categories are not \n\nrequired) also of no more than 250 words. Abbreviations, footnotes, and references should not be \n\nused in the abstract, with the exception of standard, repetitive abbreviations such as HCV, GERD, \n\netc. Case reports should not include an abstract, though a short introduction as well as a brief \n\ndiscussion highlighting the key lessons from the case are both welcome. \n\n\u2022 A list of four to six keywords should be provided directly below the abstract and for case reports, \n\non the title page. Keywords should express the precise content of the manuscript, as they are used \n\nfor indexing purposes and should preferably be terms from the Index Medicus Medical Subject \n\nHeadings (MeSH) list. \n\n\u2022 Editorials are invited by the editor and should be no longer than 1,500 words. Editorials should \n\nnot have an abstract. The total number of references should be limited to a maximum of 10. \n\nAuthors are encouraged to include a table or figure. \n\n\u2022 Correspondence should be limited to 500 words and should relate to papers published in DDS \n\nwithin the past six months. \n\n\u2022 Case reports should not exceed 600 words and should not include an abstract or more than ten \n\nreferences. Case reports should ideally include a short introduction and brief discussion, the latter \n\nhighlighting key lessons from the case. There is no maximum word count or number of references \n\n(or figures) for case series including several cases or for all other manuscript types. (Case series \n\ncan be submitted as article type Case Report or Original Article, depending in part on the number \n\nof cases being reported.) \n\n\u2022 DDS New Digestive Science articles should be limited to 2,000 words, including an abstract of \n\nless than 250 words, and should include no more than a total of 3 tables and figures and fewer \n\nthan 25 references. These submissions will be reviewed in standard fashion, but if accepted, the \n\njournal will ensure rapid online and expedited print publication. \n\n\u2022 In the body of the manuscript, the ethical guidelines followed should be identified and the \n\nstatistical methods employed should be outlined. When describing results, report P values and/or \n\nconfidence intervals. Only standard abbreviations should be used and identified with first usage. \n\nGeneric names of drugs should be used, although the brand name may be inserted in parentheses. \n\n\n\n143 \n \n\n\u2022 Tables should be double-spaced on separate pages, with the table number and table title centered \n\nabove the table and explanatory notes below the table. \n\n\u2022 The figure title and caption material should appear in the legend and not on the figure. Legends \n\nshould be typed double-spaced on pages separate from the text. Figures should be numbered in \n\none consecutive series in the order in which they are cited in the text. Please include sufficient \n\ninformation in the legends to interpret the figures without reference to the text. \n\n\u2022 Illustrations should be clear, with sharp contrast, especially where fine lines such as those of \n\ngrids or traces are to be retained. Illustrations should be no larger than 8\u00bd \u00d7 11 inches, but \n\npreferably of a size not needing enlargement or reduction. Non-traceable (raster) line-art and \n\nphotographs should ideally be provided as TIFFs of at least 600 dpi resolution. Please provide \n\ntraceable (vector) figures in EPS format. Halftone photographs should be provided as TIFFs of at \n\nleast 200 dpi resolution. \n\n\u2022 References should be cited in the text by Arabic numerals enclosed in square brackets. Only \n\nliterature that is published or in press (with the name of the journal) may be numbered and listed. \n\nAbstracts and letters to the editor may also be cited, but should ideally be less than three years old \n\nand identified as such after the title, e.g., [Abstract] or [Letter to Editor]. The references section \n\nshould be typed double-spaced on pages separate from the text and numbered consecutively in \n\nthe order in which references are cited in text. Included are last names and initials of authors, title \n\nof article, name of publication, year published, volume, and inclusive pages. For references with \n\nmore than six authors, the fourth and subsequent authors should be replaced with \u201cet al.\u201d; for \n\nreferences with between one and six authors all the authors should be listed. Abbreviations should \n\nconform to those used in Index Medicus. References must be verified by the authors against \n\noriginal documents. We recommend the use of tools such as EndNote or Reference Manager for \n\nreference management and formatting. The style and punctuation of the references conform to the \n\nfollowing examples (text enclosed in [I] symbols below, should be italicized in the manuscript): \n\n? Article: \n\nSandborn WJ, Tremaine WJ, Batts KP, et al. Fecal bile acids, short-chain fatty acids, and \n\nbacteria after ileal pouch\u2013anal anastomosis do not differ in patients with pouchitis. [I]Dig \n\nDis Sci[I]. 1995;40:1471\u20131483. \n\n? Book: \n\nBanks PA. [I]Pancreatitis[I]. New York, NY: Plenum Medical; 1979. \n\n? Contribution to a Book: \n\nCreutzfeldt W. Endocrine tumors of the pancreas. In: Volk BW, Wellmann KF, eds. \n\n[I]The Diabetic Pancreas[I]. New York, NY: Plenum Medical; 1977:551\u2013590. \n\n? Electronic: \n\nISI Web of Knowledge. Journal Citation Reports, 2007 JCR Science Edition. Available \n\nat: http://isiwebofknowledge.com. Accessed June 20, 2008. \n\nFor authors using EndNote, an output style is available that supports the formatting of in-text \n\ncitations and reference list. \n\n? EndNote style (zip, 1 kB) \n\nCOPYRIGHT \n\nSubmission of a manuscript to Digestive Diseases and Sciences is a representation that the \n\nmanuscript has not been published previously in any form, including symposia and proceedings \n\nof meeting, except in brief abstract form, and is not currently under consideration for publication \n\nelsewhere. Once a manuscript is accepted by the editorial office, authors (or their employers, if \n\nthey hold the copyright) must sign a statement transferring copyright to Springer \n\nScience+Business Media, Inc., before the manuscript can be officially accepted for publication. \n\nAuthors will receive the statement via email from the production editor; they need not provide a \n\ncopyright transfer at manuscript submission. Such a written transfer, which previously was \n\nassumed to be implicit in the act of submitting a manuscript, is necessary under the U.S. Copyright \n\nhttp://static.springer.com/sgw/documents/1205537/application/zip/EndNote+style.zip\n\n\n144 \n \n\nLaw in order for the publisher to carry through the dissemination of research results and reviews \n\nas widely and effectively as possible. \n\nSPRINGER OPEN CHOICE \n\nIn addition to the normal publication process (whereby an article is submitted to the journal and \n\naccess to that article is granted to customers who have purchased a subscription), Springer now \n\nprovides an alternative publishing option: Springer Open Choice. A Springer Open Choice article \n\nreceives all the benefits of a regular subscription-based article, but in addition, is made available \n\npublicly through Springer\u2019s online platform SpringerLink. To publish via Springer Open Choice, \n\nupon acceptance please visit http://www.springeronline.com/openchoice to complete the relevant \n\norder form and provide the required payment information. Payment must be received in full before \n\npublication or articles will publish as regular subscription-model articles. We regret that Springer \n\nOpen Choice cannot be ordered for published articles. \n\n? http://www.springeronline.com/openchoice/ \n\nABBREVIATION \n\nThe correct abbreviation of Digestive Diseases and Sciences for abstracting and indexing \n\npurposes is: Dig. Dis. Sci. or Dig Dis Sci. \n\nISSN AND EISSN \n\nThe international standard serial number (ISSN) for Digestive Diseases and Sciences is 0163-\n\n2116, and the electronic international standard serial number (EISSN) is 1573-2568. \n\nDoes Springer provide English language support? \n\nManuscripts that are accepted for publication will be checked by our copyeditors for spelling and \n\nformal style. This may not be sufficient if English is not your native language and substantial \n\nediting would be required. In that case, you may want to have your manuscript edited by a native \n\nspeaker prior to submission. A clear and concise language will help editors and reviewers \n\nconcentrate on the scientific content of your paper and thus smooth the peer review process. \n\nThe following editing service provides language editing for scientific articles in all areas Springer \n\npublishes in:  \n\n? Edanz English editing for scientists \n\nUse of an editing service is neither a requirement nor a guarantee of acceptance for publication. \n\nPlease contact the editing service directly to make arrangements for editing and payment. \n\nFor Authors from China \n\n??????????????????????????????????????\n\nSpringer???????????????????????????????????\n\n??????????????????????????????????????\n\n??????????????????????Springer?????????????\n\n???? \n\n? ???? \n\nFor Authors from Japan \n\n??????????????????????????????????????\n\n????????Edanz????????????????????????????\n\n??????????????????????????????????????\n\n?????? \n\n? ???????????? \n\nFor Authors from Korea \n\nhttp://www.springeronline.com/openchoice/\nhttp://www.edanzediting.com/springer\nhttp://www.liwenbianji.cn/springer\nhttp://www.edanzediting.co.jp/springer\n\n\n145 \n \n\n?? ?? ??? ?? ????? ?? ??? ??? ??? ??? Edanz ??? \n\n??? ????. ??? ??, ?? ? \n\n?? ?? ?? ?? ??? ??? ?? Edanz Editing Global ????? ??? ??? \n\n???????. \n\n? Edanz Editing Global \n\nINQUIRIES \n\nAll inquiries should be addressed to the editor-in-chief or to the managing editor, preferably by \n\nemail: \n\nEditor-in-Chief \n\nJonathan D. Kaunitz, MD, FACG, AGAF \n\nUCLA School of Medicine \n\nBldg. 114, 217E \n\nWest Los Angeles VAMC \n\nLos Angeles, CA 90073 \n\nManaging Editor \n\nMeghan Keeffe \n\nEmail: dds.journal@gmail.com \n\nFax: 415-383-8428 \n\n \n\nhttp://www.edanzediting.com/springer\n\n\tIncreased Hepatic Arterial Blood Flow Measured by Hepatic Perfusion Index in Hepatosplenic Schistosomiasis: New Concepts for an Old Disease\n\tAbstract\n\tBackground\n\tAims\n\tMethods\n\tResults\n\tConclusions\n\n\tIntroduction\n\tPatients and Methods\n\tPatients\n\tInclusion Criteria\n\tControls\n\tExclusion Criteria\n\n\n\tMethods\n\tStatistical Analysis\n\n\tResults\n\tDiscussion\n\tAcknowledgments\n\tReferences"}]}}}